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STIMULATION OF THE MEDIAL FOREBRAIN BUNDLE IN C57BL/6J MICE
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Virginia Commonwealth University, 2013
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Cannabinoid agonists, including delta-9-tetrahydrocannabinol (THC), are found
rewarding by humans. In addition to human self-reports and experimental studies that show
marijuana is rewarding, contributions from preclinical studies also have implicated cannabinoid
receptors in reward-motivated behavior. One way to assess these preclinical effects of
cannabinoids is intracranial self-stimulation (ICSS), where an animal performs a response to
receive electrical stimulation of a specific brain area or circuit known to be involved in

rewarding activities. Drugs of abuse, such as psychomotor stimulants, facilitate responding for
ICSS. While a few studies have shown facilitating effects of cannabinoids in rats, several have
shown the opposite effect, and no studies so far have evaluated cannabinoids in mouse ICSS.
Furthermore there are no studies evaluating specific inhibitors of endocannabinoid catabolic
enzymes in ICSS in any species. In these studies we assessed the cannabinoid agonist THC, as
well as the fatty acid amide hydrolase (FAAH) inhibitor, PF-3845, the monoacylglycerol lipase
(MAGL) inhibitor JZL184, and the combined FAAH/MAGL inhibitor SA-57 in ICSS of the
medial forebrain bundle in C57BL/6 mice. Additionally, we assessed the psychomotor stimulant
cocaine as a positive control to facilitate ICSS. These studies were complimented with
spontaneous locomotor activity and food-maintained operant experiments to assess the
sensitivity of ICSS to cannabinoids. Additionally, brain endocannabinoid levels were measured
in brain regions associated with the mesolimbic system after enzyme inhibitor treatments.
THC, JZL184, and SA-57 all produced time-dependent reductions in ICSS that were
mediated through CB1 receptors, as they were blocked by pre-treatment with the CB1 antagonist
rimonabant, but not with the CB2 antagonist SR144528. PF-3845 also reduced ICSS, but did so
independent of CB1 and CB2 receptors, and only with one dose (30.0 mg/kg) that has not been
assessed previously in vivo. We showed that ICSS was more sensitive to the rate-reducing effects
of cannabinoids than other measures of behavior with motor components including spontaneous
locomotor activity and operant nose-poking for food, and that the reduction of ICSS produced by
both JZL184 and SA-57 is accompanied by increases in 2-AG in mesolimbic brain areas. Thus,
cannabinoids do not facilitate ICSS in C57BL/6 mice over a range of doses and pre-treatment
times, similar to most studies with rats. These data suggest that cannabinoids may produce
rewarding effects through non-mesolimbic areas of the brain.

Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain
Bundle in C57Bl/6J Mice
Endogenous Cannabinoid System
The endocannabinoid system is composed of two known cannabinoid receptor types:
cannabinoid receptor types 1 and 2 (CB1 and CB2) (Gerard, Mollereau, Vassart, & Parmentier,
1991; Matsuda, Lolait, Brownstein, Young, & Bonner, 1990) as well as the endogenous ligands
that bind to these receptors. Cannabinoid receptors are G-protein-coupled and activating them
inhibits calcium influx into cells and reduces the accumulation of cyclic adenosine
monophosphate (cAMP), ultimately producing an inhibitory effect (Howlett et al., 1990;
Pertwee et al., 2010). CB1 receptors are located on pre-synaptic terminals of several neuron types
including GABAergic, glutamatergic, cholinergic, serotonergic, and noradrenergic neurons, and
their stimulation inhibits the release of neurotransmitter into the synapse (Cadogan, Alexander,
Boyd, & Kendall, 1997; Katona et al., 2000; Robbe, Alonso, Duchamp, Bockaert, & Manzoni,
2001). Most behavioral effects produced by cannabinoids have been found to be mediated
through CB1 receptors. For example the classical tetrad of behavioral effects (hypolocomotion,
hypothermia, catalepsy, and antinociception) and discriminative stimulus effects have been
shown to be mediated through CB1 receptors, as they were blocked by the CB1 receptor
antagonist, rimonabant, in different species including mice, rats, and rhesus monkeys (Compton,
Aceto, Lowe, & Martin, 1996; Rinaldi-Carmona et al., 1994; Wiley, Lowe, Balster, & Martin,
1995).
Some recent studies have demonstrated behavioral effects related to CB2 receptor
activation. CB2 receptors have been thought to be predominantly located in the periphery and on
immune cells during states of inflammation, but are also located on subpopulations of neurons
and microglial cells (Ashton, Friberg, Darlington, & Smith, 2006; Baek, Zheng, Darlington, &
1

Smith, 2008; Gong et al., 2006; Onaivi, 2006; Onaivi et al., 2006; Stella, 2010; Van Sickle et al.,
2005). However, there is controversy over whether CB2 receptors are present on neurons, as the
antibodies used to detect them are not highly selective. Recent studies have implicated CB2
receptors as mediators of cocaine reinforcement and nicotine reward (Ignatowska-Jankowska,
Muldoon, Lichtman, & Damaj, 2013; Xi et al., 2011). Xi and colleagues found that the CB2
receptor agonist, JWH133, dose-dependently inhibited cocaine self-administration, cocaineinduced activation of locomotor activity, and cocaine-induced increases in dopamine in the
nucleus accumbens (Xi, et al., 2011). These effects were all prevented by treatment with the CB2
antagonist, AM630, or when assessed in CB2 -/- mice (Xi, et al., 2011). Ignatowska-Jankowska
and colleagues found that nicotine conditioned place preference (CPP) was blocked by pretreatment with the CB2 antagonist, SR144528; and the CB2 agonist 0-1966 enhanced nicotine
CPP (Ignatowska-Jankowska, Muldoon, et al., 2013). These are some of the first studies
implicating CB2 receptor activation in drug reward. Interestingly, CB2 receptor activity produces
paradoxical effects on cocaine and nicotine behavior, as agonists block cocaine reward and
enhance nicotine reward, and antagonists reverse blockade of cocaine self-administration and
block nicotine reward. Taken together, these findings suggest that CB2 receptors may be involved
in drug reward, and their effects seem to be specific to distinct drugs of abuse.
Endocannabinoids
The endogenous cannabinoids (endocannabinoids) include the lipid molecules Narachidonoylethanolamine (anandamide; AEA), 2-arachidonoylglycerol (2-AG) (Devane et al.,
1992; Mechoulam et al., 1995; Sugiura et al., 1995) as well as arachidonyl dopamine, nolandin
ether, and virodhamine (Bisogno et al., 2000; Hanus et al., 2001; Porter et al., 2002). This
dissertation focuses on 2-AG and AEA, as they are the predominant endocannabinoid ligands,
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and pharmacological tools are available to evaluate them. AEA was discovered in 1992, and was
the first endocannabinoid isolated, while screening endogenous ligands for CB1 receptor binding
(Devane, et al., 1992). 2-AG was discovered simultaneously by two groups in 1995, when it was
isolated from canine intestinal tissue (Mechoulam, et al., 1995) and rat brain tissue (Sugiura, et
al., 1995), and found to bind to CB1 and CB2 receptors. AEA is thought to be primarily
synthesized through phosphodiesterase activity or through cleavage of phospholipase C and a
phosphatase (Liu et al., 2006). It was originally proposed that AEA is created primarily through
the cleavage of N-arachidonylphosphatidylethanolamine (NAPE) by NAPE-phospholipase D
(PLD), but a study by Leung and colleagues suggested that NAPE-PLD is not the major
biosynthetic pathway for AEA, as NAPE-PLD knock-out mice were found to have similar
amounts of AEA as wild-type controls (Leung, Saghatelian, Simon, & Cravatt, 2006). 2-AG is
primarily synthesized through the cleavage of diacylglycerol (DAG) by the enzyme DAG lipasealpha (DAGLα) (Gao et al., 2010; Tanimura et al., 2010). This was confirmed by the observation
that DAGLα knock-out mice have significantly lower levels of 2-AG in brain compared to wildtype controls. 2-AG and AEA are primarily metabolized by the respective degradative enzymes
monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH).
As shown on Fig. 1, endocannabinoids are released from post-synaptic neuron terminals
and move across the synapse and bind to CB1 receptors located on pre-synaptic neurons (Ahn,
McKinney, & Cravatt, 2008). AEA and 2-AG are rapidly metabolized soon after they are
released. FAAH is located within the post-synaptic terminal (Gulyas et al., 2004) and is
primarily responsible for the degradation of AEA into arachidonic acid and ethanolamine.
FAAH also metabolizes roughly thirteen other fatty acid amides including oleamide,
oleylethanolamide (OEA) and palmitoylethanolamide (PEA) (Cravatt et al., 1995). Other

3

enzymes have the ability to metabolize AEA including FAAH-2 and N-acylethanolaminehydrolyzing acid amidase (NAAA), though the former is only found in human and primates.
Both are found in higher relative abundance in peripheral tissues and are inferior to FAAH in
their ability to metabolize AEA (Tsuboi et al., 2005; Ueda, Yamanaka, & Yamamoto, 2001; Wei,
Mikkelsen, McKinney, Lander, & Cravatt, 2006). Similarly, 2-AG can be hydrolyzed by a
number of different enzymes including FAAH, neuropathy target esterase (NTE), hormone
sensitive lipase (HSL), alpha/beta hydrolase 6 and 12 (ABHD6, ABHD12), cyclooxygenase-2
(COX2), or MAGL, but the majority of 2-AG (85%) is degraded by the enzyme MAGL located
within the presynaptic terminal. Any remaining 2-AG is typically deactivated by enzymes
alpha/beta ABHD6 or ABHD12 and converted to arachidonic acid (AA) and glycerol (Belfrage,
Jergil, Stralfors, & Tornqvist, 1977; Blankman, Simon, & Cravatt, 2007; Dinh, Freund, &
Piomelli, 2002; Goparaju, Ueda, Yamaguchi, & Yamamoto, 1998; Kim & Alger, 2004; van
Tienhoven, Atkins, Li, & Glynn, 2002). In addition to being the main enzyme responsible for
breaking down 2-AG, MAGL is also the major biosynthetic enzyme for arachidonic acid and its
metabolites (Nomura et al., 2011). Hydrolysis of 2-AG produces arachidonic acid (AA) and
glycerol; disruption of MAGL activity significantly decreases free AA, as well as the eicosanoids
derived from it, including prostaglandins E2 (PGE2), PGD2, PGF2, and thromboxane B2
(TXB2). This decrease in AA is associated with decreased inflammatory responses (Nomura, et
al., 2011).

4

Figure 1. Depiction of a synapse with endocannabinoid system components including CB1
receptors, ligands, and biosynthetic and degradative pathways. Figure adapted from (Ahn, et al.,
2008).
5

AEA and 2-AG: Distinct Endocannabinoids
Although AEA and 2-AG are structurally similar and have been shown to bind to CB1
and CB2 receptors, they are pharmacologically distinct ligands. There are a few important
observed differences between these two endocannabinoids that set them apart from each other. 2AG is found at 170-1000 fold greater concentrations in the central nervous system than AEA
(Sugiura et al., 2002). This relationship was confirmed at the synaptic level with a study that
measured AEA and 2-AG in mouse and rat nucleus accumbens shell after FAAH and MAGL
inhibitor administration using microdialysis (Wiskerke et al., 2012). Wiskerke and colleagues
consistently observed basal levels of 2-AG at 9-16 fold those of AEA in the interstitial space in
the nucleus accumbens shell of mice and 2-8 fold higher in rats (Wiskerke, et al., 2012), which
suggests that 2-AG may be more relevant for CB1 receptor signaling. Although the ratio between
the amounts of AEA and 2-AG in whole brain tissue is less than when measured in the interstitial
space, 2-AG is still consistently found in greater quantities there also.
AEA is a partial agonist at cannabinoid receptors in vitro, while 2-AG is a full agonist in
stimulating GTPgammaS binding, as AEA reduced the functional activity of 2-AG, which
suggests differential efficacy of the two endocannabinoids at cannabinoid receptors (Gonsiorek
et al., 2000). Related to this fact 2-AG, but not AEA, has been shown to prolong depolarizationinduced suppression of inhibition/excitation (DSI, DSE). Suppression of inhibition/excitation
refers to suppression of inhibitory or excitatory neuronal transmission via hyperpolarization of a
depolarized neuron, which suppresses the release of a neurotransmitter. 2-AG can cause a
suppression of stimulatory or excitatory neurotransmitters mediated by CB1 receptors, while
AEA does not, indicating that 2-AG may be more relevant for neuronal retrograde signaling (Pan
et al., 2009). Furthermore, in addition to binding to CB1 and CB2 receptors, AEA has also been
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shown to activate the transient receptor potential cation channel subfamily V member 1 (TrpV1),
and other substrates metabolized by FAAH including OEA and PEA have been shown to bind to
peroxisome proliferator-activated alpha receptors (PPARα) receptors; while 2-AG and targets of
MAGL inhibition lack affinity for those receptors (Jhaveri et al., 2008; Ross, 2003; Zygmunt et
al., 1999).
The availability of each endocannabinoid is regulated independently by distinct
enzymatic pathways. As mentioned above, AEA is broken down by FAAH in the postsynaptic
neuron, and other enzymes which do not affect 2-AG including FAAH-2 and NAAA, while 2AG primarily is broken down by MAGL in the presynaptic neuron, and also can be metabolized
by ABHD6, ABHD12, HSL, NTE, or FAAH. Additionally, FAAH metabolism of AEA does not
contribute substantially to available arachidonic acid pools in the brain, while disruption of 2-AG
metabolism leads to significant reductions of available AA (Nomura, et al., 2011). In addition to
differences in the metabolic inactivation of AEA and 2-AG, their biosynthetic precursors also
vary, as AEA is synthesized primarily through phosphodiesterase activity or through cleavage of
phospholipase C and a phosphatase, while 2-AG in the brain is synthesized primarily through the
cleavage of diacylglycerol (DAG) by the enzyme DAG lipase-alpha (DAGLα) (Gao, et al., 2010;
Tanimura, et al., 2010). These differences between biosynthetic and degradative pathways
suggest AEA and 2-AG have distinct physiological functions.
Tolerance to cannabinoid tetrad effects and regulation of cannabinoid receptors is
differentially modulated when MAGL or FAAH are inhibited repeatedly. Previous studies have
shown that potentially negative outcomes such as CB1 receptor down-regulation, desensitization,
and cannabinoid somatic withdrawal symptoms occur after repeated administration with a high
dose of the MAGL inhibitor JZL184 (40.0 mg/kg) and in MAGL knock-out mice. However, it
7

should be noted that follow-up studies to the initial reports have demonstrated that repeated
partial inhibition of MAGL (low doses of JZL184; 4.0 mg/kg) does not affect CB1 receptor
function, and can still produce therapeutic effects in preclinical assays (Kinsey et al., 2013).
Repeated FAAH inhibition using genetic or pharmacological means fails to produce either of
these undesirable effects (Falenski et al., 2010; Schlosburg et al., 2010).
Endocannabinoids are synthesized locally and are produced “on-demand”, meaning that
unlike many neurotransmitters, endocannabinoids are produced immediately before being
released, rather than being stored in vesicles for later use. The heterogeneous distribution of
AEA and 2-AG as well as the ability of endocannabinoids to be inactivated by rapid synthesis
and degradation makes specific endocannabinoid enzymes intriguing targets for pharmaceutical
development. For example, MAGL inhibition leads to increased 2-AG accumulation in brain, but
only in a regionally dependent manner, and will presumably only activate a subset of CB1
receptors near where it is produced and released. This is in contrast to exogenous administration
of direct-acting cannabinoid receptor agonists, which activate cannabinoid receptors throughout
the brain and periphery. In addition to the therapeutic potential of endocannabinoid deactivation
inhibitors, they also represent an excellent tool to probe the cannabinoid system. The endogenous
cannabinoid system is involved intricately in many distinct physiological and psychological
processes including cognition, emotion, pain, and inflammation, and reward (Pertwee, 2012).
FAAH and MAGL inhibitors are particularly useful tools for the investigation of
endocannabinoid-mediated effects.
Behavioral Effects of MAGL Inhibition
MAGL inhibitors have been shown to produce a variety of behavioral effects. JZL184
was the first marginally selective irreversible MAGL inhibitor developed, which produced up to
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10-fold elevations of whole brain 2-AG compared to basal levels after acute administration of a
high dose (40.0 mg/kg) (J. Z. Long, Li, et al., 2009) without affecting AEA levels. JZL184 has
some activity at FAAH also, as repeated administration produces a small, but significant increase
in brain AEA concentrations (Schlosburg, et al., 2010). Recently, novel MAGL inhibitors
KML29 and MJN110 have been produced and have been reported to be more selective for
MAGL over FAAH than JZL184, with observed efficacy in both rats and mice (IgnatowskaJankowska et al., 2013; Niphakis et al., 2013).
JZL184 has been used as a pharmacological tool to investigate the role of 2-AG in
treating several different conditions/symptoms including anxiety, pain, and ulcers. It has been
demonstrated that JZL184 decreases anxiety-like behavior in both rats and mice in the elevated
plus maze test (Aliczki, Balogh, Tulogdi, & Haller, 2012; Sciolino, Zhou, & Hohmann, 2011)
and mice in the marble burying assay (Kinsey, O'Neal, Long, Cravatt, & Lichtman, 2011).
JZL184 produces antinociception in a mouse model of neuropathic pain in the chronic
constriction injury of the sciatic nerve (CCI) assay (Kinsey et al., 2009), a model of
inflammatory pain using the carrageenan inflammatory assay (Ghosh et al., 2012), formalininduced pain (Guindon, Guijarro, Piomelli, & Hohmann, 2011) and a rat model of sodium monoiodoacetate induced osteoarthritis pain (Sagar et al., 2010). Further, JZL184 has been shown to
decrease gastric hemorrhaging produced by gavage of the non-selective cyclooxygenase inhibitor
diclofenac (Kinsey et al., 2011) as well as reduce alterations and inflammation of the colon
induced by the trinitrobenzene sulfonic acid (TNBS) model of colitis in mice (Alhouayek,
Lambert, Delzenne, Cani, & Muccioli, 2011).
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Behavioral Effects of FAAH Inhibition
Similar to MAGL inhibitors, there have been a few FAAH inhibitors developed over the
past years, with selectivity for FAAH increasing over time. FAAH inhibitors, to name a few,
include URB-597 (Kathuria et al., 2003; Piomelli et al., 2006) , OL-135 (Boger et al., 2005), PF622, PF-750 (Ahn et al., 2007), PF-3845 (Ahn et al., 2009) and more recently, JNJ5003 (Hill et
al., 2012). FAAH inhibitors have been utilized to examine the effects of increased AEA in
various models of behavior and disease states. Most notably, there has been interest in
developing them for the treatment of pain. There has only been one clinical trial to date using a
FAAH inhibitor, PF-04457845 (PF-7845), which is structurally similar to PF-3845, but
optimized for human FAAH (Huggins, Smart, Langman, Taylor, & Young, 2012; Li et al.,
2012). PF-7845 did not show any analgesic efficacy in treating osteoarthritis; however it has not
been tested to treat other types of pain or conditions in the clinic. In preclinical assays, FAAH
inhibitors have been shown to be effective in collagen-induced models of arthritis (Kinsey,
Naidu, Cravatt, Dudley, & Lichtman, 2011), LPS-induced allodynia (Booker et al., 2012),
neuropathic pain (Caprioli et al., 2012), and multiple sclerosis pain models (Pryce et al., 2013),
among others pain assays. In addition to antinociception, FAAH inhibitors have shown positive
effects in various preclinical assays including enhancing active stress-coping strategies measured
using the tail suspension test with URB597 (Gobbi et al., 2005; Naidu et al., 2007), tail pinch test
(Haller, Goldberg, Pelczer, Aliczki, & Panlilio, 2013) and preventing restraint stress-induced
biochemical markers in the amygdala with JNJ5003 (Hill, et al., 2012). Anxiolytic effects of
FAAH inhibitors have been reported in studies evaluating animals using the elevated-zero maze
(Kathuria, et al., 2003) and elevated-plus maze (Haller, et al., 2013; Patel & Hillard, 2006).
FAAH inhibitors have also been shown to enhance both the acquisition (Varvel, Wise, Niyuhire,
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Cravatt, & Lichtman, 2007; L. E. Wise, Harloe, & Lichtman, 2009) and extinction (Varvel, et al.,
2007) of aversive spatial memory tasks.
Behavioral Effects of Combined FAAH and MAGL Inhibition
FAAH or MAGL inhibition alone do not produce all of the disruptive effects commonly
associated with cannabinoid agonists including catalepsy and THC-like discriminative stimulus
effects (J. Z. Long, Nomura, et al., 2009). Combined inhibition of FAAH and MAGL, however,
has been shown to produce more THC-like effects than either enzyme inhibited alone (J. Z.
Long, Nomura, et al., 2009; Niphakis, Johnson, Ballard, Stiff, & Cravatt, 2012; L. E. Wise et al.,
2012). Dual FAAH/MAGL inhibition has also been shown to substitute for THC in drug
discrimination studies, produce catalepsy in mice, as well as produce THC-like memory deficits
in Morris water maze learning, all of which were shown to be mediated through CB1 receptors (J.
Z. Long, Nomura, et al., 2009; L. E. Wise, et al., 2012). The effects produced by combined
FAAH and MAGL inhibition are reflective of the fact that AEA and 2-AG have distinct
signaling pathways. Specifically, it seems that 2-AG signaling produces more cannabimimetic
effects than AEA (J. Z. Long, Nomura, et al., 2009).
Although combined inhibition of FAAH and MAGL may produce undesirable effects, it
has also shown some promising effects in some preclinical assays, as it has been shown to reduce
somatic withdrawal signs in mice during spontaneous morphine withdrawal (Ramesh et al.,
2013); as well as produce enhanced reduction of inflammation and hypersensitivity to nonnoxious stimuli in the preclinical assay of carrageenan inflammation in mice (Ghosh and
Lichtman, unpublished).
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Cannabinoids and Reward
Abuse-related effects of cannabinoids have been demonstrated in humans through
positive subjective effect ratings associated with marijuana use (Hart et al., 2010; Hart, van
Gorp, Haney, Foltin, & Fischman, 2001), as well as through human brain imaging studies
implicating reward-relevant brain responses in the bilateral amygdala and hippocampus during
marijuana cue presentations and voluntary self-administration in marijuana-dependent
individuals (Goldman et al., 2013). In recent years the use of synthetic cannabinoid agonists by
humans has risen dramatically, as “herbal incense blend” products containing synthetic
cannabinoids have become commercially available (Brents & Prather, 2013).
Of particular importance, the majority of human reports of rewarding effects of
cannabinoids refer to inhaled marijuana or synthetic cannabinoid blends (Calhoun, Galloway, &
Smith, 1998). THC is not commonly used for recreational purposes by humans. In fact,
dronabinol (Marinol), which is synthetic THC delivered in capsules with sesame oil, is classified
as a schedule III compound by the FDA, while marijuana schedule I, meaning it has less abuse
and dependence liability than marijuana and certain synthetic cannabinoid agonists. There has
been no evidence of dronabinol prescriptions being diverted to non-medical use, and marijuana
users have not reported any interest in the drug (Calhoun, et al., 1998). Furthermore, the effects
of oral dronabinol have a slow onset, which reduces its potential for abuse, and the majority of
people who try it for recreational purposes report it produces dysphoric effects (Calhoun, et al.,
1998), or at most modest reinforcing effects (Hart, Haney, Vosburg, Comer, & Foltin, 2005).
Interestingly, dronabinol has been found to reduce symptoms of marijuana withdrawal without
producing many negative side-effects, or affecting the subjective effects of smoked marijuana
(Vandrey et al., 2013). Although THC is the main active constituent in marijuana, there are
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hundreds of other chemicals present the plant material typically smoked by humans. Thus,
preclinical research with THC may not be completely applicable to human use of marijuana. In
addition to marijuana containing other chemicals, the route of administration also differs, as few
preclinical studies have delivered cannabinoids via inhalation as they are typically consumed by
humans (Niyuhire, Varvel, Martin, & Lichtman, 2007; Wiebelhaus et al., 2012).
Preclinical Models of Reinforcement and Reward-Associated Behavior
Reinforcing and rewarding properties of cocaine and other drugs of abuse are assessed in
animals using various behavioral measures. Three of the most used preclinical assays to assess
abuse liability of drugs are drug self-administration, conditioned place preference (CPP), and
intracranial self-stimulation (ICSS). Descriptions of these assays and the respective effects of
cannabinoids are detailed below.
Self-Administration
A preclinical measure of drug reinforcement that has high face validity is drug selfadministration. In this paradigm, subjects learn to perform a specific operant task, such as
pressing a lever, spinning a wheel, or nose-poking, to obtain a specific drug reinforcer. Studies
have shown that animals can learn to self-administer many substances that humans are known to
abuse including cocaine (Panlilio & Goldberg, 2007), heroin (S. A. Chen et al., 2006), and
ethanol (Mittleman, Van Brunt, & Matthews, 2003). While cannabinoids have been
demonstrated to be self-administered by laboratory animals, historically researchers have had
difficulty demonstrating consistent cannabinoid self-administration in any species of animals
(Tanda & Goldberg, 2003). However, some studies have demonstrated self-administration of
cannabinoid full agonists in mice and rats (Fattore, Cossu, Martellotta, & Fratta, 2001; Flores,
Maldonado, & Berrendero, 2013; Martellotta, Cossu, Fattore, Gessa, & Fratta, 1998; Takahashi
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& Singer, 1979, 1980). The rodent studies that have demonstrated self-administration of
cannabinoids have employed specific methodological techniques that may have increased the
likelihood to train self-administration of a cannabinoid agonist including food-deprivation,
restraint-stress, short time-course of studies, and co-administration of food or water with
cannabinoids, which can make interpretation of their results difficult. Squirrel monkeys have
been demonstrated to self-administer cannabinoids (Justinova, Solinas, Tanda, Redhi, &
Goldberg, 2005; Justinova, Tanda, Redhi, & Goldberg, 2003; Justinova, Yasar, Redhi, &
Goldberg, 2011; Tanda, Munzar, & Goldberg, 2000). Initial studies utilized squirrel monkeys
that had previously learned to self-administer cocaine, but follow-up studies demonstrated that
naïve squirrel monkeys can also be trained to administer THC (Justinova, et al., 2003) as well as
the endogenous cannabinoid AEA and the longer lived methanandamide (Justinova, et al., 2005)
and 2-AG (Justinova, et al., 2011). Overall, cannabinoid self-administration is far less robust
compared to other abused drugs and relies heavily upon non-traditional manipulations, making it
difficult to interpret results.
Conditioned Place Preference
The conditioned place preference (CPP) model is based on the Pavlovian principle of
classical conditioning. Presumed drugs of abuse are assessed by pairing a given drug to an
experimental chamber with specific contextual cues, and then allowing an animal to choose
whether or not to spend time in that environment while in a drug-free state. The drug serves as a
unconditioned stimulus (US) and the specific environment it is paired to serves as a conditioned
stimulus (CS). If the subjects choose to spend more time in the drug-paired environment than a
similar, but distinct environment, it is inferred that there is a positive association between the
drug and the context in which it was administered (Tanda & Goldberg, 2003).
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While most drugs of abuse including psychomotor stimulants and opiates produce CPP,
cannabinoids often fail to do so, or only do so within an extremely limited range of doses, with a
large degree of inconsistency between studies (Cheer, Kendall, & Marsden, 2000; McGregor,
Issakidis, & Prior, 1996; Sanudo-Pena et al., 1997). Even when cannabinoids are found to
produce CPP, this effect can be dependent on timing of injections, and other procedural
manipulations. Additionally, conditioned place aversion is often observed with higher doses
(Braida, Pozzi, Cavallini, & Sala, 2001; Ghozland et al., 2002; Lepore, Vorel, Lowinson, &
Gardner, 1995).
Intracranial Self-Stimulation
Intracranial self-stimulation (ICSS) is a methodology in which a subject performs an
operant response in order to receive electrical stimulation of a brain region implicated in reward
function. ICSS has most commonly been used to assess the motivational effects and abuse
liability of drugs (Carlezon & Chartoff, 2007), but has also been used to assess affective signs of
drug withdrawal and other aversive states (Cryan, Hoyer, & Markou, 2003; Markou & Koob,
1991; Schulteis, Markou, Cole, & Koob, 1995). ICSS was first discovered serendipitously by
Olds and Milner in 1954 while attempting to stimulate the reticular formation (Milner, 1989;
Olds & Milner, 1954). James Olds noticed that a particular rat in which he had implanted an
electrode seemed to “seek out” the electrical stimulation that he applied, and he confirmed that
the stimulation served as a reinforcer after constructing a crude operant chamber and allowing
the rat to lever press for stimulation. He later realized that the electrode was bent when it was
inserted into the brain, and had actually terminated in the septum, and concluded that this brain
area was involved in reward (Milner, 1989). Gradually, various methodologies for studying
reward substrates and effects of drugs grew out of his early research. Today, these methodologies
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are referred to collectively as ICSS or brain stimulation reward. ICSS is one of the most salient
forms of reinforcement, and it is based on electrical activation of the mesolimbic dopamine
system (Kornetsky, 2004; Roy A. Wise, 2002). A stimulating electrode is implanted into one of
several possible sites including the various parts of the hypothalamus including the medial
forebrain bundle, or other areas including the septum, which have projections to the ventral
tegmental area (VTA). A large group of dopaminergic neurons in the VTA known as A10
neurons project to forebrain areas including the nucleus accumbens and prefrontal cortex. ICSS
is mediated mainly through activation of glutamatergic projections to dopaminergic neurons in
the VTA, which stimulates dopamine release originating from the VTA to the nucleus
accumbens (Shizgal, Schindler, & Rompre, 1989), where it activates GABAergic medium spiny
neurons in the nucleus accumbens. Dopamine release in the nucleus accumbens is associated
with natural rewards, including palatable feeding and increases in spontaneous locomotor
activity, as well as drug reward (Cheer, Aragona, et al., 2007; Neill, Fenton, & Justice, 2002; R.
A. Wise, 2005). This indirect stimulation of dopamine neurons in the nucleus accumbens is
thought to maintain ICSS behavior.
There are several different methodologies of ICSS, including discrete trial, auto-titration,
rate-based studies, and rate-frequency. All of the models except rate-based vary the electrical
current during session, which allows for analysis of drug effects across a range of response rates,
and reinforcer values. This dissertation will mainly focus on rate-frequency procedures. During
baseline conditions subjects typically respond at low rates for lower frequencies of stimulation,
and at increasingly higher rates as frequency is increased. Many drugs of abuse, and specifically
psychomotor stimulants such as cocaine, produce an increase in total responses, and manifests as
a leftward shift from baseline on the rate-frequency response curve (Corbett, 1991; Fish et al.,
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2012; Robinson, Agoglia, Fish, Krouse, & Malanga, 2012). This profile of effects also is referred
to as a decrease in the reward threshold because the frequency, or number of pulses per train in
the medial forebrain bundle necessary to maintain responding is reduced. ICSS is also used to
assess affective signs of drug withdrawal and other aversive states (Cryan, et al., 2003; Markou
& Koob, 1991; Schulteis, et al., 1995), as these manipulations can produce a reduction of ICSS,
or an increase in reward threshold, reflected by a rightward shift of the rate-frequency curve.
Many animal species will respond for brain stimulation including mice, rats, monkeys, and
humans (Bewernick, Kayser, Sturm, & Schlaepfer, 2012; Olds & Milner, 1954; Randt &
Quartermain, 1972; Rolls, Burton, & Mora, 1980). The first procedure in mice was established
by Randt and Quartermain in 1972 (Randt & Quartermain, 1972) and was followed by several
studies in mice by Cazala and Cardo (Cazala & Cardo, 1972).
Cannabinoid facilitation of ICSS has been difficult to observe and studies have resulted
in inconsistent observations similar to the effects of cannabinoids on reward or reinforcement in
other preclinical models. Some studies have shown that THC reduces reward thresholds of ICSS
in rats (Gardner et al., 1988; Katsidoni, Kastellakis, & Panagis, 2013; Lepore, Liu, Savage,
Matalon, & Gardner, 1996), while others have demonstrated that THC (Fokos & Panagis, 2010;
Stark & Dews, 1980) and synthetic full agonists WIN 55,212-2 (Vlachou, Nomikos, & Panagis,
2003) and CP 55,940 (Arnold, Hunt, & McGregor, 2001) fail to affect ICSS responding. The
majority of studies with cannabinoids and ICSS have found threshold increasing, or responseattenuating effects of various cannabinoid drugs including THC (Kwilasz & Negus, 2012;
Vlachou, Nomikos, Stephens, & Panagis, 2007), synthetic agonists WIN 55,212-2 (Mavrikaki,
Markaki, Nomikos, & Panagis, 2010; Vlachou, Nomikos, & Panagis, 2005), levonantradol
(Kucharski, Williams, & Kornetsky, 1983), nabilone and canbisol (Stark & Dews, 1980), CP
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55,940 (Kwilasz & Negus, 2012; Vlachou, et al., 2005), AMG-3 (Antoniou et al., 2005), and
HU-210 (Vlachou, et al., 2005), and endocannabinoid enhancing (and purportedly enhancing)
drugs URB-597, PMSF, and OMDM-2 (Vlachou, Nomikos, & Panagis, 2006) and the supposed
AEA transport inhibitor AM-404 (Vlachou, Stamatopoulou, Nomikos, & Panagis, 2008). For a
complete summary of cannabinoid agonist and endocannabinoid modulator effects on ICSS, see
Table 1. A common trend among ICSS studies with THC was that low doses produced
facilitation, or leftward shifts of the rate-frequency curves, or did not affect responding, and
higher doses reduced responding, or produced a rightward shift in the curve (Katsidoni, et al.,
2013; Lepore, et al., 1996). Furthermore, three of the four studies that found a
facilitating/threshold decreasing effect of THC utilized Lewis rats (Gardner, et al., 1988; Lepore,
et al., 1996); evidence that THC-induced facilitation of ICSS is a strain-dependent effect. Of
particular importance to the present studies is that no cannabinoid compounds have been
assessed in mouse ICSS.
The effects of CB1 receptor antagonists on ICSS are also somewhat inconsistent between
studies. The CB1 antagonist, rimonabant, has been shown to attenuate ICSS responding or reduce
reinforcement in some studies, usually at higher doses (De Vry, Schreiber, Eckel, & Jentzsch,
2004; Deroche-Gamonet, Le Moal, Piazza, & Soubrie, 2001; Trujillo-Pisanty et al., 2011; Xi, et
al., 2011), while it produces no change on ICSS responding in others (Antoniou, et al., 2005;
Arnold, et al., 2001; Kwilasz & Negus, 2012; Vlachou, et al., 2003; Vlachou, et al., 2005, 2006;
Vlachou, et al., 2007; Vlachou, et al., 2008). For a complete summary of cannabinoid antagonist
effects in ICSS, see Table 1 on pages 18 - 21. Certainly dose is a factor, as higher doses tend to
disrupt responding, and lower doses tend to have no effect on ICSS. As shown in Table 1, doses
of 3.0 mg/kg rimonabant or higher tend to produce rightward shifts in ICSS, or attenuate
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responding. These discrepancies may also be due to differences in endocannabinoid tone
produced by distinct experimental procedures. For example, procedural variations that produce
more stress than others may alter the endocannabinoid tone. The differences in amount of AEA
or 2-AG available to bind to CB1 receptors may alter the way that CB1 antagonists affect ICSS
behavior. If there is an abundance of endocannabinoids available and binding to CB1 receptors,
CB1 antagonists could conceivably produce more aversive effects than when an antagonist is
administered under less stressful conditions. Also, similar to results with agonists, all
assessments of CB1 antagonists have been conducted in rats. Certainly, there may be a species
difference in response to CB1 antagonists, as the facilitation caused by agonists seems to be
strain-dependent in rats. For a summary of all cannabinoid ICSS studies ICSS, see Table 1.

19

Table 1
Summary of Cannabinoids Agonist, Antagonist, and Endocannabinoid Modulating Drug Effects in ICSS
Cannabinoid Agonists
Rat
ICSS
Drug Dose/R.O.A.
Strain Test Effect
Reference
THC

0.1 & 1.0 mg/kg i.p.

S-D

R-F

*

decreased thresholds w/0.1 mg/kg (n=8)
increased thresholds w/1.0 mg/kg (n=8)

(Katsidoni, et al., 2013)

*

THC
CP

0.1 – 10.0 mg/kg i.p.
10.0 - 320 μg/kg i.p.

S-D

R-F

*

THC

0.5 & 1.0 mg/kg i.p.

S-D

R-F

n.s. trend of increased thresholds w/1 mg/kg (note: (Fokos & Panagis, 2010)
showed same trend in rats exposed to chronic
unpredictable stress as control rats) (n=7)

THC

0.5 – 2.0 mg/kg i.p.

S-D

R-F

*

(Vlachou, et al., 2007)

THC
THC
THC

1.0 mg/kg i.p.
1.0 mg/kg i.p.
1.0 mg/kg i.p.

Lewis R-F
S-D
Fischer344

decreased thresholds
no change in thresholds
no change in thresholds (n=9? not reported, but
Determined from degrees of freedom reported)

(Lepore, et al., 1996)

THC

1.0 & 1.5 mg/kg i.p.

Lewis ???

decreased thresholds (n not reported)

(Gardner et al., 1989)

THC

1.5 mg/kg i.p.

Lewis A-T

decreased thresholds (n=10? not reported, but
determined from degrees of freedom reported)

(Gardner, et al., 1988)

L-E

n.s. decreased response rates by 50% (n=3)
decreased response rates w/1 & 4 mg/kg (n=6)
decreased response rates w/0.32 mg/kg (n=6)

(Stark & Dews, 1980)

THC 10.0 mg/kg; oral
nabilone 0.12 - 4.0 mg/kg; oral
canbisol 0.25 & 0.32 mg/kg; oral

Rate

attenuated responding w/3.2 & 10 mg/kg (n=6)
attenuated responding w/100 & 320 μg/kg (n=5)

increased thresholds w/1.0 & 2.0 mg/kg (n=6-9)
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(Kwilasz & Negus, 2012)

Drug Dose/R.O.A.
WIN

0.1 – 3.0 mg/kg i.p.

WIN 0.1 – 3.0 mg/kg i.p.
CP
10.0 – 100.0 μg/kg i.p.
HU-210 10.0 – 100.0 μg/kg i.p.

Rat
Strain

ICSS
Test Effect

Reference

S-D

R-F

increased thresholds w/1 mg/kg (n=5-6)

(Mavrikaki, et al., 2010)

S-D

R-F

*

increased thresholds w/3 mg/kg (n=7)
increased thresholds w/100 μg/kg (n=8)
*
increased thresholds w/30 & 100 μg/kg (n=7)

(Vlachou, et al., 2005)

no change in thresholds (n=4-9)

(Vlachou, et al., 2003)

*

WIN

0.1 – 1.0 mg/kg i.p.

S-D

CP

10.0 – 50.0 μg/kg i.p.

Lewis R-F

no change in thresholds (n=7)

(Arnold, et al., 2001)

^

S-D

R-F

*

(Antoniou, et al., 2005)

levonantradol
(0.0125 - 0.3 mg/kg; s.c.)

CDF

D-T

increased thresholds w/0.2 & 0.3 mg/kg (n=4)

(Kucharski, et al., 1983)

AMG-3 1.0 – 8.0 mg/kg i.p.

R-F

increased thresholds w/8.0 mg/kg (n=14)

Endocannabinoid Enzyme/Transport Inhibitors
#

AM-404 1.0 – 30.0 mg/kg i.p.

S-D

R-F

*

(Vlachou, et al., 2008)

URB-597 0.3 – 3.0 mg/kg i.p.
%
PMSF 15.0 – 60.0 mg/kg i.p.
#
OMDM-2 3.0 – 30.0 mg/kg i.p.

S-D

R-F

*

(Vlachou, et al., 2006)

S-D

R-F

no change in responding; 0.02 mg/kg blocked
(Katsidoni, et al., 2013)
facilitation produced by 0.1 mg/kg and attenuation
by 1.0 mg/kg THC (listed above)

$

increased thresholds w/30 mg/kg (n=11)

increased thresholds w/1 and 3 mg/kg (n=7)
increased thresholds w/15, 30, & 60 mg/kg (n=7)
*
increased thresholds w/30 mg/kg (n=5)

Cannabinoid Antagonists
RIM

0.02 mg/kg
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Drug
RIM

Rat
Strain

Dose/R.O.A.
1.0 mg/kg i.p.

ICSS
Test Effect

Reference

S-D

R-F

no change in responding; 1 mg/kg blocked (n=5-6) (Kwilasz & Negus, 2012)
attenuated responding by 3.2 mg/kg THC (listed above

RIM 0.1 – 10.0 mg/kg i.p.
AM-251 0.1 – 10.0 mg/kg i.p.

L-E

R-F

!

RIM

0.02 mg/kg i.p.

S-D

R-F

no change in thresholds (n=6), blocked threshold (Vlachou, et al., 2008)
increase by 30 mg/kg AM-404 (n=6) (listed above)

RIM

0.02 mg/kg i.p.

S-D

R-F

no change in thresholds, blocked threshold increase (Vlachou, et al., 2007)
by 2 mg/kg THC (n=6) (listed above)

RIM

0.02 – 1.0 mg/kg i.p.

S-D

R-F

no change in thresholds; 0.02 mg/kg blocked
threshold increase by URB-597 and OMDM-2
(n=5-7) (listed above)

RIM

0.02 – 3.0 mg/kg i.p.

S-D

R-F

no change in thresholds (n=9), blocked threshold (Vlachou, et al., 2005)
increase by 100 μg/kg CP (n=9) and 3 mg/kg WIN
(n=11) with 0.02 mg/kg SR

S-D

R-F

no change in thresholds (n=6), blocked threshold
increase by 100 μg/kg HU-210 (n=6) with 1 & 3
mg/kg AM251 (listed above)

W-f

R-F

decreased responses on FR10 schedule of ICSS
(De Vry, et al., 2004)
w/3 & 10 mg/kg SR (n=3-12) (note: also reduced
operant responding for food in female and male rats
w/1, 3, & 10 SR)

AM-251 1.0 & 3.0 mg/kg i.p.

RIM

1.0 – 10.0 mg/kg i.p.

increased thresholds w/10 mg/kg (n=6-7)
no change in thresholds (n=7-9)

(Xi et al., 2008)

!
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(Vlachou, et al., 2006)

Drug Dose/R.O.A.

Rat
Strain

ICSS
Test Effect

Reference

RIM

0.02 & 0.3 mg/kg i.p.

S-D

R-F

no change in thresholds (n=9) (note: reversed the
effects of WIN, which blocked cocaine-induced
threshold decreases) (listed above)

(Vlachou, et al., 2003)

RIM

1.0 – 20.0 mg/kg i.p.

S-D

R-F

increased thresholds w/20 mg/kg SR (n=6)
(listed above)

(Arnold, et al., 2001)

RIM 0.3 – 10.0 mg/kg i.p.
2001)

S-D

R-F

increased thresholds w/1, 3, and 10 mg/kg (n=8)

(Deroche-Gamonet, et al.,

AM-251

3.0 mg/kg i.p.

L-E

MT

decreased the price (lever press duration) able to
sustain ICSS responding without significantly
affecting frequency threshold (n=8)

(Trujillo-Pisanty, et al., 2011)

AM-251 1.0 mg/kg i.p.

S-D

R-F

no change in thresholds (n=14), blocked threshold (Antoniou, et al., 2005)
increase by 8 mg/kg ^AMG-3 (n=14) (listed above)

Table 1 was adapted from (Panagis, Vlachou, & Nomikos, 2008) and expanded upon.
Symbol definitions: *effect was also blocked by a CB1 antagonist, ^∆(8)-THC analogue with cannabimimetic properties, $FAAH
inhibitor, #purported AEA uptake/transport inhibitor, %nonselective serine protease inhibitor (non-selectively inhibits FAAH),
!
produced a reduction in cocaine-facilitated ICSS.
Abbreviations: R.O.A. = route of administration, S-D = Sprague-Dawley, L-E = Long-Evans, CDF = albino CDF, W-f = Wister
(female), R-F = rate frequency, A-T = auto-titration, Rate = stimulation parameters were not varied and rate was measured, DT =
discrete trials, MT = reinforcement mountain, THC = tetrahydrocannabinol, RIM = rimonabant, WIN = WIN 55212-2 a synthetic full
agonist at the CB1 receptor, AEA = anandamide, CP = CP 55,940 a synthetic full agonist at the CB1 receptor, n.s. = not statistically
significant, levonantradol = CP 50,556-1
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The results with CB1 antagonists in ICSS provide evidence that the endocannabinoid
system is involved in mesolimbic reward. Since high doses of CB1 antagonists can reduce ICSS,
it may indicate that endocannabinoid tone is necessary to produce normal mesolimbic reward
functioning. If blockade of endocannabinoid tone reduces responding for mesolimbic activation,
2-AG and/or AEA may be necessary for normal functioning in that system. It is important to
note however, that rimonabant has also been shown to disrupt other behaviors, including operant
responding for food, so the effect may not be specific to brain stimulation reward (De Vry, et al.,
2004; Marusich & Wiley, 2012).
Cannabinoid Activity in the Mesolimbic System
As briefly discussed earlier, the mesolimbic system is a dopaminergic signaling pathway
that contains projections and interconnections to and from the ventral tegmental area (VTA),
amygdala, hippocampus, and prefrontal cortex, and to the nucleus accumbens. It is largely
comprised of dopaminergic projections from the VTA, and is innervated by many excitatory and
inhibitory inputs including glutamatergic and GABAergic inputs (Bielajew & Shizgal, 1986).
This system has been studied exhaustively as a potential common pathway of drug and non-drug
reward and reward-motivated behavior, and it has been reported that ICSS activates this system
and increases dopamine in this system (Cheer, Wassum, et al., 2007; Neill, et al., 2002; R. A.
Wise, 2005). Many psychomotor stimulants including cocaine and amphetamine interact with
this pathway due to their direct activity at dopaminergic neurons.
Cannabinoid receptors and endocannabinoids are located within the mesolimbic system.
CB1 receptors are located in the nucleus accumbens, VTA, PFC, as well as the amygdala and
many other regions (Hrabovszky et al., 2012; Yoshida et al., 2006). Additionally, AEA and 2AG and their precursors have been found throughout these regions (Matyas et al., 2008; Melis et
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al., 2006; Yoshida, et al., 2006). Also, of interest to this study, the biosynthetic enzyme of 2-AG,
diacylglycerol lipase (DAGL) is found in the membranes of dopaminergic neurons in the VTA
(Matyas, et al., 2008; Yoshida, et al., 2006), though CB1 receptors are not present on those
neurons. Specifically, CB1 receptors have been found within GABAergic and glutamatergic
terminals in the VTA and nucleus accumbens (Kortleven, Fasano, Thibault, Lacaille, & Trudeau,
2011; Matyas, et al., 2008). The presence of cannabinoid receptors and endocannabinoids in
these regions suggests a role for cannabinoid modulation of dopamine release.
Interestingly, rat studies with exogenous cannabinoids have been shown to increase
dopamine release in brain regions in the mesolimbic system including the nucleus accumbens
(NAc) and prefrontal cortex. For example, i.v. administration of the CB1 agonist WIN55,212-2
increases dopamine release in the NAc core and shell (Cheer, Wassum, Heien, Phillips, &
Wightman, 2004; Tanda, Pontieri, & Di Chiara, 1997), i.v. THC mimics those effects (Tanda, et
al., 1997) Conversely, i.v. administration of the CB1 antagonist, RIM, blocks enhanced dopamine
release in the NAc shell produced by drugs of abuse such as cocaine, ethanol, nicotine, and THC
measured with in vivo voltammetry (Cheer, Wassum, et al., 2007) and microdialysis (Tanda, et
al., 1997). Furthermore, THC has been shown to strain-dependently enhance dopamine release
in the nucleus accumbens and medial prefrontal cortex (J. Chen, Paredes, Lowinson, & Gardner,
1990; J. P. Chen et al., 1990; J. P. Chen, Paredes, Lowinson, & Gardner, 1991). In another study,
i.v. administration of THC was shown to produce increases in striatal dopamine release
measured with microdialysis (Malone & Taylor, 1999). Further evidence of cannabinoid
involvement in the mesolimbic system shows that micro-injection of THC into the VTA also
enhances dopamine release (J. Chen, Marmur, Pulles, Paredes, & Gardner, 1993). In addition to
these data, cannabinoid agonists have been shown to increase dopaminergic neuron firing in the
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rat VTA, which has projections to the nucleus accumbens. This effect has been shown with i.v.
administration of the cannabinoid agonists THC, WIN 55,212-2, and CP 55,940 measured by
whole cell electrophysiology (French, 1997; French, Dillon, & Wu, 1997; Gessa, Melis,
Muntoni, & Diana, 1998). These studies suggest that cannabinoids may produce rewarding
effects through a similar mechanism to other drugs of abuse including psychomotor stimulants
and opiates.
A generally accepted theory of how cannabinoids may modulate activity in the
mesolimbic system was proposed by Carl Lupica’s group in 2005. As mentioned earlier, CB1
receptors are generally located on pre-synaptic neuron terminals where their activation reduces
the release of a specific neurotransmitter from that terminal (Cadogan, et al., 1997; Katona, et al.,
2000; Robbe, et al., 2001). Additionally, GABAergic projections are responsible for tonic
inhibition of spontaneous dopamine firing in the VTA, while glutamatergic projections excite
dopaminergic neurons, as depicted on Fig. 2. Lupica and colleagues propose that CB1 stimulated
dopamine release is maintained through CB1 receptors on GABAergic primary and interneurons
projecting onto dopaminergic neurons in the VTA (Lupica & Riegel, 2005). By reducing
GABAergic signaling, which normally inhibits dopaminergic activity, it could result in a
functional increase in dopamine. It is important to note though, that CB1 receptors are located on
GABAergic neuron terminals, (Fernandez-Ruiz, Hernandez, & Ramos, 2010; Katona, et al.,
2000; Ong & Mackie, 1999) as well as on glutamatergic and cholinergic neuron terminals
(Fernandez-Ruiz, et al., 2010; Lu, Ong, & Mackie, 1999; Ong & Mackie, 1999). In contrast to
GABAergic CB1 receptor activation, CB1 receptors on glutamate neurons can reduce
spontaneous dopaminergic neuron firing (Fig. 2). There is evidence however, that CB1 receptors
are found in higher levels in GABAergic interneurons than on cholinergic or glutamatergic
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projecting neurons, which indicates they may be more sensitive to cannabinoid activation
(Marsicano & Lutz, 1999). Additionally, electrophysiology data shows that the cannabinoid
agonist, WIN55,212-2 is more potent at reducing neuronal transmission in GABAergic neurons
than glutamatergic neurons (Hajos & Freund, 2002a, 2002b; Ohno-Shosaku et al., 2002).
This evidence supports observations that cannabinoids can produce biphasic effects in
some behavioral tests measuring reward or reinforcement, and may only do so within a limited
dose-range. High doses of CB1 agonists produce different effects than low doses, which may
indicate the balance of CB1 receptor activation shifts from GABAergic to
glutamatergic/cholinergic in the VTA.
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Figure 2. A depiction of cannabinoid receptors and endocannabinoid activity on GABAergic and
glutamatergic axons projecting to dopaminergic neurons in the ventral tegmental area (VTA).
Cannabinoid receptor activation on GABAergic neurons increases dopaminergic firing, while
activation of cannabinoid receptors on glutamatergic neurons produces the opposite effect.
Figure adapted from (Lupica & Riegel, 2005).
Rationale
Although reward-associated effects of cannabinoids are difficult to assess using
preclinical measures, there is much evidence that marijuana produces positive subjective effects
in humans, including positive subjective effect ratings associated with marijuana use (Hart, et al.,
2010; Hart, et al., 2001), and brain imaging studies implicating reward-relevant brain areas
during marijuana cue presentations in marijuana-dependent individuals (Goldman, et al., 2013).
Several studies have demonstrated that THC facilitates ICSS (Gardner, et al., 1988; Lepore, et
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al., 1996), which suggests that ICSS may allow for evaluation of reinforcement-potentiating
effects associated with cannabinoids. Additionally, blockade of CB1 receptors has been shown to
reduce ICSS behavior, which provides further evidence that the endocannabinoids and
cannabinoid receptors are involved in mesolimbic brain functioning.
Neurochemical correlates associated with other drugs of abuse in the mesolimbic system
are also observed during cannabinoid administration. For example, exogenous cannabinoids
increase dopamine release in brain areas including the nucleus accumbens and prefrontal cortex
as measured with in vivo microdialysis or voltammetry (Cheer, et al., 2004; Cheer, Wassum, et
al., 2007; J. Chen, et al., 1993; J. Chen, et al., 1990; J. P. Chen, et al., 1991; Malone & Taylor,
1999; Ng Cheong Ton et al., 1988; Tanda, et al., 1997). Additionally, cannabinoid agonists have
been shown to increase dopaminergic neuron firing in the rat VTA (French, 1997; French, et al.,
1997; Gessa, et al., 1998), suggesting they activate the mesolimbic system, and may in fact
potentiate reinforcement produced by stimulation of the medial forebrain bundle.
Almost all of the findings with THC and reward-related behaviors discussed above have
been demonstrated in rats. However, there are far fewer studies investigating these effects in
mice. As shown on table 1, there have been no studies involving cannabinoid agonists or
antagonists with ICSS in mice. C57BL/6 mice are known to engage in certain drug-taking
behaviors that other strains and species do not, such as freely drinking unsweetened ethanol
diluted with water (Elmer, Meisch, & George, 1987). Furthermore, alcohol has been shown to
facilitate ICSS in mice (Fish et al., 2010), while producing mixed effects in rats depending on
strain and ICSS assay used (Carlson & Lydic, 1976; Schaefer & Michael, 1992; Schaefer,
Richardson, Bonsall, & Michael, 1988). Additionally, there have been three studies
demonstrating self-administration of i.v. WIN55,212-2 in mice (Flores, et al., 2013; Martellotta,

29

et al., 1998; Mendizabal, Zimmer, & Maldonado, 2006), and reports of increases in dopamine in
the nucleus accumbens with systemic administration of the synthetic cannabinoid agonist
WIN55,212-2, which suggests that this strain may be a good candidate to observe ICSS
facilitation with cannabinoids, and demonstrate cannabinoid rewarding effects in a preclinical
mouse model (Robledo, Trigo, Panayi, de la Torre, & Maldonado, 2007).
The effects of THC and selective FAAH, MAGL and combined FAAH/MAGL
inhibitors have not been investigated in mouse ICSS assays. Furthermore, no published studies to
date have evaluated MAGL inhibitors, or the FAAH inhibitor PF-3845 in any species with ICSS.
In this study, we assessed THC and selective inhibitors of FAAH, MAGL, and a novel dual
FAAH/MAGL using ICSS to infer the consequences of increased endocannabinoid levels on
operant responding for electrical stimulation of the medial forebrain bundle. Mechanism of
action for any observed effects were evaluated with CB1 and CB2 antagonism tests. We also
investigated spontaneous locomotor behavior and operant responding for food pellets in order to
ascertain whether these pharmacological treatments affected other behavioral measures in a
similar fashion as ICSS. Additionally, we measured brain endocannabinoid levels in regions
associated with the mesolimbic system including the prefrontal cortex, ventral mid-brain
(approximation of VTA), nucleus accumbens and amygdala after specific enzyme inhibitor
treatments to determine changes after drug treatment. The cerebellum was assessed as a nonmesolimbic region.
Overall Hypothesis
Cannabinoid agonists and endocannabinoid enzyme inhibitors will potentiate
reinforcement maintained by self-stimulation of the medial forebrain bundle in C57BL/6 mice.
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Selection of Pharmacological Agents
The CB1 agonist THC was assessed in ICSS to determine the effect of the primary active
constituent in marijuana. The MAGL inhibitor JZL184 was used to assess elevation of 2-AG and
other effects attributable to MAGL inhibition. JZL184 is a selective and readily available MAGL
inhibitor that is irreversible, and has been shown to produce 10-fold elevations in whole mouse
brain 2-AG that persist over 12 hours after administration (J. Z. Long, Li, et al., 2009). JZL184
also produces increases of interstitial 2-AG in the mouse nucleus accumbens, and although it has
been shown to inhibit FAAH when given repeatedly, it does not affect interstitial AEA levels
when give acutely (Wiskerke, et al., 2012). The FAAH inhibitor PF-3845 was used to assess
consequences of preventing AEA degradation, and other effects attributable to FAAH inhibition.
PF-3845 is highly selective for FAAH inhibition and also produces up to 10-fold increases of
AEA that persist over a similar time-course as JZL184 increasing levels of 2-AG (Ahn, et al.,
2009). The dual (FAAH/MAGL) inhibitor SA-57 was used to assess the effects of combined
inhibition of both endocannabinoid degrading enzymes on ICSS responding. SA-57 produces
dose-related elevations in AEA and 2-AG, and has a higher affinity for FAAH than MAGL
(Niphakis, et al., 2012). Cocaine HCl was used as a positive control, as it reliably facilitates
ICSS in a robust fashion (Corbett, 1991; Fish, et al., 2012; Robinson, et al., 2012).
Methods
Subjects
A total of 245 male C57Bl/6 mice aged 8 – 10 weeks (22-30g), obtained from Jackson
Laboratories (Bar Harbor, Maine) were used for the experiments described (78 for ICSS studies,
13 for operant studies, 90 for endocannabinoid measurement, and 64 for locomotor activity
studies). Mice were between 8 and 12 weeks of age at the time of either surgery, brain dissection
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for endocannabinoid quantification, operant training, or locomotor activity testing. Mice were
maintained on a 12:12 hour light/dark cycle beginning at 6:00 AM, individually housed, and
given free access to food and water. All experiments were conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals, and have been approved by the Virginia
Commonwealth University Institutional Animal Care and Use Committee (IACUC).
Drugs
Cocaine HCl (obtained from NIDA drug supply) was dissolved in 0.9% saline. JZL184,
rimonabant, SR144528, and THC (obtained from NIDA drug supply) SA-57 (obtained from
Micah Niphakis, TSRT, La Jolle, CA), and PF-3845 (obtained from Organix, Woburn, MA) was
dissolved in a vehicle solution (VEH) of 1 part ethanol, 1 part Emulphor-620 (Rhone-Poulenc,
Princeton, NJ), and 18 parts 0.9% saline (1:1:18).
Apparatus
ICSS testing was conducted using eight standard (18 X 18 X 18 cm) mouse operant
conditioning chambers (Med Associates Inc., St. Albans, VT, USA). Each chamber was
equipped with a retractable lever located in the right-hand position on the front chamber wall, 2
LED stimulus lights, a chamber house-light, and a tone-generator. The outside of each chamber
was equipped with a suspended electrical commutator connected to a shock generator, as well as
to a tether that is fed through a hole in the top of the chamber, in order to be connected to the
electrode attached to a mouse. Chambers were enclosed within sound and light attenuating
chambers equipped with exhaust fans. MED Associates Inc. software was used to control
manipulations in the operant chambers and record data during training and testing sessions.
Operant responding for food tests were conducted in mouse operant conditioning chambers (Med
Associates Inc.) similar to those described above. Each chamber was equipped with two nose
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poke apertures (instead of levers), a food hopper to deliver sweetened food pellets (Bio-Serv) to
a recessed well within the chamber. All other aspects of the chamber were identical to those used
for ICSS testing, except they lack tone generators, and all equipment related to electrical
stimulation, including commuators, tethers, etc. Locomotor activity testing was conducted in
Plexiglas boxes (17.5 X 8.5 X 8 in) with plastic floor inserts, capped with clear Plexiglas lids,
and enclosed within light and sound attenuating chambers. Locomotor activity was recorded
during the tests, using Unibrain Fire-I digital cameras and analyzed using ANY-maze software
(Stoelting, Kiel, WI) track and quantify movements.
Stereotaxic Surgery
Surgical procedures for implanting electrodes in mice for ICSS studies were similar to
those previously reported (Carlezon & Chartoff, 2007). Mice were anesthetized with isoflurane
and received constant delivery during surgical procedures. Bipolar twisted stainless steel
electrodes (0.125 mm single wire diameter without insulation; Plastics One, Roanoke, VA) were
implanted into the right medial forebrain bundle of the mice using coordinates similar to those
reported by Straub and colleagues: 2.0 mm posterior of bregma, 0.8 mm lateral from midline,
and 4.8 mm below dura (Straub, Carlezon, & Rudolph, 2010). After the hole for the electrode
was drilled, three holes were bored into the skull surrounding the area the electrode would be
placed, anchoring screws were secured in those holes. Finally, an electrode was inserted and
fixed to the skull using dental cement. Mice were given post-operative care for five days
following surgery including treatment with bacitracin and acetaminophen, and were introduced
to operant chambers one week after surgery.
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Behavioral Procedures
Locomotor activity. Mice were acclimated to testing room 24 hours before testing
began. After mice were given selected drugs/doses, they were returned to their home cages for
two hours. Following the two hour pre-treatment time mice were immediately placed in the
Plexiglas activity observation boxes and recording using Any-maze software (Stoelting, Kiel,
WI) began. Activity was assessed for 25 minutes and mice were returned to home cages at the
conclusion of the test. All tests were recorded, and distance travelled, time-immobile, and
adjusted speed (distance/time – time immobile) was calculated. Box assignment and time-of test
were counter-balanced between the different drug/dose conditions. Separate groups of mice were
used for each treatment condition. Mice were exposed to the Plexiglas observation boxes once
under a single experimental condition to prevent habituation from altering results.
Operant responding for food. Mice were initially food deprived to 85% of their free
feeding weight, before being exposed to operant chambers. During 15 minute operant sessions,
mice were assigned one nose-poke aperture, while the aperture on the opposite side of the
chamber was blocked with a rubber stopper to prevent spontaneous responding. Responding in
the aperture under a fixed ratio 1 (FR-1) schedule of reinforcement resulted in delivery of 1 food
pellet reinforcers (Bio-Serv), and FR value was gradually increased to a FR-10 schedule of
reinforcement. A computer with logic interface and MED-PC software (Med Associates) was
used to manipulate rate of reinforcement and record data from training and test sessions. Mice
began testing when they maintained at least 20 responses per minute, and total responses
remained within 10% of the prior 2 training days for at least 3 consecutive training days. These
criteria were evaluated before every operant test was conducted, also ensuring that mice had a
minimum of 96 hours between testing conditions. Subjects were given a minimum 1 week wash-
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out period before beginning testing a new compound. On test days, mice were injected in the
testing room, and allowed to remain in home cages during the given pre-treatment time. Vehicle
(VEH) solution tests were conducted at the beginning and end of every dose-effect curve to
assess response rate stability over time. Dose conditions were tested using a quasi-randomized
design to control for order effects.
ICSS. Seventy-eight mice were implanted with electrodes, twenty-one mice were able to
complete at least one experiment, while fifty-seven mice either didn’t reach testing criteria, or
lost electrode viability before completing a single test series. After recovery, mice began leverpress training. Mice were trained to lever press on a fixed-ratio 1 (FR1) schedule of
reinforcement, where each lever press delivered a 0.5-s train of square-wave cathodal pulses
(0.1-ms pulse duration) at a frequency of 141 Hz, and was accompanied by a stimulus light,
house light, and tone cue presentation. Amplitudes of stimulation were adjusted for each mouse
on an individual basis to produce maximal responding at this stage. Mice were exposed to daily
30 - 60 min FR1 training sessions until they maintained stable responding at a reasonable
response rate (i.e. ≥ 35 responses per minute). Stimulation amplitudes were adjusted individually
between 20 and 300 μA in order to maintain maximal rates before testing began.
After stable responding was maintained, mice were moved to rate-frequency training.
During rate-frequency training mice were presented with and allowed to respond for a series of
10 descending stimulation frequencies at 0.05 log unit increments (56-158 Hz), in contrast to
only being exposed to one frequency (141 Hz) during FR training. During each frequency
presentation within each series, mice were first given a 5 s time-out in which levers were not
present in the boxes, followed by 5 s during which the lever was extended and 5 non-contingent
stimulations at a given frequency were delivered, followed by a 60 s period when they were
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allowed to respond for stimulations at that specific frequency. The lever was then retracted, the
stimulation frequency decreases by 0.05 log units, and the next frequency presentation begins.
For example the first frequency presentation is 158 Hz, after the 60 s response period has
concluded, and mice were allowed to respond for 141 Hz for the next 60 s, followed by 126, and
so on until they are presented with the tenth and last frequency (56 Hz), which concluded the
series. These frequency presentation series’ were repeated between 3 and 5 times per training
session. Current amplitudes were further individually adjusted if needed for each subject to
maintain ≥ 50% baseline maximal responding in at least three and fewer than eight frequencies.
The first series of frequency presentations each day was considered a daily “warm-up” period
and data is excluded from all analyses. The next two series were averaged together to create the
baseline response curve for that day. Following a given treatment, mice were again allowed to
respond for two series of frequencies, which were averaged together for analysis. When the total
responses during baseline varied by less than 20% within each mouse for 3 consecutive days of
assessment, and VEH/saline tests produced between 80 and 120% of baseline responding for at
least two consecutive assessments, and visual analysis of rate-frequency curves confirmed they
were curvilinear, mice were deemed able to begin testing.
On test days, mice were placed in the chambers and allowed to respond during the
“warm-up” and baseline phases. Immediately after baseline responding, mice were removed
from operant chambers, placed in their home cages, injected with drug, saline, or VEH, and
returned to home cages for pre-treatment time before beginning testing. Mice were then returned
to the operant chambers to respond during two additional series of frequency presentations,
which were considered the test series. Mice first received injections of vehicle (VEH) and/or
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saline to ensure that neither solution affected the frequency response curves before beginning
dose response curves.
Drugs were tested with a minimum of 72 hours between tests, and at least 1 week
between drugs, to ensure drug clearance and baseline assessments were made before all tests, to
ensure the subjects were responding normally before drugs are administered. VEH or saline tests
were conducted before and after determining dose-effect curves to ensure that conditioned
effects did not develop over time, and that baselines remained stable throughout the course of the
experiment. Mice were exposed to doses in ascending or descending order in a counter-balanced
design. Antagonist test conditions were tested in a quasi-randomized order. This study used a
mixed design wherein some subjects completed only one drug curve, and other subjects
completed all drug tests. All drugs tested included some drug-naïve subjects. Cannabinoid effects
on ICSS were reproducible over time during time-course and antagonist testing.
Analytical Procedures
Tissue extraction and quantification of AEA, 2-AG and AA. Drug naïve subjects were
injected with VEH, JZL184 (4.0 and 40.0 mg/kg) or SA-57 (1.0 or 10.0 mg/kg) i.p. two hours
prior to sacrificing. Immediately following cervical dislocation and decapitation, brains of C57
male mice were removed, dissected, and the prefrontal cortex, nucleus accumbens, ventral midbrain, amygdala, and cerebellum were removed. The selected brain regions of interest were
dissected from whole fresh brains. The prefrontal cortex was dissected by making a cut at the
posterior extent of the anterior olfactory nucleus after which the olfactory nuclei were removed.
This sample included frontal association, primary and secondary motor, anterior cingulate,
prelimbic and orbital frontal cortices. The next cut was made anterior to the optic chiasm to
produce a thick coronal section. The nucleus accumbens was dissected by removing the cortex
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ventrally and the septum and nucleus of the horizontal limb of the diagonal band medially and
then collecting the tissue surrounding the anterior commissure. The amygdala (including the
central nucleus, basolateral and basomedial nuclei) dissection was made by first cutting caudal to
the optic chiasm, and then making a second cut directly caudal to the median eminence. The
amygdala was isolated by removing piriform cortex lateral of the amygdala and taking the region
included in the bifurcated corpus collosum and all regions ventral to that. The ventral midbrain
dissection was made by making a cut rostral to the cerebellar peduncles, then removing the
remaining hypothalamic subregions ventrally and substantia nigra laterally. Isolation of ventral
midbrain was made by removing the remaining regions below the red nucleus and includes the
ventral tegmental area and interfascicular nucleus. The cerebellum was then removed from the
brain stem.
On the day of processing, the pre-weighed tissues were homogenized with 1.4 ml
chloroform: methanol (2:1 v/v containing 0.0348g PMFS/ml) after the addition of internal
standards to each sample (2 pmole AEA –d8, 1 nmole 2-AG-d8 and 1 nmole AA-d8).
Homogenates were then mixed with 0.3 ml of 0.73% w/v NaCl, vortexed and then centrifuged
for 10 min at 2054g (4 C). The aqueous phase plus debris were collected and extracted again
twice with 0.8 ml chloroform. The organic phases from the three extractions were pooled and the
organic solvents were evaporated under nitrogen gas. Dried samples were reconstituted with 0.1
ml chloroform and mixed with 1 ml cold acetone. The mixtures were then centrifuged for 5 min
at 2054g and 4 C to precipitate the proteins. The upper layer of each sample was collected and
evaporated under nitrogen. Dried samples were reconstituted with 0.1 ml methanol and placed in
autosample vials for analysis.
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LC/MS/MS was used to quantify AEA, 2-AG and AA. The mobile phase consisted of
(10:90) water: methanol with 0.1% ammonium acetate and 0.1% formic acid. The column used
was a Discovery  HS C18, 2.1* 150 mm, 3 micron (Supelco, USA). Ions were analyzed in
multiple reaction monitoring mode and the following transitions were monitored in positive
mode: (348>62) and (348>91) for AEA; (356>62) for AEA-d8; (379>287) and(379>269) for 2AG ; (387>96) for 2AG-d8; (300>62) and in negative mode : (303>259) and (303>59) for AA
and (311>267) for AA-d8. A calibration curve was constructed for each assay based on linear
regression using the peak area ratios of the calibrators. The extracted standard curves ranged
from 0.039 pm to 40 pm for AEA, from 0.0625nm to 64 nm for 2-AG and from 1 nm to 32 nm
for AA.
Data Analysis
The independent variable measured in the ICSS studies was stimulations per min during
each frequency trial. ICSS response data were evaluated using two separate methods. In the first
method, data were normalized to the highest response rate recorded during the baseline ratefrequency curve generated for each individual mouse. This transformation allowed us to display
the data as the percent maximum control rate (% MCR) and normalized individual response rates
between subjects. These data were used to generate the rate-frequency curves which were
assessed using repeated-measures, two-way ANOVAs (treatment x frequency) between baseline
and treatment curves for each drug/dose tested. Holm-Sidak tests were used for post-hoc
analyses of rate-frequency results which allowed multiple comparisons at all frequencies.
A second method to analyze the data was also used in order to perform between-dose
comparisons, and provide summary data. The total number of stimulations during the test series
was divided by the total number of responses during the baseline series and multiplied by 100 to
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produce percent baseline stimulations (% Baseline Stimulations) (Negus, Morrissey, Rosenberg,
Cheng, & Rice, 2010). This effectively collapsed all the separate frequency stimulation rates into
an overall stimulation count and allowed for comparison of data between days/treatments. This
calculation was performed for all doses of each drug and VEH/saline and those values were
analyzed using repeated-measures one-way ANOVAs. Dunnett’s post-hoc test were used
following significant ANOVAs to compare treatment groups to VEH controls.
Distance travelled, time-immobile, and adjusted mean speed (distance/(time – time
immobile)) were observed during locomotor activity studies and analyzed using independent
sample 1-way analysis of variance (ANOVA), and followed up with Dunnett’s post-hoc tests. In
the operant responding for food studies response rate was the independent variable of interest,
and was analyzed using repeated-measures 1-way ANOVAs, post-hoc analyses were conducted
using Dunnett’s post-hoc test. Brain endocannabinoid and AA levels (pm/g or nm/g) were
analyzed using individual one-way ANOVA for each brain region and substrate measured.
Significant ANOVAs were assessed using Dunnett’s post-hoc analysis.
Results
Cocaine ICSS Dose-Response Assessment
This study evaluated the ability of cocaine to facilitate ICSS in C57Bl/6 mice. Seven
mice were assessed with ICSS after saline and cocaine (1.0, 5.0 and 10.0 mg/kg), and data were
analyzed using repeated-measures two-way ANOVAs (treatment x frequency) for each test
conducted. Saline and 1.0 mg/kg cocaine did not affect ICSS responding, while 5.0 and 10.0
mg/kg cocaine significantly facilitated self-stimulations. Saline produced a main effect of
frequency (F 9, 54 = 47.16, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.005, p > 0.05),
and no interaction (F 9, 54 = 1.83, p > 0.05) (Fig. 3a); similarly, 1.0 mg/kg cocaine showed a main
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effect of frequency (F 9, 36 = 48.23, p < 0.0001), but no main effect of treatment (F 1, 4 = 0.09, p >
0.05), and no interaction (F 9, 36 = 1.83, p > 0.05) (Fig. 3b). Higher doses of cocaine (5.0 and 10.0
mg/kg) significantly and robustly facilitated ICSS. Cocaine (5.0 mg/kg) had a main effect of
frequency (F 9, 54 = 33.27, p < 0.0001), treatment (F 1, 6 = 76.72, p < 0.001) and an interaction (F
9, 54 =

11.52, p < 0.0001) (Fig. 3c); 10.0 mg/kg cocaine also produced a main effect of frequency

(F 9, 54 = 63.04, p < 0.0001), treatment (F 1, 6 = 37.69, p < 0.001) and an interaction between
frequency and treatment (F 9, 54 = 4.15, p < 0.001) (Fig. 3d), indicating that 5.0 and 10.0 mg/kg
cocaine facilitated ICSS responding. Post-hoc analysis revealed increases at five and seven
frequencies respectively as shown on Fig. 3c and d. Baseline rate-frequency stimulation rates did
not differ over the course of testing; there was a main effect of frequency (F 9, 36 = 81.22, p <
0.0001), but no main effect of baseline day (F 3, 12 = 0.95, p > 0.05), and no interaction (F 27, 108 =
0.82, p > 0.05) (Fig. 3e).
The percent baseline stimulations data were analyzed using a repeated-measures one-way
ANOVA. Cocaine facilitated ICSS (F 4, 12 = 18.56, p < 0.001) (Fig. 3f); post-hoc analysis showed
that 5.0 and 10.0 mg/kg cocaine produced significant facilitation of ICSS, while 1.0 mg/kg did
not differ from saline treatment. These results are in accordance with the rate-frequency analysis.
Cocaine produced a dose-related facilitation of ICSS, as has been shown in the literature.
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Figure Continued
Figure 3. Cocaine ICSS assessment. Panels a – e show rate-frequency stimulation values (±
SEM) after saline or cocaine (1.0, 5.0, and 10.0 mg/kg); percent maximum control rate is
displayed on the Y-axis, log-frequency values are shown on the x-axis. Panel e shows all
baselines during testing. Panel f shows percent baseline stimulations (± SEM) from all tests.
With rate-frequency tests, interactions that achieved significance and were accompanied by
significant post-hoc analyses are denoted by asterisks at values that are significantly different
from baseline, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates
(stimulations/min; mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a)
saline: B (31.98 ± 3.14) T (32.09 ± 3.06); (b) 1.0 mg/kg cocaine: B (27.83 ± 2.76) T (29.61 ±
5.40); (c) 5.0 mg/kg cocaine: B (31.25 ± 2.10) T (47.51 ± 2.75); (d) 10.0 mg/kg cocaine: B
(36.26 ± 4.40) T (61.44 ± 2.66).
THC ICSS Experiments
THC dose-response assessment. These experiments were conducted to determine the
effect of THC on brain-stimulation reinforcement. ICSS was assessed in seven mice after
treatment of vehicle (VEH) and THC (0.3, 1.0, 3.0, 5.6, and 10.0 mg/kg). Data were analyzed
using two-way repeated-measures ANOVAs (treatment x frequency) for each condition.
Analysis of rate frequency data showed that VEH, 0.3 and 1.0 mg/kg THC did not alter
responding from baseline while 3.0, 5.6, and 10.0 mg/kg THC reduced ICSS. With VEH, there
was a main effect of frequency (F 9, 54 = 52.09, p < 0.0001), but no main effect of treatment (F 1, 6
= 1.21, p > 0.05) and no interaction (F 9, 54 = 1.03, p > 0.05) (Fig. 4a). THC (0.3 mg/kg) produced
a main effect of frequency (F 9, 54 = 71.93, p < 0.0001), but no main effect of treatment (F 1, 6 =
4.28, p > 0.05) and no interaction (F 9, 54 = 1.13, p > 0.05) (Fig. 4b). Similarly, 1.0 mg/kg THC
produced a main effect of frequency (F 9, 54 = 60.20, p < 0.0001), but no main effect of treatment
(F 1, 6 = 3.16, p > 0.05) and no interaction (F 9, 54 = 0.67, p > 0.05) (Fig. 4c). As mentioned above,
3.0 mg/kg THC led to a significant reduction of ICSS; there were significant main effects of
frequency (F 9, 54 = 53.27, p < 0.0001) and drug treatment (F 1, 6 = 8.15, p < 0.05). However, the
interaction between treatment and frequency did not achieve significance (F 9, 54 = 1.83, p > 0.05)
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(Fig. 4d). Higher doses of THC (i.e., 5.6 and 10 mg/kg) also produced significant decreases in
ICSS. THC (5.6 mg/kg) produced main effects of frequency (F 9, 54 = 44.15, p < 0.0001) and
treatment (F 1, 6 = 13.54, p < 0.05), but no interaction (F 9, 54 = 1.05, p > 0.05) (Fig. 4e). THC
(10.0 mg/kg) produced main effects of frequency (F 9, 54 = 46.58, p < 0.0001) and treatment (F 1,
6=

60.55, p < 0.001) as well as an interaction (F 9, 54 = 5.83, p < 0.0001) (Fig. 4f). Post-hoc

analysis showed that stimulations were significantly reduced at eight frequencies, which are
denoted on Fig. 4f. These findings indicated that THC (3.0, 5.6, and 10.0 mg/kg) reduced ICSS.
All baseline rate-frequency curves were analyzed after all doses were assessed in order to
ascertain if ICSS behavior differed over time (Fig. 5a). Two-way ANOVA revealed a main effect
of frequency (F 9, 54 = 46.58, p < 0.0001), but no main effect of baseline day (F 6, 36 = 0.70, p >
0.05) and no interaction between treatment and baseline day (F 54, 324 = 1.2, p > 0.05).
Additionally, a second VEH test was conducted and compared to the initial VEH assessment and
showed VEH tests did not differ (Fig. 5b). There was a main effect of frequency (F 9, 54 = 68.82,
p < 0.0001), but no main effect of treatment (F 1, 6 = 0.24, p > 0.05) and no interaction (F 9, 54 =
0.91, p > 0.05). These findings indicate that ICSS remained stable throughout the course of this
experiment.
Percent baseline stimulations were calculated and evaluated using one-way repeated
measures ANOVA. VEH percent baseline stimulations were used for comparison. THC reduced
percent baseline stimulations (F 6, 30 = 24.14, p < 0.0001). The three lowest doses of THC (0.3,
1.0, and 3.0 mg/kg) did not differ from VEH (Fig. 6). In contrast, the higher doses of THC (i.e.,
5.6 and 10.0 mg/kg) did significantly reduce percent baseline stimulations. Post-hoc analysis
showed that the respective doses of THC produced 73.56 % and 30.71% baseline stimulations
and were significantly lower (p < 0.05; p < 0.01) than VEH percent baseline stimulations (Fig.
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6). These results confirm rate-frequency analysis that 5.6 and 10.0 mg/kg THC produced a
significant reduction of ICSS. Interestingly, rate-frequency analysis showed 3.0 mg/kg THC
produced a small reduction in ICSS, but that effect was not detected when analyzing percent
baseline stimulations.
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Figure 4. THC ICSS dose-response assessment. Panels a – f show rate-frequency stimulation
values (± SEM) after VEH or THC (0.3, 1.0, 3.0, 5.6, and 10.0 mg/kg); percent maximum
control rate is displayed on the Y-axis, log-frequency values are shown on the x-axis. Significant
main effects of treatment are denoted by asterisks by the figure legend; interactions that achieved
significance and were accompanied by significant post-hoc results and are denoted by asterisks
at values that are significantly different from baseline. ****p < 0.0001, ***p < 0.001, **p <
0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ± SEM) during baseline (B)
and test (T) sessions were as follows: (a) VEH: B (27.67 ± 2.98) T (27.25 ± 3.23); (b) 0.3 mg/kg
THC: B (30.94 ± 3.72) T (28.93 ± 4.15); (c) 1.0 mg/kg THC: B (29.49 ± 3.52) T (27.16 ± 3.85);
(d) 3.0 mg/kg THC: B (30.61 ± 5.21) T (26.72 ± 4.39); (e) 5.6 mg/kg THC: B (35.06 ± 4.84) T
(25.22 ± 4.17); (f) 10.0 mg/kg THC: B (33.47 ± 4.60) T (10.85 ± 2.77).
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Figure 4. Baseline ICSS tests. Mean rate-frequency stimulation values (± SEM) during (a)
baselines of THC tests and (b) comparing initial VEH tests to VEH tests after THC testing was
completed. Percent maximum control rate is displayed on the Y-axis, log-frequency values are
shown on the x-axis. Raw overall response rate (stimulations/min; mean ± SEM) during VEH 1
was (27.25 ± 3.23) and VEH 2 was (28.81 ± 3.53) (Panel b).
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Figure. 6. THC ICSS percent baseline stimulations. Fig. 6 shows percent baseline stimulations
(± SEM) from all THC tests. The one-way ANOVA was significant and post-hoc analysis
showed significant differences from VEH, which are denoted with asterisks. ****p < 0.0001,
***p < 0.001, **p < 0.01, *p < 0.05
THC time-course assessment. This study was conducted to assess the time-course of the
ICSS rate-reduction produced by 10.0 mg/kg THC. Seven mice completed THC time-course
testing, in which ICSS was assessed at 5 min, as well as 0.5, 2, 4, 8, 24, and 48 h after
administration of VEH or 10.0 mg/kg THC. Two-way repeated measures ANOVAs (Treatment x
Frequency) were used to compare rate-frequency curves of VEH and THC at each time-point.
Stimulations after 10.0 mg/kg THC were significantly reduced compared with VEH at 5 min,
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0.5, 2, 4, and 8 h after injection. Baseline rate-frequency curves between the two conditions did
not differ from each other, as indicated by a main effect of frequency (F 9, 54 = 42.73, p <
0.0001), but no main effect of treatment (F 1, 6 = 0.12, p > 0.05) and no interaction (F 9, 54 = 0.41,
p > 0.05) (Fig. 7a). At the five minute time-point, there was a main effect of frequency (F 9, 54 =
69.58, p < 0.0001) and treatment (F 1, 6 = 6.84, p < 0.05), but no interaction (F 9, 54 = 0.71, p >
0.05) (Fig. 7b). At the 30 minute time-point there was a main effect of frequency (F 9, 54 = 52.82,
p < 0.0001), treatment (F 1, 6 = 202.20, p < 0.0001) and an interaction (F 9, 54 = 9.05, p < 0.0001)
(Fig. 7c). Post-hoc analysis showed reductions at six specific frequencies which are denoted on
Fig. 7c. At the two hour time-point there was a main effect of frequency (F 9, 54 = 39.26, p <
0.0001), treatment (F 1, 6 = 82.48, p < 0.001), and an interaction (F 9, 54 = 12.44, p < 0.0001) (Fig.
7d). Post-hoc analysis showed reductions at six specific frequencies which are denoted on Fig.
7d. At the four hour time-point there was a main effect of frequency (F 9, 54 = 25.96, p < 0.0001),
treatment (F 1, 6 = 79.54, p < 0.001) and an interaction (F 9, 54 = 10.15, p < 0.0001) (Fig. 7e). Posthoc analysis revealed reductions at five specific frequencies which are denoted on Fig. 7e. Eight
hours after injection, there was a main effect of frequency (F 9, 54 = 27.45, p < 0.0001), treatment
(F 1, 6 = 50.42, p < 0.001) and an interaction (F 9, 54 = 4.22, p < 0.001) (Fig. 7f). Post-hoc analysis
showed reductions at six frequencies which are denoted on Fig. 7f. ICSS returned to VEH levels
at 24 and 48 h after administration; at 24 hours, there was a main effect of frequency (F 9, 54 =
39.08, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.55, p > 0.05) and no interaction (F
9, 54 =

0.87, p > 0.05) (Fig. 7g). Similarly, at 48 hours after injection, there was a main effect of

frequency (F 9, 54 = 37.13, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.35, p > 0.05)
and no interaction (F 9, 54 = 1.41, p > 0.05) (Fig. 7h). The reduction of ICSS produced by THC
occurs as early as five minutes after administration and returned to baseline within 24 h.
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A two-way repeated-measures ANOVA (Time-point x Treatment) was used to compare
the percent baseline stimulations of VEH and 10.0 mg/kg THC across all time-points (Fig. 8).
10.0 mg/kg THC produced a reduction from VEH percent baseline stimulations, as there was a
main effect of time-point (F 6, 36 = 44.14, p < 0.0001), treatment (F 1, 6 = 128.5, p < 0.0001) and
an interaction between time-point and treatment (F 6, 36 = 17.09, p < 0.0001). Post-hoc analysis
revealed THC reduced ICSS at 0.5, 2, 4, and 8 h, while it did not differ from VEH at 5 min, 24
and 48 h as denoted on Fig. 8. The reduction of ICSS produced by 10.0 mg/kg began 30 min
after administration, and returned to baseline levels within 24 h, which is similar to ratefrequency analysis results.
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Figure 7. THC ICSS time-course evaluation. Panels a – h show rate-frequency stimulation
values (± SEM) after VEH or THC (10.0 mg/kg) at each time-point (5 min, 0.5, 2, 4, 8, 24 and
48 h); percent maximum control rate is displayed on the Y-axis, log-frequency values are shown
on the x-axis. Significant main effect of treatment is denoted by asterisks by the figure legend.
Interactions that achieved significance and were accompanied by significant post-hoc analyses
are denoted by asterisks at values that are significantly different from VEH. ****p < 0.0001,
***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ±
SEM) during VEH (V) and 10.0 mg/kg THC (T) conditions were as follows: (a) Baseline: V
(31.2 ± 3.90) T (30.99 ± 4.36); (b) 5 min: V (28.12 ± 4.16) T (23.24 ± 3.74); (c) 30 min: V
(25.34 ± 3.36) T (7.24 ± 1.90); (d) 2 h: V (26.21 ± 3.61) T (4.51 ± 1.92); (e) 4 h: V (24.13 ±
3.57) T (6.89 ± 2.77); (f) 8 h: V (28.10 ± 3.53) T (13.61 ± 4.69); (g) 24 h: V (27.83 ± 3.50) T
(25.79 ± 4.54); (h) 48 h: V (29.14 ± 4.17) T (28.34 ± 4.43).
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Figure 8. THC ICSS percent baseline stimulations time-course evaluation. Percent baseline
stimulations (± SEM) between VEH and THC (10.0 mg/kg) tests were compared across timepoints. The two-way ANOVA was significant and post-hoc analysis showed significant
differences from VEH, which are denoted with asterisks. ****p < 0.0001
THC: Evaluation of CB1 receptors. In this study, we tested whether the CB1
antagonist/inverse agonist rimonabant (RIM) would block the rate-decreasing effects of THC
(10.0 mg/kg) on ICSS. Six mice completed testing and the data were analyzed using a withinsubjects two-way ANOVA (treatment x frequency) for each dose combination tested.
Administration of VEH with VEH did not produce a change from baseline; there was a main
effect of frequency (F 9, 54 = 69.10, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.001, p
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> 0.05) and no interaction (F 9, 54 = 1.21, p > 0.05) (Fig. 9a). Combined treatment of VEH and
10.0 mg/kg THC reduced stimulations from baseline similar to THC alone; there was a main
effect of frequency (F 9, 54 = 58.59, p < 0.0001), treatment (F 1, 6 = 251.8, p < 0.0001) and an
interaction (F 9, 54 = 6.97, p < 0.0001) (Fig. 9b); post-hoc analysis showed reductions at seven
frequencies which are denoted on Fig. 9b. RIM (3.0 mg/kg) and VEH administration did not
produce a change from baseline, indicating that CB1 antagonism does not affect ICSS; there was
a main effect of frequency (F 9, 54 = 44.65, p < 0.0001), but no main effect of treatment (F 1, 6 =
0.32, p > 0.05) and no interaction (F 9, 54 = 0.92, p > 0.05) (Fig. 9c). RIM (3.0 mg/kg) blocked the
reduction of ICSS produced by THC (10.0 mg/kg), as stimulations did not differ from baseline,
indicated by a main effect of frequency (F 9, 54 = 34.02, p < 0.0001), but no main effect of
treatment (F 1, 6 = 0.79, p > 0.05), and no interaction (F 9, 54 = 1.78, p > 0.05) (Fig. 9d). Baseline
rate-frequency curves did not differ under any condition tested (Fig. 9e). There was a main effect
of frequency (F 9, 54 = 46.98, p < 0.0001), but no main effect of baseline day (F 3, 18 = 0.98, p >
0.05), and no interaction between baseline day and frequency (F 27, 162 = 1.10, p > 0.05).
A two-way ANOVA (3.0 mg/kg rimonabant vs. vehicle x 10.0 mg/kg THC vs. vehicle)
was conducted using the percent baseline stimulation data. The reduction produced by 10.0
mg/kg THC was blocked by administration of 3.0 mg/kg RIM. There was a main effect of first
treatment (VEH vs. RIM) (F 1, 6 = 54.41, p < 0.001), a main effect of the second treatment (VEH
vs. THC) (F 1, 6 = 54.41, p < 0.001) and an interaction between first and second treatment (F 1, 6 =
90.81, p < 0.0001) (Fig. 9f). Post-hoc analysis revealed that percent baseline stimulations were
reduced (p < 0.0001) in mice treated with 10.0 mg/kg THC, but only when first treated with
VEH. RIM (3.0 mg/kg) pre-treatment blocked the reduction in stimulations produced by 10.0
mg/kg THC. These results indicate that CB1 receptors mediate the rate-decreasing effects of 10.0
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mg/kg THC on ICSS. Furthermore, the CB1 antagonist, RIM (3.0 mg/kg) did not produce any
effect on ICSS alone.
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Figure. 9. THC CB1 antagonism assessment. Panel a – d shows rate-frequency data during RIM
antagonism tests. Panel e shows all baselines rate-frequency curves during CB1 testing. Percent
maximum control rate is displayed on the Y-axis, log-frequency values are shown on the x-axis.
Panel f shows percent baseline stimulations (± SEM) for all treatments. There was a significant
interaction with the two-way ANOVA for percent baseline stimulations. Significant interactions
were followed up by post-hoc analysis, and differences are denoted by asterisks at values that are
significantly different from baseline (a – e), or other treatment conditions (f). ****p < 0.0001,
**p < 0.01. Raw overall response rates (stimulations/min; mean ± SEM) during baseline (B) and
test (T) sessions were as follows: (a) VEH + VEH: B (27.67 ± 3.51) T (28.36 ± 3.48); (b) VEH +
10.0 mg/kg THC: B (29.80 ± 3.86) T (6.85 ± 2.45); (c) 3.0 mg/kg RIM + VEH: B (31.01 ± 4.96)
T (29.67 ± 4.01); (d) 3.0 mg/kg RIM + 10.0 mg/kg THC: B (28.49 ± 3.97) T (26.48 ± 3.81).
THC: Evaluation of CB2 Receptors. For this experiment, we evaluated whether the CB2
antagonist/inverse agonist SR2 would block the reduction of ICSS produced by 10.0 mg/kg
THC. Five mice completed testing and the data were analyzed using a within-subjects two-way
ANOVA (treatment x frequency) for each dose combination. Similar to CB1 testing,
administration of VEH and VEH did not produce a change from baseline ICSS; there was a main
effect of frequency (F 9, 36 = 60.04, p < 0.0001), but no main effect of treatment (F 1, 4 = 5.34, p >
0.05) and no interaction (F 9, 36 = 60.04, p > 0.05) (Fig. 10a). Similar to previous tests with 10.0
mg/kg THC, stimulations with VEH and 10.0 mg/kg THC were reduced; there was a main effect
of frequency (F 9, 36 = 28.93, p < 0.0001), treatment (F 1, 4 = 240.6, p < 0.001) and an interaction
(F 9, 36 = 4.14, p < 0.01) (Fig. 10b). Post-hoc analysis showed reductions at seven frequencies
which are denoted on Fig. 10b. SR2 (3.0 mg/kg) given with VEH did not affect baseline ICSS;
there was a main effect of frequency (F 9, 36 = 28.79, p < 0.0001), but no main effect of treatment
(F 1, 4 = 5.49, p > 0.05) and no interaction (F 9, 36 = 0.88, p > 0.05) (Fig. 10c). SR2 (3.0 mg/kg)
was not able to block the reduction in ICSS produced by 10.0 mg/kg THC; there was a main
effect of frequency (F 9, 36 = 35.66, p < 0.0001), treatment (F 1, 4 = 39.96, p < 0.01) and an
interaction (F 9, 36 = 6.13, p < 0.0001) (Fig. 10d). Post-hoc analysis showed decreases at five
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frequencies which are denoted on Fig. 10d. Baseline rate-frequency curves did not differ under
any condition tested (Fig. 10e); there was a main effect of frequency (F 9, 36 = 36.48, p < 0.0001),
but no main effect of baseline day (F 3, 12 = 0.91, p > 0.05), and no interaction between baseline
day and frequency (F 27, 108 = 1.15, p > 0.05).
A two-way ANOVA (3.0 mg/kg SR2 vs. VEH x 10.0 mg/kg THC vs. VEH) was
conducted using the percent baseline stimulations data. The reduction of ICSS produced by 10.0
mg/kg THC was not blocked by 3.0 mg/kg SR2 (Fig. 10f). There was no main effect of first
treatment (VEH vs. SR2) (F 1, 4 = 2.19, p > 0.05), but there was a main effect of second treatment
(VEH vs. THC) (F 1, 4 = 43.66, p < 0.01), as 10.0 mg/kg THC reduced ICSS. There was no
interaction between first treatment and second treatment (F 1, 4 = 2.32, p > 0.05). The reduction in
stimulations produced by 10.0 mg/kg THC was not blocked by SR2 (3.0 mg/kg), which suggests
that the attenuation of ICSS responding is not mediated through CB2 receptors, which is in
agreement with the rate-frequency findings.
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Figure. 10. THC CB2 antagonism assessment. Panels a – d shows rate-frequency data during
SR2 antagonism tests. Panel e shows all baselines rate-frequency curves during CB2 testing.
Percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the
x-axis. Panel f shows percent baseline stimulations (± SEM) for all treatments. Significant main
effects of treatment are denoted by asterisks by the figure legend. Significant interactions were
investigated with post-hoc analysis, and differences from baseline are denoted by asterisks.
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates
(stimulations/min; mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a)
VEH + VEH: B (29.99 ± 3.54) T (26.13 ± 2.67); (b) VEH + 10.0 mg/kg THC: B (28.11 ± 4.52)
T (6.72 ± 3.12); (c) 3.0 mg/kg SR2 + VEH: B (28.80 ± 4.58) T (24.11 ± 3.09); (d) 3.0 mg/kg
SR2 + 10.0 mg/kg THC: B (26.73 ± 3.83) T (8.91 ± 3.71).
THC Operant Responding for Food Assessment
In this experiment the effects of THC (5.0, 7.5, 10.0 and 20.0 mg/kg) on operant
responding for food pellets were assessed; thirteen mice were evaluated and response rates were
analyzed using a one-way repeated measures ANOVA. THC reduced operant response rates (F 4,
59 =

15.46, p < 0.0001) (Fig. 11). Post-hoc analysis showed that THC (10.0 and 20.0 mg/kg)

produced a reduction (p < 0.01; p < 0.0001 respectively) in operant response rates compared to
VEH, while 5.0 and 7.5 mg/kg THC group were not affected, though there was a trend toward
7.5 being significantly reduced (p = 0.06) (Fig. 11). The reduction of response rates produced by
THC was not specific to brain stimulation reinforcement, as it occurred in both ICSS and operant
responding for food.
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Figure. 11. THC operant responding for food. Figure showing response rate (± SEM) on the yaxis, and dose of THC or VEH on the x-axis. A significant one-way ANOVA was investigated
with post-hoc analysis, and differences from VEH are denoted by asterisks. ****p < 0.0001, **p
< 0.01
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JZL184 ICSS Experiments
JZL184 dose-response assessment. ICSS was assessed after administration of JZL184
(1.0, 4.0, 16.0 and 40.0 mg/kg) and VEH. Seven mice completed testing, and the rate-frequency
stimulation data were analyzed using a two-way, repeated-measures ANOVA (frequency x drug
treatment). When analyzing rate-frequency data VEH, 1.0, and 4.0 mg/kg JZL184 did not affect
baseline ICSS, while 16.0 and 40.0 mg/kg significantly attenuated stimulations. VEH produced a
main effect of frequency (F 9, 54 = 39.11, p < 0.0001), but no main effect of treatment (F 1, 6 =
0.23, p > 0.05) and no interaction (F 9, 54 = 0.92, p > 0.05) (Fig. 12a). JZL184 (1.0 mg/kg)
produced a main effect of frequency (F 9, 54 = 87.40, p < 0.0001), but no main effect of treatment
(F 1, 6 = 2.80, p > 0.05) and no interaction (F 9, 54 = 0.40, p > 0.05) (Fig. 12b). Similarly, 4.0
mg/kg JZL184 produced a main effect of frequency (F 9, 54 = 64.98, p < 0.0001), but no main
effect of treatment (F 1, 6 = 2.71, p > 0.05) and no interaction (F 9, 54 = 0.47, p > 0.05) (Fig. 12c).
Higher doses of JZL184 (16.0 and 40.0 mg/kg) attenuated ICSS; after 16.0 mg/kg JZL184
produced a main effect of frequency (F 9, 54 = 52.11, p < 0.0001), treatment (F 1, 6 = 14.68, p <
0.001) and an interaction (F 9, 54 = 2.18, p < 0.05) (Fig. 12d). Post-hoc analysis revealed
significant reductions at two frequencies which are denoted on Fig. 12d. JZL184 (40.0 mg/kg)
produced a main effect of frequency (F 9, 54 = 39.9, p < 0.0001), no main effect of treatment (F 1,
6=

5.78, p = 0.05), but an interaction between treatment and frequency (F 9, 54 = 2.43, p < 0.05)

(Fig. 12e); post-hoc analysis showed significant reductions at four frequencies which are denoted
on Fig. 12e.
All baseline rate-frequency curves were analyzed after all tests were completed to
determine if baseline responding differed over time (Fig. 12f). Baseline stimulations slightly
differed between test days; there was a main effect of frequency (F 9, 54 = 100.90, p < 0.0001) and
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baseline day (F 4, 24 = 3.19, p < 0.05), but no interaction between treatment and baseline day (F 36,
216 =

0.97, p > 0.05). Additionally, a second VEH test was conducted and compared to the initial

VEH assessment (data not shown); tests did not differ. There was a main effect of frequency (F 9,
54 =

55.33, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.36, p > 0.05) and no interaction

(F 9, 54 = 1.61, p > 0.05). Baselines varied slightly over time, but analysis from daily baseline
allows for minimal baseline drift. Data are always assessed in terms of change from that day’s
baseline to minimize experimental error due to baseline drift.
Percent baseline stimulations were calculated for each test and evaluated using one-way
repeated measures ANOVA. VEH was calculated to serve as a comparison to JZL184. JZL184
reduced ICSS percent baseline stimulations (F 4, 24 = 4.48, p < 0.01) (Fig. 13); post-hoc analysis
showed lower doses of JZL184 (1.0 and 4.0 mg/kg) did not affect percent baseline stimulations,
while higher doses of JZL184 (16.0 and 40.0 mg/kg) reduced (p < 0.05; p < 0.01) percent
baseline stimulations (76.28 % and 70.99 %) compared to VEH. These results agreed with the
rate-frequency analysis, as the same doses of JZL184 (16.0 and 40.0 mg/kg) produced significant
attenuation using both measure of ICSS.
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Figure Continued
Figure 12. JZL184 ICSS dose-response assessment. Panels a – e show rate-frequency stimulation
values (± SEM) after VEH or JZL184 (1.0, 4.0, 16.0 and 40.0 mg/kg). Panel f shows all baseline
rate-frequency curves during testing. Percent maximum control rate is displayed on the Y-axis,
log-frequency values are shown on the x-axis. Significant main effects of treatment are denoted
by asterisks by the figure legend. Interactions that achieved significance were investigated with
post-hoc analyses, and differences from baseline are denoted by asterisks. ****p < 0.0001, ***p
< 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ± SEM)
during baseline (B) and test (T) sessions were as follows: (a) VEH: B (33.99 ± 2.05) T (33.51 ±
2.31); (b) 1.0 mg/kg JZL184: B (28.98 ± 2.53) T (27.55 ± 2.72); (c) 4.0 mg/kg JZL184: B (28.60
± 3.90) T (26.08 ± 2.66); (d) 16.0 mg/kg JZL184: B (30.76 ± 3.76) T (23.08 ± 2.62); (e) 40.0
mg/kg JZL184: B (34.00 ± 2.28) T (23.91 ± 3.95).
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Figure. 13. JZL184 ICSS percent baseline stimulations. Fig. 13 shows percent baseline
stimulations (± SEM) from JZL184 dose-response tests. The one-way ANOVA was significant
and post-hoc analysis revealed significant differences from VEH, which are denoted with
asterisks. **p < 0.01, *p < 0.05
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JZL184 Time-course Assessment. The purpose of this study was to assess the timecourse of JZL184-induced suppression of ICSS. Self-stimulations were assessed at 1, 2, 4, 8, 24,
and 48 h after administration of VEH or 40.0 mg/kg JZL184. Six mice completed JZL184 timecourse testing, and two-way repeated-measures ANOVAs (Treatment x Frequency) were
conducted to compare rate-frequency curves between VEH and JZL184 treatment at each timepoint. JZL184 (40.0 mg/kg) significantly reduced stimulations compared to VEH at 1, 2, 4, 8 and
24 h after injection. Baselines between the two conditions did not differ from each other; there
was a main effect of frequency (F 9, 45 = 83.39, p < 0.0001), but no main effect of treatment (F 1, 6
= 0.38, p > 0.05) and no interaction (F 9, 45 = 0.63, p > 0.05) (Fig. 14a). At the one hour timepoint there was a main effect of frequency (F 9, 45 = 31.91, p < 0.0001), treatment (F 1, 5 = 7.01, p
< 0.05) and an interaction (F 9, 45 = 2.18, p < 0.05) (Fig. 14b); post-hoc analysis showed
reductions at two frequencies which are denoted on Fig. 14b. Similarly, at the two hour timepoint there was a main effect of frequency (F 9, 45 = 33.43, p < 0.0001), treatment (F 1, 5 = 7.80, p
< 0.05) and an interaction (F 9, 45 = 2.11, p < 0.05) (Fig. 14c). Post-hoc analysis showed
reductions at two frequencies which are denoted on Fig. 14c. Four hours after administration,
there was a main effect of frequency (F 9, 45 = 19.01, p < 0.0001), treatment (F 1, 5 = 11.81, p <
0.05), and an interaction (F 9, 45 = 2.71, p < 0.05) (Fig. 14d). Post-hoc analysis showed reductions
at two frequencies are denoted on Fig. 14d. At the eight hour time-point there was a main effect
of frequency (F 9, 45 = 28.31, p < 0.0001) and treatment (F 1, 5 = 61.41, p < 0.001), but no
interaction (F 9, 45 = 2.07, p = 0.05) (Fig. 14e). At 24 hours after administrations, JZL184
responding was still attenuated; there was a main effect of frequency (F 9, 45 = 63.87, p < 0.0001),
treatment (F 1, 5 = 14.21, p < 0.001) and an interaction (F 9, 45 = 2.82, p < 0.001) (Fig. 14f); posthoc analysis showed reductions at four frequencies which are denoted on Fig. 14f. 48 hours after
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administration, JZL184 stimulation rates returned to normal, as they did not differ from VEH;
there was a main effect of frequency (F 9, 45 = 48.10, p < 0.0001), but no main effect of treatment
(F 1, 5 = 0.66, p > 0.05) and no interaction (F 9, 45 = 1.41, p > 0.05) (Fig. 14g).
A two-way repeated-measures ANOVA (Time-point x Treatment) was conducted to
compare the percent baseline stimulations of VEH and 40.0 mg/kg JZL184 across all time-points
(Fig. 14h). JZL184 (40.0 mg/kg) reduced percent baseline stimulations from VEH at several
time-points after administration; there was a main effect of time-point (F 5, 25 = 12.48, p <
0.0001), treatment (F 1, 5 = 11.54, p < 0.05), and an interaction between time-point and treatment
(F 5, 25 = 2.61, p < 0.05). Post-hoc tests showed that 40.0 mg/kg JZL184 reduced percent baseline
stimulations compared to VEH treatment at 2, 4, 8 and 24 hours after treatment as denoted on
Fig. 14h. The attenuation of ICSS produced by JZL184 is apparent 2 hours after administration,
and returns to baseline within 48 hours after administration according to percent baseline
stimulations data. Similarly, the rate-frequency analysis shows reductions at 1 hour after
administration, which persist between 24 and 48 h.
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Figure 14. JZL184 ICSS time-course evaluation. Panels a – g show rate-frequency stimulation
values (± SEM) after VEH or JZL184 (40.0 mg/kg) at each time-point (1, 2, 4, 8, 24 and 48 h);
percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the
x-axis. Panel h shows percent baseline stimulations data over time. Significant main effects of
treatment are denoted by asterisks by the figure legend. Interactions that achieved significance
and were accompanied by significant post-hoc analyses are denoted by asterisks at values that
are significantly different from baseline VEH. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p <
0.05. Raw overall response rates (stimulations/min; mean ± SEM) during VEH (V) and 40.0
mg/kg JZL184 (J) conditions were as follows: (a) Baseline: V (26.78 ± 3.41) J (28.68 ± 2.27);
(b) 1 h: V (23.11 ± 3.70) J (19.48 ± 4.38); (c) 2 h: V (22.73 ± 2.19) J (14.81 ± 4.01); (d) 4 h: V
(20.28 ± 3.27) J (11.31 ± 3.78); (e) 8 h: V (23.83 ± 4.99) J (12.93 ± 3.18); (f) 24 h: V (29.33 ±
3.00) J (19.78 ± 3.56); (g) 48 h: V (26.90 ± 4.55) J (25.01 ± 2.88).
JZL184: Evaluation of CB1 receptors. In these experiments the CB1 antagonist/inverse
agonist RIM (3.0 mg/kg) was administered with JZL184 (40.0 mg/kg) to determine if it would
block the JZL184-induced attenuation of ICSS. Eight mice completed testing and the data were
analyzed using two-way
(treatment x frequency) repeated-measures ANOVAs. Administration of VEH and VEH did not
affect ICSS; there was a main effect of frequency (F 9, 63 = 39.01, p < 0.0001), but no main effect
of treatment (F 1, 7 = 2.42, p > 0.05) and no interaction (F 9, 63 = 0.42, p > 0.05) (Fig. 15a).
Administration of VEH and 40.0 mg/kg JZL184 reduced stimulations from baseline; there was a
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main effect of frequency (F 9, 63 = 34.95, p < 0.0001), treatment (F 1, 7 = 29.94, p < 0.001) and an
interaction (F 9, 63 = 6.97, p < 0.05) (Fig. 15b). Post-hoc analysis revealed reductions at six
frequencies which are denoted on Fig. 15b. RIM (3.0 mg/kg) and VEH did not produce a change
from baseline responding; there was a main effect of frequency (F 9, 63 = 52.30, p < 0.0001), but
no main effect of treatment (F 1, 7 = 1.71, p > 0.05) and no interaction (F 9, 63 = 1.42, p > 0.05)
(Fig. 15c). The attenuation of ICSS produced by 40.0 mg/kg JZL184 was blocked by treatment
with 3.0 mg/kg RIM, as stimulations did not differ from baseline; there was a main effect of
frequency (F 9, 63 = 66.55, p < 0.0001), but no main effect of treatment (F 1, 7 = 0.13, p > 0.05),
and no interaction (F 9, 63 = 0.49, p > 0.05) (Fig. 15d). Baseline rate-frequency curves did not
differ during any condition tested (Fig. 15e); there was a main effect of frequency (F 9, 63 = 66.23,
p < 0.0001), but no main effect of baseline day (F 3, 21 = 2.78, p > 0.05) and no interaction
between baseline day and frequency (F 27, 189 = 1.49, p > 0.05).
A two-way, repeated-measures ANOVA (3.0 mg/kg RIM vs. VEH x 40.0 mg/kg JZL184
vs. VEH) was conducted using the percent baseline stimulations data. RIM (3.0 mg/kg) blocked
the attenuation of ICSS produced by 40.0 mg/kg JZL184 (Fig. 15f). There was no main effect of
first treatment (RIM vs. VEH) (F 1, 7 = 3.20, p > 0.05), but there was a main effect of second
treatment (JZL184 vs. VEH) (F 1, 7 = 6.10, p < 0.05) and an interaction between first and second
treatment (F 1, 7 = 7.66, p < 0.05). Post-hoc analysis revealed that percent baseline stimulations
were reduced (p < 0.001) in mice treated with 40.0 mg/kg JZL184, but only when first treated
with VEH (Fig. 15f). Administration of 3.0 mg/kg RIM blocked the ICSS reduction produced by
40.0 mg/kg JZL184, demonstrating that the attenuation of stimulations produced by 40.0 mg/kg
JZL184 was CB1 receptor dependent. Rate-frequency findings were consistent with percent
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baseline stimulations, as that also showed a blockade of JZL184-induced attenuation of ICSS by
RIM. Similar to THC, the attenuation of ICSS was mediated through CB1 receptors.
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Figure 15. JZL184 CB1 antagonism assessment. Panel a – d shows rate-frequency data during
RIM antagonism tests. Panel e shows all baselines rate-frequency curves during CB1 testing.
Percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the
x-axis. Panel f shows percent baseline stimulations (± SEM) for all treatments. Significant
interactions were followed up by post-hoc analysis, and differences are denoted by asterisks at
values that are significantly different from baseline (a – e), or other treatment conditions (f).
****p < 0.0001, ***p < 0.001, **p < 0.01. Raw overall response rates (stimulations/min; mean ±
SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH + VEH: B (31.20 ±
3.46) T (29.14 ± 3.96); (b) VEH + 40.0 mg/kg JZL184: B (31.22 ± 3.18) T (19.31 ± 4.23); (c)
3.0 mg/kg RIM + VEH: B (29.18 ± 2.94) T (26.94 ± 2.88); (d) 3.0 mg/kg RIM + 40.0 mg/kg
JZL184: B (31.53 ± 3.22) T (28.41 ± 3.52).
JZL184: Evaluation of CB2 receptors. The purpose of this study was to evaluate
whether CB2 receptor played a necessary role in the suppressive ICSS effects produced by
JZL184 (40.0 mg/kg). The CB2 receptor antagonist/inverse agonist SR2 (10.0 mg/kg) was coadministered to determine if it would block the reduction in stimulation rate produced by
JZL184. Eight mice were used for testing and data were analyzed using two-way (treatment x
frequency) repeated-measures ANOVAs to compare each drug combination to baseline. Similar
to previous tests administration of VEH and VEH did not affect baseline responding; there was a
main effect of frequency (F 9, 63 = 46.89, p < 0.0001), but no main effect of treatment (F 1, 7 =
1.50, p > 0.05), and no interaction (F 9, 63 = 1.00, p > 0.05) (Fig. 16a). Administration of VEH
and 40.0 mg/kg attenuated ICSS from baseline, similar to results of CB1 tests; there was a main
effect of frequency (F 9, 63 = 43.63, p < 0.0001), treatment (F 1, 7 = 92.02, p < 0.0001) and an
interaction (F 9, 63 = 2.06, p < 0.05) (Fig. 16b). Post-hoc analysis showed reductions at six
frequencies which are denoted on Fig. 16b. SR2 (10.0 mg/kg) co-administered with VEH did not
affect baseline ICSS; there was a main effect of frequency (F 9, 63 = 35.02, p < 0.0001), but no
main effect of drug treatment (F 1, 7 = 1.78, p > 0.05) and no interaction (F 9, 63 = 0.79, p > 0.05)
(Fig. 16c). SR2 (10.0 mg/kg) was not able to block the effects of JZL184, as it still produced a
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main effect of frequency (F 9, 63 = 33.23, p < 0.0001), treatment (F 1, 7 = 5.87, p < 0.05) and an
interaction (F 9, 63 = 2.053, p < 0.05) (Fig. 16d). Post-hoc analysis revealed reductions at 2
frequencies which are denoted on Fig. 16d. Baseline rate-frequency curves did not differ during
any condition tested (Fig. 16e); there was a main effect of frequency (F 9, 63 = 62.05, p < 0.0001),
but no main effect of baseline day (F 3, 21 = 3.00, p > 0.05) and no interaction between baseline
day and frequency (F 27, 189 = 1.43, p > 0.05).
Percent baseline stimulations data were analyzed using a two-way, repeated-measures
ANOVA (10.0 mg/kg SR2 vs. VEH x 40.0 mg/kg JZL184 vs. VEH). The attenuation of ICSS
produced by 40.0 mg/kg JZL184 was not blocked by co-administration with SR2 (10.0 mg/kg)
(Fig. 16f). There was no main effect of first treatment (SR2 vs. VEH) (F 1, 7 = 0.56, p > 0.05), but
there was a main effect of second treatment (JZL184 vs. VEH) (F 1, 7 = 34.59, p < 0.001) and an
interaction between first treatment and second treatment (F 1, 7 = 7.17, p < 0.05). Post-hoc
analysis revealed that JZL184 significantly reduced percent baseline stimulations when coadministered with SR2 or VEH, indicating that JZL184 induced attenuation of ICSS was CB2
receptor independent. These results completely agreed with rate-frequency analysis. These
results were also similar to findings with THC which produced attenuation mediated through
CB1 receptors, and not affected by CB2 receptor antagonism.
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Figure 16. JZL184 CB2 antagonism assessment. Panels a – d shows rate-frequency data during
SR2 antagonism tests. Panel e shows all baselines rate-frequency curves during CB2 testing.
Percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the
x-axis. Panel f shows percent baseline stimulations (± SEM) for all treatments. Significant
interactions with were investigated with post-hoc analysis, and differences are denoted by
asterisks at values that are significantly different from baseline (a – e), or other treatment
conditions (f). ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates
(stimulations/min; mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a)
VEH + VEH: B (34.04 ± 3.06) T (33.88 ± 3.54); (b) VEH + 40.0 mg/kg JZL184: B (36.02 ±
3.38) T (26.98 ± 3.40); (c) 10.0 mg/kg SR2 + VEH: B (30.98 ± 4.31) T (29.47 ± 4.31); (d) 10.0
mg/kg SR2 + 40.0 mg/kg JZL184: B (30.81 ± 3.44) T (25.09 ± 3.47).
JZL184 Operant Responding for Food Assessment
In this study, operant responding for food pellets was assessed after VEH and JZL184
(1.0, 4.0, 16.0 and 40.0 mg/kg). A one-way repeated-measures ANOVA was used to analyze
response rates. JZL184 reduced operant response rates (F 4, 32 = 9.89, p < 0.0001) (Fig. 17). Posthoc analysis showed that 40.0 mg/kg JZL184 significantly attenuated (p < 0.0001) response
rates, while 1.0, 4.0, and 16.0 mg/kg JZL184 did not differ from VEH as denoted on Fig. 17.
These findings with high dose JZL184 (40.0 mg/kg) support ICSS findings, in which both 16.0
and 40.0 mg/kg JZL184 attenuated responding. This was also similar to THC, as THC (10.0
mg/kg) reduced operant response rates for both food and brain stimulation.
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Figure 17. JZL184 effects on operant responding for food. Mean response rates (± SEM) are
displayed on the y-axis, and dose of JZL184 or VEH is on the x-axis. A significant one-way
ANOVA was investigated with post-hoc analysis, and significant differences from VEH are
denoted by asterisks. ****p < 0.0001
JZL184 Spontaneous Locomotor Activity Assessment
Spontaneous locomotor activity was assessed after administration of JZL184 (4.0, 16.0
and 40.0 mg/kg) or VEH. Distance travelled (m), mean speed (m/s) and time immobile (s) were
recorded and are displayed on Fig. 18. A significant main effect of JZL184 treatment on distance
travelled was observed (F 3, 31 = 8.91, p < 0.001) (Fig. 18a). Post-hoc analysis showed that 40.0
mg/kg JZL184 reduced (p < 0.001) distance travelled, while 4.0 and 16.0 mg/kg did not differ
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from VEH. JZL184 also increased time-immobile (F 3, 31 = 30.60, p < 0.0001). Post-hoc analysis
showed that 40.0 and 16.0 mg/kg JZL184 increased (p < 0.0001; p < 0.01) time-immobile
compared to VEH, while 4.0 mg/kg did not differ from VEH (Fig. 18b). JZL184 also
significantly reduced speed of locomotion (F 3, 31 = 3.07, p < 0.05) (Fig. 18c). Post-hoc analysis
showed that 40.0 mg/kg JZL184 decreased (p < 0.05) mean adjusted speed from VEH, while 4.0
and 16.0 mg/kg did not differ from VEH. These results support ICSS and operant responding
data, as distance travelled, operant responding, and ICSS were all reduced with high dose
JZL184 (40.0 mg/kg), while time-immobile and ICSS were also affected by 16.0 mg/kg JZL184.
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Figure 18. JZL184 effects on spontaneous locomotor activity. All panels show dose of JZL184
and VEH on the x-axis. Panel a shows distance travelled on the y-axis, panel b shows timeimmobile, and panel c shows adjusted speed. Significant one-way ANOVAs were investigated
with post-hoc analysis, and significant differences from VEH are denoted by asterisks. ****p <
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05
JZL184 Endocannabinoid Quantification
Concentrations of 2-AG, AEA, and AA were determined from tissue samples from PFC,
NAc, VMB, amygdala, and cerebellum after treatment with VEH, or JZL184 (4.0 or 40.0
mg/kg). Separate one-way ANOVAs were conducted within each brain region to analyze
concentration changes from VEH treatment. JZL184 dose-dependently increased 2-AG
concentrations in the PFC (F 2, 12 = 124.2, p < 0.0001); post-hoc analysis showed that 40.0 mg/kg
JZL184 produced a 7-fold increase (p < 0.0001) of 2-AG from VEH, while treatment 4.0 mg/kg
JZL184 did not differ from VEH (Fig. 19a). JZL184 decreased AEA in the PFC by JZL184 (F 2,
12 =

4.45, p < 0.05); post-hoc analysis showed that 40.0 mg/kg JZL184 reduced (p < 0.05) AEA

concentrations to 49 % of VEH, while 4.0 mg/kg JZL184 AEA concentrations did not differ
from VEH (Fig. 19b). JZL184 decreased concentrations of AA in the PFC (F 2, 12 = 12.32, p <
0.01); post-hoc analysis showed that 40.0 mg/kg JZL184 reduced AA concentrations to 78 % of
VEH, while 4.0 mg/kg JZL184 did not affect AA (Fig. 19c).
JZL184 increased 2-AG concentrations in the NAc (F 2, 11 = 130.9, p < 0.0001); post-hoc
analysis showed that 4.0 and 40.0 mg/kg JZL184 increased (p < 0.001; p < 0.0001) 2-AG levels
over 4-fold and 10-fold respectively from VEH (Fig. 19a). JZL184 decreased AEA in the NAc
(F 2, 11 = 4.92, p < 0.05); post-hoc analysis showed that 40.0 mg/kg JZL184 reduced (p < 0.05)
AEA concentrations to 46 % of VEH levels, while 4.0 mg/kg JZL184 did not affect AEA levels
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(Fig. 19b). JZL184 did not affect AA concentrations in the NAc (F 2, 11 = 3.88, p = 0.05);
however, there was a trend toward reduction of AA (Fig. 19c).
Administration of JZL184 increased 2-AG concentrations in the VMB (F 2, 12 = 33.41, p <
0.0001); post-hoc analysis showed that 4.0 and 40.0 mg/kg JZL184 increased (p < 0.01; p <
0.0001) 2-AG over 7-fold and 13-fold VEH levels (Fig. 19a). JZL184 did not affect AEA in the
VMB (F 2, 12 = 0.42, p > 0.05), as concentrations did not differ from VEH (Fig. 19b). JZL184
reduced AA concentrations in the VMB (F 2, 12 = 4.35, p < 0.05); post-hoc analysis showed that
40.0 mg/kg JZL184 decreased (p < 0.05) AA concentrations (p < 0.05) to 61 % of VEH AA,
while 4.0 mg/kg JZL184 AA levels did not differ from VEH (Fig. 19c).
JZL184 increased 2-AG levels in the amygdala (F 2, 12 = 87.70, p < 0.0001); post-hoc
analysis showed that both 4.0 and 40.0 mg/kg JZL184 increased (p < 0.05; p < 0.0001) 2-AG
over 2-fold and 8-fold of VEH levels respectively (Fig. 19a). JZL184 did not affect AEA levels
in the amygdala (F 2, 12 = 3.69, p > 0.05) (Fig. 19b). JZL184 reduced AA concentrations in the
amygdala (F 2, 12 = 10.12, p < 0.01). Post-hoc analysis showed that 40.0 mg/kg JZL184 reduced
(p < 0.01) AA levels to 65 % of VEH concentrations, while 4.0 mg/kg JZL184 AA levels did not
differ from VEH (Fig. 19c).
Administration of JZL184 increased 2-AG in the cerebellum after (F 2, 12 = 75.91, p <
0.0001); post-hoc analysis showed that 4.0 and 40.0 mg/kg JZL184 increased (p < 0.001; p <
0.0001) 2-AG concentrations by over 2-fold and nearly 4-fold of VEH levels respectively (Fig.
19a). JZL184 did not affect AEA concentrations in the cerebellum (F 2, 12 = 1.09, p > 0.05); (Fig.
19b). JZL184 lowered AA concentrations in the cerebellum (F 2, 12 = 30.192, p < 0.0001). Posthoc analysis showed that 40.0 mg/kg JZL184 decreased AA to 69 % of VEH levels, while 4.0
mg/kg JZL184 AA concentrations did not differ from VEH (Fig. 19c).
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Figure 19. JZL184 effects on endocannabinoid and AA concentrations. All panels show brain
region on the x-axis (AMYG = amygdala, CEREB = cerebellum). Panel a shows 2-AG levels on
the y-axis, panel b shows AEA, and panel c displays AA. One-way ANOVAs were calculated
within each brain region and substrate measured. Significant one-way ANOVAs were
investigated with post-hoc analyses, and significant differences from corresponding VEH
treatment are denoted by symbols. + p < 0.0001, #p < 0.001, !p < 0.01, *p < 0.05
PF-3845 ICSS Experiments
PF-3845 dose-response assessment. This study examined the effects of FAAH
inhibition on ICSS. ICSS was assessed after administration of VEH and PF-3845 (1.0, 3.0, 10.0,
and 30.0 mg/kg). ICSS was not affected by VEH, 1.0, 3.0, or 10.0 mg/kg PF-3845, but it was
significantly attenuated by 30.0 mg/kg PF-3845. It is important to note that no other behavioral
studies have assessed doses over 10.0 mg/kg, which we will discuss further in the discussion.
VEH produced a main effect of frequency (F 9, 72 = 103.2, p < 0.0001), but no main effect of
treatment (F 1, 8 = 0.09, p > 0.05) and no interaction (F 9, 72 = 0.30, p > 0.05) (Fig. 20a). As
mentioned above, PF-3845 (1.0, 3.0 and 10.0 mg/kg) did not affect ICSS; with 1.0 mg/kg there
was a main effect of frequency (F 9, 72 = 63.36, p < 0.0001), but there was no main effect of
treatment (F 1, 8 = 5.17, p = 0.05) and no interaction (F 9, 72 = 0.72, p > 0.05) (Fig. 20b). PF-3845
(3.0 mg/kg) produced a main effect of frequency (F 9, 72 = 64.84, p < 0.0001), but no main effect
of treatment (F 1, 8 = 2.60, p > 0.05) and no interaction (F 9, 72 = 0.82, p > 0.05) (Fig. 20c). PF3845 (10.0 mg/kg) produced a main effect of frequency (F 9, 72 = 63.50, p < 0.0001), but no main
effect of treatment (F 1, 8 = 2.07, p > 0.05) and no interaction (F 9, 72 = 0.61, p > 0.05) (Fig. 20d).
The highest dose of PF-3845 (30.0 mg/kg) reduced ICSS rate; there was a main effect of
frequency (F 9, 72 = 61.19, p < 0.0001), treatment (F 1, 8 = 8.32, p < 0.05) and an interaction (F 9, 72
= 3.72, p < 0.001) (Fig. 20e). Post-hoc analysis showed reductions at four frequencies which are
denoted on Fig. 20e. All baseline rate-frequency stimulation rates were analyzed after testing to
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determine if there were any differences (Fig. 20f). There was a main effect of frequency (F 9, 72 =
110.10, p < 0.0001), but no main effect of baseline day (F 4, 32 = 0.24, p > 0.05) and no
interaction between treatment and baseline day (F 36, 288 = 0.64, p > 0.05), indicating that
baselines did not differ over time. Additionally, a second VEH test was conducted and compared
to the initial VEH assessment; VEH tests did not differ from each other (data not shown), as
there was a main effect of frequency (F 9, 72 = 79.31, p < 0.0001), but there was no main effect of
treatment (F 1, 8 = 2.39, p > 0.05) and no interaction (F 9, 72 = 0.99, p > 0.05). Similar to JZL184
treatment, the high dose of PF-3845 produced a significant reduction of ICSS.
Percent baseline stimulations were calculated for each condition and evaluated using oneway repeated measures ANOVA. PF-3845 reduced percent baseline stimulations (F 4, 24 = 4.48, p
< 0.01) (Fig. 21). Post-hoc analysis showed that 30.0 mg/kg (79.10 %) produced significant
attenuation (p < 0.05) of percent baseline stimulations from VEH. While other doses of PF-3845
(1.0, 3.0 and 10.0 mg/kg) did not affect percent baseline stimulations. These results are in
agreement with the rate-frequency data analysis, as only the high dose of PF-3845 (30.0 mg/kg)
produced a reduction of ICSS.
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Figure Continued
Figure 20. PF-3845 ICSS dose-response assessment. Panels a – e show rate-frequency
stimulation values (± SEM) after VEH or PF-3845 (1.0, 3.0, 10.0 and 30.0 mg/kg). Panel f shows
all baseline rate-frequency curves during testing. Percent maximum control rate is displayed on
the Y-axis, log-frequency values are shown on the x-axis. Interactions that achieved significance
were investigated with post-hoc analyses, and significant differences from baseline are denoted
by asterisks. ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min;
mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH: B (32.81 ±
2.19) T (32.13 ± 1.94); (b) 1.0 mg/kg PF-3845: B (32.82 ± 2.90) T (30.73 ± 2.83); (c) 3.0 mg/kg
PF-3845: B (32.59 ± 2.58) T (31.28 ± 2.91); (d) 10.0 mg/kg PF-3845: B (34.08 ± 2.40) T (32.10
± 2.72); (e) 30.0 mg/kg PF-3845: B (32.96 ± 2.55) T (27.08 ± 3.68).
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Figure 21. PF-3845 ICSS percent baseline stimulations. Fig. 21 shows percent baseline
stimulations (± SEM) after PF-3845 or VEH. The one-way ANOVA was significant and posthoc analysis revealed a significant difference from VEH, which is denoted with an asterisk. *p <
0.05
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PF-3845 time-course assessment. The purpose of this experiment was to assess the
time-course of PF-3845 induced attenuation of ICSS. Self-stimulations were assessed at 1, 2, 4,
8, 24, and 48 h after administration of 30.0 mg/kg PF-3845 or VEH. Eight mice completed
testing, and two-way repeated-measures ANOVAs (Treatment x Frequency) were conducted to
compare rate-frequency curves between VEH and PF-3845 treatment at each time-point. Ratefrequency data shows that PF-3845 (30.0 mg/kg) attenuated stimulations compared to VEH at 1,
2, 4, 8 and 24 h after injection, but did not differ from each other 48 h after administration.
Baseline rate-frequency curves between the two conditions did not differ from each other, as
there was a main effect of frequency (F 9, 63 = 71.80, p < 0.0001), but no main effect of treatment
(F 1, 7 = 1.1, p > 0.05) and no interaction (F 9, 63 = 0.90, p > 0.05) (Fig. 22a). One hour after
administration there was a main effect of frequency (F 9, 63 = 46.84, p < 0.0001), treatment (F 1, 7
= 7.99, p < 0.05) and an interaction (F 9, 63 = 2.12, p > 0.05), indicating a significant reduction of
ICSS (Fig. 22b). Post-hoc analysis showed a difference at one frequency which is denoted on
Fig. 22b. Two hours after injection, there was a main effect of frequency (F 9, 63 = 55.03, p <
0.0001) and a main effect of treatment (F 1, 7 = 3.66, p < 0.05), but no interaction (F 9, 63 = 1.36, p
> 0.05) (Fig. 22c). At the four hour time-point there was a main effect of frequency (F 9, 63 =
64.03, p < 0.0001) and treatment (F 1, 7 = 6.80, p < 0.05), but no interaction (F 9, 63 = 0.82, p >
0.05) (Fig. 22d). Eight hours after injection, there was a main effect of frequency (F 9, 63 = 51.67,
p < 0.0001) and treatment (F 1, 7 = 6.56, p < 0.05), but there was no interaction (F 9, 63 = 1.09, p >
0.05) (Fig. 22e). At the 24 h time-point, there was a main effect of frequency (F 9, 63 = 62.67, p <
0.0001), treatment (F 1, 7 = 6.47, p < 0.05) and an interaction (F 9, 63 = 3.33, p < 0.01) (Fig. 22f).
Post-hoc analysis showed differences at two frequencies which are denoted on Fig. 22f. After 48
hours, stimulations with VEH and 30.0 mg/kg PF-3845 did not differ; there was a main effect of
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frequency (F 9, 63 = 86.94, p < 0.0001), but no main effect of treatment (F 1, 7 = 3.13, p > 0.05)
and no interaction (F 9, 63 = 0.86, p > 0.05) (Fig. 22g). The reduction of ICSS produced by PF3845 (30.0 mg/kg) persisted between 24 and 48 hours after treatment, similar to the reduction
produced by the MAGL inhibitor JZL184.
Percent baseline stimulations data were analyzed using a two-way repeated-measures
ANOVA (Time-point x Treatment) to assess changes in ICSS across all time-points (Fig. 22h).
PF-3845 (30.0 mg/kg) reduced percent baseline stimulations compared to VEH, as there was a
main effect of time-point (F 5, 35 = 4.66, p < 0.01), treatment (F 1, 7 = 14.32, p < 0.01) and an
interaction between time-point and treatment (F 5, 35 = 3.75, p < 0.01). Post-hoc analysis shows
that 30.0 mg/kg PF-3845 attenuated percent baseline stimulations compared to VEH treatment at
1, 2, 4, 8 and 24 hours after treatment as denoted on Fig. 22h. These results are in agreement
with the rate-frequency analysis, as nearly all time-points were shown to be significantly reduced
with both measures. Percent baseline stimulations analysis showed that PF-3845 (30.0 mg/kg)
also reduced responding 2 h after administration, in agreement with our initial findings.
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Figure 22. PF-3845 ICSS time-course evaluation. Panels a – g show rate-frequency stimulation
values (± SEM) after VEH or PF-3845 (30.0 mg/kg) at each time-point (1, 2, 4, 8, 24 and 48 h);
percent maximum control rate is displayed on the y-axis, log-frequency values are shown on the
x-axis. Panel h shows percent baseline stimulations data over time. Significant main effects of
treatment are denoted by asterisks on the figure legend. Interactions that achieved significance
and were accompanied by significant post-hoc analyses are denoted by asterisks at values that
are significantly different from VEH. ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response
rates (stimulations/min; mean ± SEM) during VEH (V) and 30.0 mg/kg PF-3845 (P) conditions
were as follows: (a) Baseline: V (35.24 ± 2.05) P (34.84 ± 2.48); (b) 1 h: V (33.54 ± 2.26) P
(26.86 ± 2.87); (c) 2 h: V (33.69 ± 2.75) P (25.18 ± 2.67); (d) 4 h: V (33.01 ± 2.19) P (27.53 ±
2.20); (e) 8 h: V (32.37 ± 2.27) P (27.26 ± 2.32); (f) 24 h: V (33.29 ± 1.96) P (28.29 ± 1.97); (g)
48 h: V (33.94 ± 1.90) P (34.88 ± 2.69).
PF-3845: Evaluation of CB1 receptors. The purpose of this study was to examine
whether the reduction of ICSS produced by PF-3845 was CB1 dependent. Similar to JZL184
antagonist experiments, we tested whether rimonabant was able to block PF-3845 induced
attenuation of ICSS. Six mice completed testing and data were analyzed using two-way repeatedmeasures ANOVAs (treatment x frequency) for each dose combination tested. Administration of
VEH and VEH did not produce a change from baseline; there was a main effect of frequency (F
9, 45 =

56.60, p < 0.0001), but no main effect of treatment (F 1, 5 = 2.36, p > 0.05) and no
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interaction (F 9, 45 = 0.94, p > 0.05) (Fig. 23a). PF-3845 (30.0 mg/kg) given in combination with
VEH attenuated stimulations from baseline as expected; there was a main effect of frequency (F
9, 45 =

51.72, p < 0.0001), treatment (F 1, 5 = 43.55, p < 0.01) and an interaction (F 9, 45 = 2.72, p <

0.05) (Fig. 23b). Post-hoc analysis showed reductions at four frequencies which are denoted on
Fig. 23b. RIM (3.0 mg/kg) and VEH did not affect baseline ICSS; there was a main effect of
frequency (F 9, 45 = 94.34, p < 0.0001), but no main effect of treatment (F 1, 5 = 3.73, p > 0.05)
and no interaction (F 9, 45 = 1.04, p > 0.05) (Fig. 23c). RIM (3.0 mg/kg) did not block the
attenuation of ICSS produced by 30.0 mg/kg PF-3845, as the combination reduced responding
compared to baseline ICSS; there was a main effect of frequency (F 9, 45 = 47.41, p < 0.0001),
treatment (F 1, 5 = 20.23, p < 0.01), and an interaction (F 9, 45 = 3.51, p < 0.01) (Fig. 23d). Posthoc analysis showed reductions at six frequencies which are denoted on Fig. 23d. Next, we
assessed a higher dose (10.0 mg/kg) of RIM with VEH and PF-3845. ICSS after administration
of 10.0 mg/kg RIM and VEH did not differ from baseline; there was a main effect of frequency
(F 9, 45 = 31.09, p < 0.0001), but no main effect of treatment (F 1, 5 = 202, p > 0.05) and no
interaction (F 9, 45 = 0.36, p > 0.05) (Fig. 23e). However, RIM (10.0 mg/kg) was also not able to
block the PF-3845-induced attenuation of ICSS, as there was a main effect of frequency (F 9, 45 =
22.09, p < 0.0001), treatment (F 1, 5 = 41.64, p < 0.01), and an interaction (F 9, 45 = 3.48, p < 0.01)
(Fig. 23f). Post-hoc analysis revealed reductions at five frequencies which are denoted on Fig.
23f. Baseline rate-frequency responses slightly differed during the course of these experiments
(Fig. 23g); there was a main effect of frequency (F 9, 45 = 62.28, p < 0.0001) and baseline day (F
5, 25 =

3.23, p > 0.05), but there was no interaction between baseline day and frequency (F 45, 225 =

1.26, p > 0.05). Baseline rate-frequency curves during 10.0 mg/kg RIM antagonism tests did not
differ; there was a main effect of frequency (F 9, 45 = 48.20, p < 0.0001), but no main effect of
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baseline day (F 3, 15 = 0.63, p > 0.05) and no interaction between baseline day and frequency (F
27, 135 =

0.94, p > 0.05).
A two-way ANOVA (RIM vs. VEH x 30.0 mg/kg PF-3845 vs. VEH) was conducted with

the percent baseline stimulations data. RIM (3.0 and 10.0 mg/kg) was not able to block the
reduction in ICSS produced by 30.0 mg/kg PF-3845 (Fig. 23h); there was no main effect of first
treatment (VEH, 3.0 vs. 10.0 mg/kg RIM) (F 2, 10 = 0.34, p > 0.05), but there was a main effect of
second treatment (VEH vs. PF-3845) (F 2, 10 = 6.10, p < 0.0001); however there was no
interaction between first treatment and second treatment (F 2, 10 = 0.46, p > 0.05) (Fig. 23h). PF3845 (30.0 mg/kg) reduced ICSS regardless of pre-treatment. The percent baseline stimulations
assessment confirmed the rate-frequency analysis. In contrast to the effects observed with THC
and JZL184, the attenuation of stimulations after administration of 30.0 mg/kg PF-3845 was not
mediated through CB1 receptors.
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Figure 23. PF-3845 CB1 antagonism assessment. Panels a – f shows rate-frequency data during
RIM antagonism tests with 30.0 mg/kg PF-3845. Panel g shows all baselines rate-frequency
curves during CB1 testing. Percent maximum control rate is displayed on the Y-axis, logfrequency values are shown on the x-axis. Panel h shows percent baseline stimulations (± SEM)
for all treatments. Significant main effects are denoted by asterisks by the figure legend.
Significant interactions were followed up by post-hoc analysis, and differences are denoted by
asterisks at values that are significantly different from baseline (a – e). ****p < 0.0001, ***p <
0.001, **p < 0.01. Raw overall response rates (stimulations/min; mean ± SEM) during baseline
(B) and test (T) sessions were as follows: (a) VEH + VEH: B (31.53 ± 3.11) T (29.56 ± 2.23); (b)
VEH + 30.0 mg/kg PF-3845: B (33.49 ± 2.96) T (19.70 ± 2.99); (c) 3.0 mg/kg RIM + VEH: B
(32.86 ± 2.87) T (29.37 ± 3.27); (d) 3.0 mg/kg RIM + 30.0 mg/kg PF-3845: B (26.87 ± 3.61) T
(16.47 ± 2.58); (e) 10.0 mg/kg RIM + VEH: B (30.97 ± 4.24) T (28.84 ± 4.51); (f) 10.0 mg/kg
RIM + 30.0 mg/kg PF-3845: B (31.32 ± 4.50) T (22.03 ± 4.52).
PF-3845: Evaluation of CB2 receptors. These experiments were conducted to determine
if the PF-3845 induced attenuation of ICSS was mediated through CB2 receptors. ICSS was
assessed after SR2 (10.0 mg/kg) co-administered with PF-3845 (30.0 mg/kg) to determine if the
CB2 antagonist/inverse agonist SR2 could block the reduction produced by 30.0 mg/kg PF-3845.
Six mice completed testing, and data were analyzed using two-way repeated measure ANOVAs
(treatment x frequency) for each dose-combination tested, similar to JZL184 antagonist testing.
Administration of VEH and VEH did not affect ICSS rates (Fig. 24a); there was a main effect of
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frequency (F 9, 45 = 43.20, p < 0.0001), but no main effect of treatment (F 1, 5 = 2.13, p > 0.05)
and no interaction (F 9, 45 = 1.003, p > 0.05). VEH co-administered with 30.0 mg/kg PF-3845
attenuated ICSS from baseline (Fig. 24b), as there was a main effect of frequency (F 9, 45 = 27.15,
p < 0.0001), treatment (F 1, 5 = 15.10, p < 0.05) and an interaction (F 9, 45 = 2.41, p < 0.05). Posthoc analysis revealed reductions at two frequencies which are denoted on Fig. 24b. Similar to
VEH, SR2 (10.0 mg/kg) and VEH treatment did not affect self-stimulation rate (Fig. 24c); there
was a main effect of frequency (F 9, 45 = 30.18, p < 0.0001), but no main effect of treatment (F 1, 5
= 1.52, p > 0.05) and no interaction (F 9, 45 = 0.48, p > 0.05). Administration of SR2 (10.0 mg/kg)
did not block the attenuation produced by 30.0 mg/kg PF-3845, as there was a main effect of
frequency (F 9, 45 = 22.91, p < 0.0001), no main effect of treatment (F 1, 5 = 6.05, p = 0.05), but a
significant interaction between treatment and frequency (F 9, 45 = 2.11, p < 0.05) (Fig. 24d); posthoc analysis showed reductions at three frequencies which are denoted on Fig. 24d. Baseline
rate-frequency response rates did not differ across conditions tested (Fig. 24e); there was a main
effect of frequency (F 9, 45 = 33.86, p < 0.0001), but no main effect of baseline day (F 3, 15 = 1.14,
p > 0.05), and no interaction between baseline day and frequency (F 27, 135 = 1.51, p > 0.05).
Percent baseline stimulations data were analyzed with a repeated-measures two-way
ANOVA (SR2 vs. VEH x PF-3845 vs. VEH). SR2 (10.0 mg/kg) did not block the attenuation of
stimulations produced by 30.0 mg/kg PF-3845 (Fig. 24f). There was no main effect of first
treatment (VEH vs. SR2) (F 1, 5 = 4.87, p > 0.05), but there was a main effect of second treatment
(VEH vs. PF-3845) (F 1, 5 = 7.96, p < 0.05) and an interaction between first treatment and second
treatment (F 1, 5 = 8.46, p < 0.05). Post-hoc analysis revealed that PF-3845-induced attenuation of
ICSS was not blocked by the CB2 antagonist SR2, as ICSS was reduced (p < 0.01; p < 0.001)
regardless of co-administration with either VEH or SR2 (Fig. 24f). These results confirm the
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findings from rate-frequency analysis, that the attenuation of ICSS is not mediated through CB2
receptors. Interestingly, the attenuation of ICSS produced by PF-3845 (30.0 mg/kg) was not
mediated through CB1 or CB2 receptors.
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Figure 24. PF-3845 CB2 antagonism assessment. Panels a – d shows rate-frequency data during
SR2 antagonism tests with 30.0 mg/kg PF-3845. Panel e shows all baselines rate-frequency
curves during CB2 testing. Percent maximum control rate is displayed on the Y-axis, logfrequency values are shown on the x-axis. Panel f shows percent baseline stimulations (± SEM)
for all treatments. Significant interactions with were investigated with post-hoc analyses, and
differences from baseline (a – e) or other conditions (f) are denoted by asterisks. ***p < 0.001,
**p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ± SEM) during
baseline (B) and test (T) sessions were as follows: (a) VEH + VEH: B (37.10 ± 2.66) T (35.20 ±
2.92); (b) VEH + 30.0 mg/kg PF-3845: B (35.12 ± 3.24) T (27.06 ± 3.57); (c) 10.0 mg/kg SR2 +
VEH: B (34.10 ± 2.39) T (36.31 ± 2.92); (d) 10.0 mg/kg SR2 + 30.0 mg/kg PF-3845: B (37.02 ±
3.05) T (27.71 ± 4.33).
SA-57 ICSS Experiments
SA-57 dose-response assessment. This study evaluated the effect of combined inhibition
of FAAH and MAGL on ICSS. ICSS was examined after administration of the dual
FAAH/MAGL inhibitor SA-57 (1.0, 3.0, 10.0, and 17.8 mg/kg) or VEH. Seven mice completed
the study; the rate-frequency response data was analyzed using two-way repeated measures
ANOVAs (treatment x frequency) for each dose. Low dose SA-57 (1.0 mg/kg) did not affect
self-stimulation rate, while 3.0, 10.0, and 17.8 mg/kg SA-57 significantly attenuated ICSS
responding. VEH produced a main effect of frequency (F 9, 54 = 4.9, p < 0.0001), but no main
effect of treatment (F 1, 6 = 0.05, p > 0.05) and no interaction (F 9, 54 = 1.12, p > 0.05) (Fig. 25a).
Similarly, SA-57 (1.0 mg/kg) produced a main effect of frequency (F 9, 54 = 48.64, p < 0.0001),
but no main effect of treatment (F 1, 6 = 0.81, p > 0.05) and no interaction (F 9, 54 = 0.39, p > 0.05)
(Fig. 25b). As mentioned above, higher doses of SA-57 (3.0, 10.0, and 17.8 mg/kg) reduced
ICSS; 3.0 mg/kg produced a main effect of frequency (F 9, 54 = 29.95, p < 0.0001), treatment (F 1,
6=

40.88, p < 0.001) and an interaction (F 9, 54 = 2.62, p < 0.05) (Fig. 25c). Post-hoc analysis

showed reduced stimulations at five frequencies which are denoted on Fig. 25c. SA-57 (10.0
mg/kg) produced a main effect of frequency (F 9, 54 = 34.51, p < 0.0001), treatment (F 1, 6 =
55.49, p < 0.001) and an interaction (F 9, 54 = 8.17, p < 0.0001) (Fig. 25d); post-hoc analysis
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showed significant attenuation of ICSS at five frequencies which are denoted on Fig. 25d. SA-57
(17.8 mg/kg) also produced a main effect of frequency (F 9, 54 = 40.05, p < 0.0001), treatment (F
1, 6 =

170.8, p < 0.0001) and an interaction (F 9, 54 = 6.06, p < 0.0001) (Fig. 25e). Post-hoc

analysis revealed significant reductions at seven frequencies which are denoted on Fig. 25e.
Baseline rate-frequency curves were analyzed after tests were completed to determine if
there were any differences in basal responding; they did not differ as there was a main effect of
frequency (F 9, 54 = 61.21, p < 0.0001), but no main effect of baseline day (F 4, 24 = 0.47, p >
0.05), and no interaction between treatment and baseline day (F 36, 216 = 0.81, p > 0.05) (Fig. 25f).
The effect of VEH on ICSS was re-assessed after testing and compared to the initial VEH
assessment; they did not differ as there was a main effect of frequency (F 9, 54 = 56.79, p <
0.0001), but no main effect of treatment (F 1, 6 = 0.56, p > 0.05) and no interaction (F 9, 54 = 0.84,
p > 0.05).
A one-way repeated measures ANOVA was used to analyze percent baseline stimulations
data that were calculated for each condition. SA-57 attenuated percent baseline stimulations (F 4,
24 =

49.25, p < 0.0001) (Fig. 26); post-hoc analysis revealed that SA-57 (3.0, 10.0, and 17.8

mg/kg) (67.80 %, 35.06 % and 27.61 %) significantly reduced (p <0.001; p < 0.0001; p <
0.0001) percent baseline stimulations compared to VEH, while low dose SA-57 (1.0 mg/kg) did
not affect percent baseline stimulations. The results of the percent baseline stimulations analysis
agrees with rate-frequency data, as the same doses of SA-57 (3.0, 10.0, and 17.8 mg/kg)
produced attenuation with both measures.
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Figure 25. SA-57 ICSS dose-response assessment. Panels a – e show rate-frequency stimulation
values (± SEM) after VEH or JZL184 (1.0, 4.0, 16.0 and 40.0 mg/kg). Panel f shows all baseline
rate-frequency curves during testing. Percent maximum control rate is displayed on the Y-axis,
log-frequency values are shown on the x-axis. Interactions that achieved significance were
investigated with post-hoc analyses, and differences from baseline are denoted by asterisks.
****p < 0.0001, ***p < 0.001, **p < 0.01. Raw overall response rates (stimulations/min; mean ±
SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH: B (32.21 ± 3.47) T
(32.44 ± 3.89); (b) 1.0 mg/kg SA-57: B (33.21 ± 2.85) T (31.98 ± 3.80); (c) 3.0 mg/kg SA-57: B
(33.45 ± 3.41) T (23.56 ± 3.81); (d) 10.0 mg/kg SA-57: B (32.83 ± 4.02) T (12.19 ± 3.80); (e)
17.8 mg/kg SA-57: B (33.98 ± 2.98) T (9.89 ± 2.20).
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Figure 26. SA-57 ICSS percent baseline stimulations. Values represent mean percent baseline
stimulations (± SEM) after VEH or SA-57. The one-way ANOVA was significant and post-hoc
analysis revealed significant differences from VEH, which are denoted with asterisks. ****p <
0.0001, ***p < 0.001
SA-57 time-course assessment. This study assessed the attenuation of ICSS produced by
10.0 mg/kg SA-57 over time. ICSS was assessed after VEH and 10.0 mg/kg SA-57 at 1, 2, 4, 8,
24 and 48 h after injection. Similar to PF-3845 time-course tests, data were analyzed using twoway repeated measures ANOVAs (Treatment x Frequency) to compare rate-frequency
responding between VEH and SA-57 at each time-point. SA-57 (10.0 mg/kg) attenuated ICSS at
1, 2, 4 and 8 h after injection and returned to baseline 24 hours after injection. Baseline ratefrequency responding for VEH and SA-57 tests did not differ from each other; there was a main
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effect of frequency (F 9, 45 = 28.10, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.12, p >
0.05) and no interaction (F 9, 45 = 0.28, p > 0.05) (Fig. 27a). At the one hour time-point there was
a main effect of frequency (F 9, 45 = 22.06, p < 0.0001), treatment (F 1, 5 = 56.31, p < 0.001) and
an interaction (F 9, 45 = 4.73, p < 0.001) (Fig. 27b); post-hoc analysis revealed reductions at six
frequencies which are denoted on Fig. 27b. Two hours after administration there was a main
effect of frequency (F 9, 45 = 22.63, p < 0.0001), treatment (F 1, 5 = 64.32, p < 0.001) and an
interaction (F 9, 45 = 7.21, p < 0.0001) (Fig. 27c); post-hoc analysis showed reductions at six
frequencies which are denoted on Fig. 27c. Four hours after injection there was a main effect of
frequency (F 9, 45 = 47.54, p < 0.0001), treatment (F 1, 5 = 109.9, p < 0.001) and an interaction (F
9, 45 =

3.09, p < 0.01) (Fig. 27d); post-hoc analysis revealed reductions at five frequencies which

are denoted on Fig. 27d. Eight hours after administration, there was a main effect of frequency
(F 9, 45 = 38.47, p < 0.0001) and treatment (F 1, 5 = 17.35, p < 0.01), but no interaction (F 9, 45 =
1.50, p > 0.05) (Fig. 27e). At the 24 hour time-point 10.0 mg/kg SA-57 stimulations did not
differ from VEH; there was a main effect of frequency (F 9, 45 = 34.50, p < 0.0001), but no main
effect of treatment (F 1, 5 = 0.72, p > 0.05) and no interaction (F 9, 45 = 0.34, p > 0.05) (Fig. 27f).
Similarly, at the 48 hour time-point, there was a main effect of frequency (F 9, 45 = 34.69, p <
0.0001), but no main effect of treatment (F 1, 5 = 0.003, p > 0.05) and no interaction (F 9, 45 =
0.80, p > 0.05) (Fig. 27g).
A repeated-measures two-way ANOVA (Time-point x Treatment) was used to analyze
percent baseline stimulations of VEH and 10.0 mg/kg SA-57 across all time-points (Fig. 27h).
SA-57 decreased ICSS at several time-points, as there was a main effect of time-point (F 5, 25 =
34.73, p < 0.0001), treatment (F 1, 5 = 22.06, p < 0.01), and an interaction between time-point and
treatment (F 5, 25 = 33.30, p < 0.0001). Post-hoc analysis revealed significant attenuation of ICSS
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1, 2, 4 and 8 hours after treatment. These data are concordant with results of rate-frequency
analysis; the attenuation of ICSS produced by SA-57 (10.0 mg/kg) was apparent 1 h after
administration and returned to normal responding within 24 h.
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Figure 27. SA-57 ICSS time-course evaluation. Panels a – g show rate-frequency stimulation
values (± SEM) after VEH and SA-57 (10.0 mg/kg) at each time-point (1, 2, 4, 8, 24 and 48 h);
percent maximum control rate is displayed on the y-axis, log-frequency values are shown on the
x-axis. Panel h shows percent baseline stimulations data over time. Significant main effects of
treatment are denoted by asterisks next on the figure legend. Significant interactions were
investigated with post-hoc analyses, and differences from VEH are denoted by asterisks. ****p <
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean
± SEM) during VEH (V) and 10.0 mg/kg SA-57 (S) conditions were as follows: (a) Baseline: V
(34.53 ± 4.98) S (35.09 ± 3.93); (b) 1 h: V (32.78 ± 3.76) S (11.13 ± 4.10); (c) 2 h: V (30.93 ±
4.16) S (8.58 ± 3.11); (d) 4 h: V (30.68 ± 3.70) S (13.85 ± 3.51); (e) 8 h: V (31.50 ± 4.20) S
(21.78 ± 2.77); (f) 24 h: V (31.76 ± 3.73) S (33.77 ± 4.65); (g) 48 h: V (33.14 ± 4.96) S (32.72 ±
3.52).
SA-57: Evaluation of CB1 receptors. This experiment was conducted to determine if
SA-57 induced attenuation of ICSS can be blocked by the CB1 antagonist/inverse agonist RIM.
Six mice completed the experiments, and data were analyzed using a two-way repeated measures
ANOVA (treatment x frequency) for each dose combination tested. Administration of VEH and
VEH did not differ from baseline, as there was a main effect of frequency (F 9, 63 = 35.71, p <
0.0001), but no main effect of treatment (F 1, 5 = 0.01, p > 0.05), and no interaction (F 9, 45 = 0.19,
p > 0.05) (Fig. 28a). VEH and 10.0 mg/kg SA-57 administration reduced ICSS rates; there was a
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main effect of frequency (F 9, 45 = 30.82, p < 0.0001), treatment (F 1, 5 = 116.60, p < 0.001) and an
interaction (F 9, 45 = 5.55, p < 0.0001) (Fig. 28b). Post-hoc analysis revealed reductions at six
frequencies which are denoted on Fig. 28b. Treatment with 3.0 mg/kg RIM and VEH did not
affect baseline ICSS; there was a main effect of frequency (F 9, 45 = 28.08, p < 0.0001), but no
main effect of treatment (F 1, 5 = 0.38, p > 0.05). There was an interaction (F 9, 45 = 2.36, p <
0.05), but post-hoc analysis revealed that there were no differences at any frequency (Fig. 28c).
RIM (3.0 mg/kg) was not able to block SA-57 induced attenuation of ICSS, as co-administration
with 10.0 mg/kg SA-57 reduced ICSS from baseline; there was a main effect of frequency (F 9, 45
= 27.37, p < 0.0001), but no main effect of treatment (F 1, 5 = 5.01, p > 0.05). However, there was
an interaction (F 9, 45 = 2.41, p < 0.05) (Fig. 28d); post-hoc analysis showed a reduction at one
frequency which is denoted on Fig. 28d. RIM (10.0 mg/kg) co-administered with VEH did not
affect baseline ICSS, as there was a main effect of frequency (F 9, 45 = 28.04, p < 0.0001), but no
main effect of treatment (F 1, 5 = 0.37, p > 0.05) and no interaction (F 9, 45 = 1.92, p > 0.05) (Fig.
28e). Administration of RIM (10.0 mg/kg) blocked the rate-reducing effects produced by SA-57,
as stimulations after co-administration with 10.0 mg/kg SA-57 did not differ from baseline.
There was a main effect of frequency (F 9, 45 = 21.27, p < 0.0001), but no main effect of
treatment (F 1, 5 = 0.11, p > 0.05), and no interaction (F 9, 45 = 1.76, p > 0.05) (Fig. 28f). Baselines
did not differ during any condition tested (Fig. 28g), as there was a main effect of frequency (F 9,
45 =

39.17, p < 0.0001), but no main effect of baseline day (F 5, 25 = 2.01, p > 0.05) and no

interaction between baseline day and frequency (F 45, 225 = 1.07, p > 0.05).
A repeated-measures two-way ANOVA (RIM vs. VEH x 10.0 mg/kg SA-57 vs. VEH)
was conducted to analyze the percent baseline stimulations data. RIM blocked the attenuation of
percent baseline stimulations produced by 10.0 mg/kg SA-57 (Fig. 28h). There was a main effect
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of first treatment (VEH vs. RIM) (F 2, 10 = 11.40, p < 0.01), second treatment (VEH vs. SA-57)
(F 1, 5 = 43.68, p < 0.01) and an interaction between first treatment and second treatment (F 2, 10 =
25.90, p < 0.05). Post-hoc analysis revealed reductions in percent baseline stimulations after 10.0
mg/kg SA-57, but only when first treated with VEH or 3.0 mg/kg RIM. The reduction in
stimulations produced by 10.0 mg/kg SA-57 was blocked by pre-treatment with 10.0 mg/kg
RIM, and therefore was mediated through CB1 receptors. These data confirm the results of ratefrequency analysis, and also coincide with results of JZL184 and THC studies, which were also
found to produce effects mediated through CB1 receptors. Though, they were blocked with 3.0
mg/kg RIM, while the antagonism of SA-57s attenuation required 10.0 mg/kg RIM. It is also
noteworthy that high dose RIM (10.0 mg/kg) did not affect basal ICSS.
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Figure 28. SA-57 CB1 antagonism assessment. Panels a – f shows rate-frequency data during
RIM antagonism tests with 10.0 mg/kg SA-57. Panel g shows all baselines rate-frequency curves
during CB1 testing. Percent maximum control rate is displayed on the y-axis, log-frequency
values are shown on the x-axis. Panel h shows percent baseline stimulations (± SEM) for all
treatments. Significant interactions were followed up by post-hoc analyses, and differences from
baseline (a – g) or other conditions (h) are denoted by asterisks. ****p < 0.0001, ***p < 0.001,
**p < 0.01. Raw overall response rates (stimulations/min; mean ± SEM) during baseline (B) and
test (T) sessions were as follows: (a) VEH + VEH: B (34.83 ± 3.65) T (34.88 ± 3.64); (b) VEH +
10.0 mg/kg SA-57: B (36.48 ± 3.76) T (10.97 ± 3.30); (c) 3.0 mg/kg RIM + VEH: B (33.64 ±
4.43) T (35.88 ± 5.23); (d) 3.0 mg/kg RIM + 10.0 mg/kg SA-57: B (34.32 ± 3.50) T (28.11 ±
5.18); (e) 10.0 mg/kg RIM + VEH: B (36.69 ± 5.45) T (38.65 ± 6.61); (f) 10.0 mg/kg RIM +
10.0 mg/kg SA-57: B (35.07 ± 4.71) T (34.02 ± 6.63).
SA-57: Evaluation of CB2 receptors. This study assessed the involvement of CB2
receptors in the reduction of ICSS produced by SA-57 using the CB2 antagonist/inverse agonist
SR2 (10.0 mg/kg). Six subjects completed tests, and data were analyzed using two-way repeated
measures ANOVAs (treatment x frequency). VEH and VEH administration did not affect ICSS
behavior; there was a main effect of frequency (F 9, 45 = 32.61, p < 0.0001), but no main effect of
treatment (F 1, 5 = 0.004, p > 0.05) and no interaction (F 9, 45 = 1.06, p > 0.05) (Fig. 29a).
Administration of VEH and 10.0 mg/kg SA-57 reduced self-stimulation rate; there was a main
effect of frequency (F 9, 45 = 46.55, p < 0.0001), treatment (F 1, 5 = 73.80, p < 0.001) and an
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interaction (F 9, 45 = 5.24, p < 0.0001) (Fig. 29b). Post-hoc analysis showed significant decreases
at seven frequencies which are denoted on Fig. 29b. SR2 (10.0 mg/kg) co-administered with
VEH did not affect ICSS; there was a main effect of frequency (F 9, 45 = 29.76, p < 0.0001), but
no main effect of treatment (F 1, 5 = 0.05, p > 0.05) and no interaction (F 9, 45 = 0.85, p > 0.05)
(Fig. 29c). SR2 (10.0 mg/kg) did not block the reduction of ICSS produced by 10.0 mg/kg SA57, as there was a main effect of frequency (F 9, 45 = 30.81, p < 0.0001), treatment (F 1, 5 = 84.46,
p < 0.001) and an interaction (F 9, 45 = 4.84, p < 0.0001) (Fig. 29d). Post-hoc analysis revealed
reductions at seven frequencies which are denoted on Fig. 29d. Baseline rate-frequency
stimulations did not differ during any condition tested (Fig. 29e); there was a main effect of
frequency (F 9, 45 = 41.88, p < 0.0001), but no main effect of baseline day (F 3, 15 = 1.14, p >
0.05), and no interaction between baseline day and frequency (F 27, 135 = 0.98, p > 0.05).
Percent baseline stimulations data were analyzed using a two-way, repeated-measures
ANOVA (RIM vs. VEH x 10.0 mg/kg SA-57 vs. VEH). SR2 (10.0 mg/kg) did not block the
attenuation of stimulations produced by 10.0 mg/kg SA-57 (Fig. 29f); there was no main effect
of first treatment (VEH vs. SR2) (F 1, 5 = 1.07, p > 0.05), but there was a main effect of second
treatment (VEH vs. SA-57) (F 1, 5 = 153.6, p < 0.0001), as SA-57 produced a reduction of ICSS.
There was no interaction between first treatment and second treatment (F 1, 5 = 1.14, p > 0.05).
SA-57 (10.0 mg/kg) reduced ICSS when co-administered with either 10.0 mg/kg SR2 or VEH,
indicating that the reduction in stimulations is not mediated through CB2 receptors. Results are
confirmed by rate-frequency analysis, where SR2 (10.0 mg/kg) was unable to block the
reduction attenuation produced by SA-57. These findings are similar to those obtained with
THC, PF-3845, and JZL184 as none of these drugs produce ICSS modulating effects that are
CB2 receptor dependent.

114

a

b

VEH + VEH
120

V E H + 1 0 .0 S A - 5 7
120

B a s e lin e

B a s e lin e
V E H + 1 0 .0 S A - 5 7
100

80

80

% MCR

% MCR

VEH + VEH
100

60

60

**
***

40

40

****

20

20

0

0

****
****

1 .7

1 .7 5

1 .8

1 .8 5

1 .9

1 .9 5

2 .0

2 .0 5

2 .1

2 .1 5

2 .2

2 .2 5

1 .7

1 .7 5

1 .8

1 .8 5

L o g F re q u e n c y

c

****

1 .9

1 .9 5

2 .0

2 .0 5

2 .1

2 .1 5

2 .2

2 .2 5

L o g F re q u e n c y

d

1 0 .0 S R 2 + V E H
120

1 0 .0 S R 2 + 1 0 .0 S A -5 7
120

B a s e lin e

B a s e lin e

1 0 .0 S R 2 + V E H

1 0 .0 S R 2 + 1 0 .0 S A - 5 7

100

100

80

80

% MCR

% MCR

*

60

40

60

***

40

*** ****
20

20

0

0

****

1 .7

1 .7 5

1 .8

1 .8 5

1 .9

1 .9 5

2 .0

2 .0 5

2 .1

2 .1 5

2 .2

****
1 .7

2 .2 5

1 .7 5

L o g F re q u e n c y

1 .8 5

*

****

1 .9

1 .9 5

2 .0

2 .0 5

2 .1

2 .1 5

2 .2

L o g F re q u e n c y

B a s e lin e s

e

1 .8

e

120

P e rc e n t B a s e lin e S tim u la tio n s
120

B a s e lin e V E H + V E H

VEH
S A - 5 7 ( 1 0 .0 m g /k g )

B a s e lin e V E H + 1 0 .0 S A - 5 7

****

B a s e lin e 1 0 .0 S R 2 + V E H
100

100

% B a s e lin e S tim u la tio n s

B a s e lin e 1 0 .0 S R 2 + 1 0 .0 S A - 5 7

% MCR

80

60

40

80

60

40

***

20

20

0

0
1 .7

1 .7 5

1 .8

1 .8 5

1 .9

1 .9 5

2 .0

2 .0 5

2 .1

2 .1 5

2 .2

V + V

2 .2 5

L o g F re q u e n c y

Figure Continues
115

V + SA

10 SR 2 + V 10 SR 2 + SA

2 .2 5

Figure Continued
Figure 29. SA-57 CB2 antagonism assessment. Panels a – d shows rate-frequency data during
SR2 antagonism tests with 10.0 mg/kg SA-57. Panel e shows all baselines rate-frequency curves
during CB2 testing. Percent maximum control rate is displayed on the y-axis, log-frequency
values are shown on the x-axis. Panel f shows percent baseline stimulations (± SEM) for all
treatments. Significant main effects were denoted on figure legends. Significant interactions with
were investigated with post-hoc analyses, and differences from baseline (a – e) are denoted by
asterisks. ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min;
mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH + VEH: B
(38.23 ± 3.87) T (38.37 ± 3.91); (b) VEH + 10.0 mg/kg SA-57: B (35.89 ± 3.45) T (16.99 ±
3.57); (c) 10.0 mg/kg SR2 + VEH: B (34.09 ± 2.78) T (34.20 ± 2.46); (d) 10.0 mg/kg SR2 + 10.0
mg/kg SA-57: B (34.45 ± 4.37) T (13.63 ± 4.09).
SA-57 Spontaneous Locomotor Activity Assessment
Spontaneous locomotor activity was assessed after VEH or SA-57 treatment (1.0, 3.0 and
10.0 mg/kg). Distance travelled (m), mean speed (m/s) and time immobile (s) were analyzed
using one-way ANOVAs (Fig. 30). SA-57 reduced distance travelled (F 3, 32 = 14.78, p <
0.0001). Post-hoc analysis revealed that 10.0 mg/kg SA-57 significantly reduced (p < 0.0001)
distance travelled, while 1.0 and 3.0 mg/kg SA-57 did not differ from VEH (Fig. 30a). Timeimmobile increased with SA-57 (F 3, 32 = 85.14, p < 0.0001). Post-hoc analysis showed that 10.0
mg/kg SA-57 increased (p < 0.0001) time-immobile, while 1.0 and 3.0 mg/kg did not produce an
effect (Fig. 30b). SA-57 did not affect adjusted speed of locomotion (F 3, 32 = 0.33, p > 0.05)
(Fig. 30c). Similar to ICSS results, 10.0 mg/kg SA-57 reduced locomotor behavior, but in
contrast, 3.0 mg/kg SA-57 did not disrupt spontaneous locomotor activity, but reduced ICSS.
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Figure 30. SA-57 spontaneous locomotor activity. All panels show dose of SA-57 and VEH on
the x-axis. Panel a shows distance travelled on the y-axis, panel b shows time-immobile, and
panel c shows adjusted speed. Significant one-way ANOVAs were investigated with post-hoc
analysis, and significant differences from VEH are denoted by asterisks. ****p < 0.0001
SA-57 Endocannabinoid Quantification Experiment
This experiment assessed the ability of SA-57 to alter endocannabinoid levels in specific
brain regions. Concentrations of 2-AG, AEA, and AA were determined from samples of
PFC,NAc, VMB, amygdala, and cerebellum after treatment with VEH, or SA-57 (1.0 or 10.0
mg/kg). Separate one-way ANOVAs were conducted within each brain region to analyze
concentration changes from VEH treatment.
SA-57 increased 2-AG in the PFC (F 2, 12 = 161.4, p < 0.0001); post-hoc analysis showed
that treatment with 10.0 mg/kg SA-57 increased (p < 0.0001) concentrations of 2-AG to over 16fold of VEH concentrations, while treatment 1.0 mg/kg did not differ from VEH (Fig. 31a).
Administration of SA-57 increased AEA in the PFC (F 2, 12 = 7.07, p < 0.01); post-hoc analysis
showed that both 1.0 and 10.0 mg/kg SA-57 increased (p < 0.01) AEA to almost 3-fold of VEH
levels (Fig. 31b). SA-57 decreased AA concentrations in the PFC (F 2, 12 = 9.36, p < 0.01); posthoc analysis showed that 10.0 mg/kg SA-57 reduced AA concentrations to 66 % of VEH levels,
while 1.0 mg/kg SA-57 did not affect AA levels (Fig. 31c).
Treatment with SA-57 increased 2-AG in the NAc (F 2, 12 = 708.0, p < 0.0001); post-hoc
analysis showed that 1.0 mg/kg SA-57 did not differ from VEH, but 10.0 mg/kg SA-57 increased
(p < 0.0001) 2-AG to over 12-fold VEH concentrations (Fig. 31a). SA-57 increased AEA in the
NAc by (F 2, 12 = 7.55, p < 0.01); post-hoc analysis showed that 1.0 and 10.0 mg/kg SA-57
increased (p < 0.01; p < 0.05) AEA to over 2-fold VEH concentrations (Fig. 31b).
Administration of SA-57 reduced AA tissue concentration in the NAc; there was a main effect of
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SA-57 treatment (F 2, 12 = 4.05, p < 0.05), but post-hoc analysis showed that 1.0 and 10.0 mg/kg
SA-57 AA levels did not differ from VEH (Fig. 31c).
SA-57 treatment increased 2-AG in the VMB (F 2, 12 = 33.41, p < 0.0001); post-hoc
analysis showed that 10.0 mg/kg SA-57 increased 2-AG to over 6-fold of VEH concentrations,
while 1.0 mg/kg SA-57 did not differ from VEH levels (Fig. 31a). SA-57 increased AEA in the
VMB (F 2, 12 = 9.49, p < 0.01); both 1.0 and 10.0 mg/kg SA-57 increased (p < 0.05; p < 0.01)
AEA concentrations to 5-fold and 8-fold VEH levels respectively (Fig. 31b). SA-57 did not
modulate AA concentrations in the VMB (F 2, 12 = 0.01, p > 0.05) (Fig. 31c).
SA-57 increased 2-AG in the amygdala (F 2, 12 = 112.00, p < 0.0001); post-hoc analysis
showed that 10.0 mg/kg SA-57 increased (p < 0.0001) 2-AG to over 11-fold VEH
concentrations, while 1.0 mg/kg SA-57 did not affect 2-AG levels (Fig. 31a). Treatment with
SA-57 increased AEA in the amygdala (F 2, 12 = 3.69, p < 0.01); post-hoc analysis showed that
low dose SA-57 (1.0 mg/kg) increased (p < 0.01) AEA to over 3-fold VEH levels, while the high
dose SA-57 (10.0 mg/kg) did not affect AEA concentrations (Fig. 31b). SA-57 reduced AA
tissue concentrations in the amygdala (F 2, 12 = 32.71, p < 0.0001); post-hoc analysis showed that
low dose SA-57 (1.0 mg/kg) did not affect AA, while high dose SA-57 (10.0 mg/kg) reduced (p
< 0.0001) AA concentrations to 46 % of VEH levels (Fig. 31c).
Administration of SA-57 increased 2-AG in the cerebellum after treatment with SA-57 (F
2, 12 =

165.4, p < 0.0001); post-hoc analysis showed that high dose SA-57 (10.0 mg/kg) increased

2-AG increased (p < 0.0001) to over 4-fold VEH concentrations. In contrast, low dose SA-57
(1.0 mg/kg) 2-AG levels did not differ from VEH (Fig. 31a). SA-57 produced an increase of
AEA in the cerebellum (F 2, 12 = 27.30, p < 0.0001); post-hoc analysis showed that both 1.0 and
10.0 mg/kg SA-57 increased (p < 0.001; p < 0.0001) AEA concentrations to over 5-fold and 6-
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fold VEH levels respectively (Fig. 31b). SA-57 treatment decreased AA in the cerebellum (F 2, 12
= 32.15, p < 0.0001); post-hoc analysis showed that high dose SA-57 (10.0 mg/kg) significantly
reduced (p < 0.0001) AA to 57 % of VEH levels, while low dose SA-57 (1.0 mg/kg) did not
affect AA concentrations (Fig. 31c).
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Figure 31. SA-57 endocannabinoid and AA concentrations. All panels show brain region on the
x-axis (AMYG = amygdala, CEREB = cerebellum). Panel a shows 2-AG levels on the y-axis,
panel b shows AEA, and panel c displays AA. One-way ANOVAs were calculated within each
brain region and substrate measured. Significant one-way ANOVAs were investigated with posthoc analyses, and significant differences from corresponding VEH treatment are denoted by
symbols. + p < 0.0001, #p < 0.001, !p < 0.01, *p < 0.05
Discussion
These studies were conducted to evaluate the effects of the exogenous agonist THC, and
catabolic enzyme inhibitors of the endocannabinoids AEA and 2-AG on ICSS and other
behaviors. One of the goals of this study was to determine the impact of THC on operant
responding for brain stimulation reward. In general, pharmacological treatments that reduce the
amount of electrical stimulation needed to maintain reinforcement are interpreted as reducing
brain reward thresholds, or potentiating reinforcement produced by brain stimulation (R. A.
Wise, 2005). Conversely, treatments that reduce ICSS, or increase the amount of stimulation
needed to maintain reinforcement are interpreted as increasing reward thresholds or producing
anhedonia, or general motor impairment (Cryan, et al., 2003; Markou & Koob, 1991). The goal
of these studies is to test whether exogenous and endogenous cannabinoids alter reward
motivated behaviors mediated through the mesolimbic system. In these studies, we utilized
JZL184 to inhibit MAGL, PF-3845 to inhibit FAAH, and SA-57 the dual FAAH/MAGL
inhibitor in order to discern the effects of 2-AG, AEA, and the combination, respectively. To our
knowledge, none of these drugs have been tested with ICSS in mice, and PF-3845, JZL184, and
SA-57 have not been tested in any species.
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Cocaine
Cocaine (5.0 and 10.0 mg/kg) produced a dose-related increase of ICSS, or leftward shift
in the frequency response curve, indicating decreased reward thresholds, or increased brainreward function. These studies were conducted because cocaine reliably increases mouse ICSS
behavior, indicative of enhanced brain-reward function. Thus, cocaine was employed as a
positive control for this study (Fish, et al., 2012; Robinson, et al., 2012). These data show that
psychomotor stimulants potentiate ICSS in the C57BL/6 mouse, as cocaine produced a robust
facilitation of ICSS.

123

Table. 2
Summary of THC and Enzyme Inhibitor Results
Results
Drug

ICSS

% Baseline
R-F
Stimulations

THC (s.c.)
↓
Doses (mg/kg): (3, 5.6 & 10)
Antagonist Doses:
JZL184 (i.p.)
↓
Doses (mg/kg): (16 & 40)
Antagonist Doses:

↓

↓

(16 & 40)

NAc:
VMB:
Amygdala:
Cerebellum:

↑(40)
↑(4&40)
↑(4&40)
↑(4&40)
↑(4&40)

(40)
R-F = 1 – 24 h
% baseline = 1 – 24 h

↓

↓

(30)

(30)
R-F = 1 – 24 h
% baseline = 2 – 24 h

SA-57 (i.p.)
↓
↓
Doses (mg/kg): (3, 10 & 17.8) (3, 10 & 17.8)
Antagonist Doses:

Brain Region: PFC:

(10)
R-F = 5 min – 8 h
% baseline = .5 – 8 h

↓

2-AG

Receptor Mediation
CB1
CB2

↓

(5.6 & 10)

PF-3845 (i.p.)
↓
Doses (mg/kg):
(30)
Antagonist Doses:

JZL184

ICSS
Time-course

AEA

↓(40)
↓(40)

↓
(10)
R-F = 1 – 8 h
% baseline = 1 – 8 h
AA

↓(40)

YES
(10)
(3.0 RIM)

Spontaneous
locomotor Activity

↓

N.T.

(10 & 20)

↓

↓

(40)

(40)
(16: immobility only)

YES
(40)
(3.0 RIM)

NO
(40)
(10.0 SR2)

NO
(30)
(10.0 RIM)

NO
(30)
(10.0 SR2)

N.T.

N.T.

YES
(10)
(10.0 RIM)

NO
(10)
(10.0 SR2)

N.T.

↓

SA-57

2-AG

PFC:
NAc:

↓(40)
↓(40)
↓(40)

NO
(10)
(3.0 SR2)

Operant (food)
Responding

VMB:
Amygdala:
Cerebellum:

↑(10)
↑(10)
↑(10)
↑(10)
↑(10)

(10)

AEA

AA

↑(1&10) ↓(10)
↑(1&10)
↑(1&10)
↑(1)
↓(10)
↑(1&10) ↓(10)

CB1 and CB2 Antagonists
One intriguing finding of this study was that the CB1 antagonist, RIM (3.0 and 10.0
mg/kg), did not produce a disruption of ICSS in C57BL/6 mice as shown on Table 2. This may
be a species-specific effect, as all other studies that have reported disruption of ICSS with CB1
antagonists assessed rats. Some rat studies have reported decreases in baseline ICSS after
moderate doses of RIM including 1.0 and 3.0 mg/kg (De Vry, et al., 2004; Deroche-Gamonet, et
al., 2001; Trujillo-Pisanty, et al., 2011) while others don’t report disruption of ICSS until higher
doses of 10.0 mg/kg RIM (Xi, et al., 2008) or higher (Arnold, et al., 2001). Specifically, Arnold
and colleagues observed that doses up to 10.0 mg/kg RIM did not disrupt ICSS in Lewis rats
(Arnold, et al., 2001), so our findings in mice are not unprecedented. It is well-accepted that CB1
antagonists disrupt ICSS behavior, and it has been cited as indirect evidence that cannabinoids
can enhance dopamine levels in the mesolimbic system (Tanda & Goldberg, 2003). The
inconsistency of RIM effects in this assay raises questions about how endocannabinoids function
in the mesolimbic system. The present data indicate that C57BL/6 mice may not be sensitive to
ICSS-facilitating effects of cannabinoids, since they were not affected by high doses of RIM.
Interestingly though, the only other study that has shown no effect on ICSS with a dose of 10.0
mg/kg RIM was conducted in Lewis rats, which is a strain that has produced facilitation of ICSS
with THC (Arnold, et al., 2001; Gardner, et al., 1988; Lepore, et al., 1996). The lack of ratedecreasing effects with CB1 antagonism does not necessarily mean that agonists would be
precluded from producing the opposite effect. Thus, C57BL/6 mice may still show facilitating
effects of ICSS with cannabinoid agonists. Similar to the CB1 antagonist RIM, the CB2
antagonist SR2 (3.0 and 10.0 mg/kg) did not produce an effect on ICSS alone. We did not expect
SR2 to reduce ICSS when administered alone, but given recent reports about the role of CB2 in
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drug reward, it was interesting to confirm that it had no effect (Ignatowska-Jankowska, Muldoon,
et al., 2013; Xi, et al., 2011). This is a novel finding, as CB2 antagonists have not been assessed
in ICSS in any species to our knowledge.
THC
As summarized on Table 2, THC produced a dose-related attenuation of ICSS behavior
or a rightward shift in the frequency-response curve. Two potential interpretations of this finding
are that THC reduced brain reward functioning, or simply reduced behavior through a nonmesolimbic mediated, or non-specific motor effect. Although we hypothesized that THC would
facilitate ICSS in the mouse, there is much evidence to the contrary reported in the rat (see table
1). In fact, the majority of studies that reported low doses of THC facilitating ICSS used a
specific strain of rat (Lewis), so it is likely a strain-specific effect (Gardner, et al., 1988; Lepore,
et al., 1996). Similar to many studies discussed in the introduction, low doses of THC (0.3 and
1.0 mg/kg) did not affect ICSS. The most recent study with THC and ICSS showed that only
low-dose THC (0.1 mg/kg) produced facilitating effects, while 1.0 mg/kg THC reduced
responding in Sprague-Dawley rats (Katsidoni, et al., 2013). We did not assess any doses lower
than 0.3 mg/kg THC, as there was no effect with 1.0 or 0.3 mg/kg THC. Lower doses may have
potentially facilitated ICSS in the C57BL/6J mouse, but we assessed a 10-fold range of
ineffective doses, and there was no trend toward increasing ICSS with the lowest dose of THC
(0.3 mg/kg) (p = 0.08). If anything there was a trend toward decreasing responding as shown on
Fig. 4d. Additionally, time-course evaluations with low doses of THC may have unmasked
facilitating effects. In the present study, we elected to focus on the ICSS decreasing effects of
THC, as they were the prominent effects observed during initial dose-response tests. The
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attenuation of ICSS produced by 10.0 mg/kg returned to baseline between 8 and 24 hours after
administration.
It is important to note that the 3 studies that show ICSS is facilitated by THC analyzed
changes in “threshold,” which typically uses linear regression to determine calculate the
frequency which maintains a given level of responding (e.g. 0%, 50%, etc.). Threshold analysis
is a common way to analyze ICSS data; the methods used to determine thresholds and changes in
thresholds however, vary greatly between laboratories. ICSS rate-frequency response curves are
typically curvilinear or sigmoidal shaped. Thus, by using linear regression to determine lines,
some of the data is usually left out of analysis to create a straight slope. In addition to removing
data from analysis, some investigators also “interpolate” data points, or add data when data
doesn’t follow a linear trend. These practices make can make the data analysis process more
subjective than traditional statistical measures such as ANOVA. Also, because of the wide range
of response patterns shown between subjects and tests, exhaustive lists of “rules” for inclusion
and exclusion of data must be created by experimenter. These rules are almost never reported in
the methods section of papers, making it very difficult to infer how the experimental values were
actually calculated. Because of all of these potential issues with analyzing ICSS thresholds, we
chose to analyze data using standard repeated-measures, two-way (frequency x treatment)
ANOVAs. By doing so, we were able to analyze all data without altering or removing any
information, thereby limiting subjectivity. We also calculated percent baseline stimulations,
which similar to threshold determinations is a summation measure, but more objective.
Although there is supporting biochemical evidence that exogenous cannabinoids increase
both tonic and phasic dopamine in the nucleus accumbens, it is important to note that many of
those reports used synthetic agonists such as WIN 55,212-2 (Cheer, et al., 2004; Cheer, Wassum,
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et al., 2007), although some showed a similar effect with THC (J. Chen, et al., 1990; J. P. Chen,
et al., 1991). It is important to note also that nearly all of those studies examined cannabinoid
agonists that were administered i.v., as route of administration can have a considerable influence
on drug effects. The i.v. route of administration may provide the most relevant data to human
cannabinoid use, as humans typically inhale marijuana. Both inhalation and i.v. administration
allow drugs reach the brain much more quickly, and with less early metabolism than other
routes, which has been associated with higher abuse and dependence liability. It remains to be
determined whether i.v. administration of THC could potentially produce a facilitation of ICSS
in C57BL/6 mice. Additionally, although THC and other cannabinoid agonists produce increases
in dopamine levels in the nucleus accumbens, the magnitude of the increase is not nearly as large
as that produced by cocaine, or other psychomotor stimulants. THC can produce increases in
extracellular dopamine in the nucleus accumbens up to about 150 % of baseline dopamine
(Tanda, et al., 1997). In contrast, cocaine has been shown to increase dopamine levels to over
400% of basal levels (Panos & Baker, 2010). Furthermore, stimuli other than drugs of abuse can
also produce increases in dopamine in the nucleus accumbens. For example, studies have shown
that an aversive tail-pinch can produce increases in dopamine measured by in vivo voltammetry
(D'Angio, Serrano, Rivy, & Scatton, 1987). This suggests that dopamine release in the nucleus
accumbens may be related to salient stimuli in general, rather than being specific to drugs of
abuse. This is important to take into consideration when evaluating data on cannabinoid agonistinduced increases in extracellular dopamine.
In the present study, THC-induced reduction of ICSS was found to be mediated through
CB1 receptors, as it was blocked with RIM (3.0 mg/kg) pre-treatment. This effect has been
established in rat studies using ICSS, as rightward shifts of rate-frequency response curves
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produced by THC were blocked by pre-treatment with RIM (Kwilasz & Negus, 2012; Vlachou,
et al., 2007). Even though we found that CB1 antagonism blocked THC-induced reduction of
ICSS, we wanted to rule out the involvement of CB2 receptors. As expected, CB2 blockade did
not prevent the attenuation of ICSS produced by THC. Although CB2 receptors have recently
been implicated in cocaine reinforcement and nicotine reward (Ignatowska-Jankowska,
Muldoon, et al., 2013; Xi, et al., 2011), they do not appear to be involved in the reduction of selfstimulations produced by THC.
The rate-reducing effects produced by THC were not specific to ICSS alone; we found
that high dose THC (10.0 mg/kg) also reduced operant responding for food pellets, while 5.0
mg/kg did not affect response rates. These results may seem incongruent with studies in the
literature, as cannabinoid agonists have been shown to increase food intake (Wiley et al., 2005).
But it is important to note that food intake is a different measure than performing an operant
response for food pellets. The latter requires a trained behavior that has a large motor
component, while the former requires a less complex, more naturalistic feeding behavior. The
reduction of nose-poking to receive food-pellets may represent more of an overall motor effect
than a feeding-specific effect. Similar to these effects seen on ICSS and food-maintained operant
responding, THC also reduced spontaneous locomotor activity. A recent study in rats reported
that 1.0 mg/kg THC reduced locomotor activity, while a lower dose (0.1 mg/kg) increased
locomotor activity (Katsidoni, et al., 2013). Many other studies in mice have reported decreases
in locomotor activity with 3.0 mg/kg or higher doses of THC (Kinsey, O'Neal, et al., 2011; L. E.
Long et al., 2010; Varvel et al., 2006; Wiley et al., 2013). This decrease in overall activity
produced by cannabinoids makes interpretation of the ICSS effects presented here difficult.
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Cannabinoid Catabolic Enzyme Inhibitors
JZL184. The MAGL inhibitor JZL184 (16.0 and 40.0 mg/kg) produced a decrease in
ICSS responding, or a rightward shift of the rate-frequency curve, which might be interpreted as
a decrease in brain-reward function in the mesolimbic system. These results are similar to what
we and others have reported with THC and other cannabinoid agonists, but with a lesser
magnitude of reduction. This finding is also concurrent with the one study in the ICSS literature
that has assessed a 2-AG modulating drug. Vlachou and colleagues have shown the purported
AEA transport inhibitor AM-404 reduces ICSS responding in rats through a CB1 dependent
mechanism (Vlachou, et al., 2008). The relevance of this finding to the present study is related to
findings by Wiskerke and colleagues, who have reported that AM-404 (1.0 mg/kg) causes
increases of extracellular 2-AG in the nucleus accumbens shell of rats, while not affecting AEA
levels (Wiskerke, et al., 2012). AM-404 may be attenuating ICSS via increased 2-AG in brainreward relevant regions (e.g. NAc) which converges with our JZL184 data in ICSS. The MAGL
inhibitor JZL184 also affects ICSS through a similar mechanism. Similar to our data with THC,
the attenuation of ICSS produced by JZL184 was a CB1 dependent effect, and it was not affected
by CB2 antagonism (Vlachou, et al., 2006; Vlachou, et al., 2008). The time-course of JZL184induced suppression of ICSS behavior lasted up to 48 h after treatment, which was longer than
THC-induced attenuation or ICSS, though the reduction of responding was not as drastic. This
finding is consistent with the fact that JZL184 is an irreversible MAGL inhibitor that can
produce increases in brain 2-AG that last up to 24 h (J. Z. Long, Li, et al., 2009).
In addition to attenuating ICSS, JZL184 (40.0 mg/kg) reduced operant responding for
food and decreased spontaneous locomotor activity. As mentioned above, the reduction in nosepoke behavior is probably not reflective of a decrease in motivation for feeding, but more of a
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general motor effect. Studies that have shown increases in food-intake with cannabinoids have
not assessed feeding via an operant response (Wiley, et al., 2005). The reduction in operant
responding for food by JZL184 (40.0 mg/kg) was of a similar magnitude (≈ 50%) to that
produced by THC (10.0 mg/kg).
PF-3845. The FAAH inhibitor PF-3845 reduced ICSS responding, but only at a very high
dose (30.0 mg/kg). It is important to note that no other studies in the literature have assessed a
dose of 30.0 mg/kg PF-3845. The results were followed up with a time-course study, where we
found it produced a moderate attenuation of ICSS that persisted until between 24 and 48 h after
treatment. The effect was recapitulated during antagonism tests, where we found that PF-3845induced reduction of ICSS was not mediated through CB1 or CB2 receptors. It was interesting, as
the magnitude of effect was near that produced by JZL184, though not mediated through
cannabinoid receptors. There are a few possible explanations for the observed effects of PF3845. This high dose of PF-3845 could simply be producing a non-specific effect, given the fact
that 30.0 mg/kg is a 3-fold higher dose than the highest reported in the literature (Ahn, et al.,
2009; Booker, et al., 2012; Ramesh et al., 2011; Wiskerke, et al., 2012). PF-3845 (30.0 mg/kg)
could also be producing its effects through a substrate other than AEA. FAAH is implicated in
the metabolism of fatty acid amides other than AEA, including PEA, and OEA. It has been
shown that AEA, OEA, PEA, and other fatty acid amides have been shown to bind to
peroxisome proliferator-activated alpha (PPARα) receptors, at TRPV1 receptors and other noncannabinoid receptors (Jhaveri, et al., 2008; Ross, 2003; Zygmunt, et al., 1999). These receptors
are also found throughout brain regions in the mesolimbic system (Luchicchi et al., 2010; Melis
et al., 2010; Melis, et al., 2006). We will be pursuing this line of research in the future by
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assessing antagonism of these receptors known to interact with AEA and other substrates
increased during FAAH inhibition.
SA-57. The combined FAAH/MAGL inhibitor SA-57 (3.0, 10.0, and 17.8 mg/kg) also
produced an attenuation, or rightward shift of ICSS, indicating it may be producing a reduction
of brain-reward functioning in the mesolimbic pathway. The magnitude of ICSS reduction
produced by SA-57 was more similar to that of THC than JZL84 or PF-3845. SA-57 produced its
effects on brain-reward functioning within 1 h after administration and returned to normal
stimulation rates within 24 h. Similar to THC and JZL184, but in contrast to PF-3845, SA-57induced attenuation of ICSS was mediated through CB1 receptors, and was also not affected by
CB2 antagonism. Interestingly, a higher dose of the CB1 antagonist RIM (10.0 mg/kg) was
required to block the effects produced by SA-57 than was used to block THC or JZL184 (3.0
mg/kg). This may indicate the involvement of a greater number of CB1 receptors following
administration of SA-57 (10.0 mg/kg) than with attenuation caused with THC and JZL184, since
more antagonist was required to block the effect. SA-57 (10.0 mg/kg) reduced locomotor activity
of naïve mice, similar to JZL184.
Endocannabinoids in Brain
High dose JZL184 (40.0 mg/kg) increased 2-AG in all brain regions ranging between 4fold and 13-fold of VEH levels, while low dose JZL184 (4.0 mg/kg) significantly increased 2AG in all regions except prefrontal cortex. JZL184 (40.0 mg/kg) also produced a decrease in
AEA in the prefrontal cortex and nucleus accumbens and trended toward a reduction in the
amygdala. Not surprisingly, JZL184 (40.0 mg/kg) also significantly reduced AA levels in almost
all regions.
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High-dose SA-57 (10.0 mg/kg) increased 2-AG in all brain regions, while low-dose SA57 (1.0 mg/kg) did not affect 2-AG levels as shown on Fig. 31. There was also a significant
increase in AEA with 1.0 and 10.0 mg/kg SA-57 in nearly all brain regions, and reduced AA
levels in the PFC, amygdala, and cerebellum only with high-dose SA-57 (10.0 mg/kg).
It was notable that 2-AG levels were increased across all brain regions with JZL184 (4.0
and 40.0 mg/kg); 4.0 mg/kg only failed to increase 2-AG in the prefrontal cortex, although there
was a trend toward significance (p = 0.09). If the reduction ICSS via MAGL inhibition is a 2AG-mediated effect, which it seems to be since it is CB1 mediated, the biochemical data could
mean that the effect was driven by 2-AG elevation in the PFC. This is conceivable, since the
PFC is responsible for executive functioning and the control of goal-directed behavior, and it has
been reported that cannabinoid receptors, as well as diacylglycerol lipase-alpha, a 2-AG
biosynthetic enzyme, are localized on glutamatergic neurons in the PFC (Lafourcade et al.,
2007). Disrupting cannabinoid signaling in the PFC could interfere with motivated behavior by
reducing dopamine output.
When assessing the brain level endocannabinoid data after SA-57, it was apparent that 2AG elevation was necessary for disruption of ICSS through CB1 receptors. Low-dose SA-57 (1.0
mg/kg) significantly increased AEA in all brain regions, but failed to alter ICSS behavior.
However, the combined FAAH/MAGL inhibitor SA-57 produced a higher degree of attenuation
than either FAAH or MAGL inhibition alone, so it seems that AEA played a role in this
behavior. There are a few different reasons for why that might be. FAAH and MAGL inhibition
combined may simply increase the amount of free endocannabinoids in the brain, producing an
additive effect of AEA and 2-AG. AEA and 2-AG could also be producing their effects in
distinct synapses within these brain regions. Although this study has shown increases in all brain
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regions measured, we are not able to detect disparities between AEA and 2-AG at the synaptic
level using these measures. That would be better assessed using in vivo microdialysis. As was
noted in the introduction, AEA and 2-AG have distinct biosynthetic and metabolic pathways,
which may underlie their differences in behavioral effects. For example, MAGL is located presynaptically, while FAAH is located in the post-synaptic terminal. It appears that AEA and 2-AG
are producing cooperative effects in this assay. Dual FAAH and MAGL inhibition has also been
shown to produce more THC-like effects than inhibiting either independently, including memory
deficits, and substituting for the discriminative stimulus of THC (J. Z. Long, Nomura, et al.,
2009; L. E. Wise, et al., 2012).
Additionally, we showed that the reduction in response rates produced by PF-3845 was
CB1 receptor independent, suggesting that it is suppressing ICSS through a completely different
mechanism than SA-57, JZL184, and THC. It may be producing its effects through increased
levels of AEA, as demonstrated with the neurochemical data. If this is the case, these effects are
mediated through non-cannabinoid receptors activated by AEA (e.g., PPARα, TrpV1), or via a
non-specific mechanism. It would have been helpful for the interpretation of endocannabinoid
level results to assess intermediate doses of JZL184 and SA-57. Moderate doses of JZL184 (16.0
mg/kg) and SA-57 (3.0 mg/kg) both produced effects in ICSS, but not in distance travelled or
operant responding for food in the case of JZL184.
General Discussion
Given the decreases in ICSS following treatment with direct and indirect cannabinoid
agonists, it was important to test whether these compounds produced hypolocomotion, a welldocumented cannabinoid behavioral effect. These experiments were intended to help delineate
potential reward-attenuating effects from non-selective decreases in motor function. Both
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JZL184 and SA-57 reduced spontaneous locomotor activity, but only with the highest dose tested
(40.0 and 10.0 mg/kg, respectively). They also both decreased responding for ICSS, but at
slightly lower doses (16.0 and 3.0 mg/kg, respectively). This is evidence that ICSS is more
sensitive to the behaviorally disruptive effects of cannabinoids than spontaneous locomotor
activity. An alternative explanation could be that spontaneous locomotor behavior is less
physically demanding than lever pressing, and is an innate behavior, and therefore higher doses
of CB1 agonists are required to disrupt the behavior. Furthermore, spontaneous locomotor
activity may be less goal-directed than operant responding for reinforcement, which could help
differentiate motor suppression from effects on motivated behavior.
Further evidence that ICSS is more sensitive to the disruptive effects of cannabinoids was
that only high dose JZL184 (40.0 mg/kg) disrupted operant-responding for food pellets.
However, it should be noted that there were a number of procedural differences between operant
responding for food and brain stimulation. First, and most obvious, the reinforcer is different
(food vs. electrical stimulation). Second, the operant response is different, as lever-pressing was
required for ICSS experiments and nose-poking was the operant in the food-responding
experiments. Third, the test session length varied between the two tasks, operant responding for
food sessions were 15 min, while ICSS test sessions were 24 min. Finally, in the operant
responding tasks, subjects were food-deprived, while ICSS subjects were maintained at freefeeding weights. The differences in response topography between nose-poking and lever pressing
have to be considered; nose-poking is a more innate response than lever pressing. It would be
logical that the effort required for a given behavior would correlate with disruption of behavior.
For example, as nose-poking is a more innate behavior than lever pressing, all other things being
equal, lever-pressing should be disrupted before nose-poking. This has been demonstrated by
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(Gerhardt & Liebman, 1981) who have shown that nose-poking is less susceptible to druginduced gross motor effects than lever pressing behavior. ICSS is known to produce robust
reinforcement, so it is intriguing that it is disrupted before a more innate response like nosepoking. Certainly it seems that ICSS is more sensitive to disruption by cannabinoids than
spontaneous locomotor activity or operant responding for food. Food-deprivation could also play
a role in the drug effects produced as some drug effects are enhanced, and some are reduced
during food-deprivation (D'Cunha, Sedki, Macri, Casola, & Shalev, 2013; Shalev, 2012). Of
course, the caveat with interpreting these results is that cannabinoids can have both stimulatory
and suppressive effects on food intake and food-motivated behavior.
One potential explanation for the actions of endocannabinoids on reward-related
measures is that these neurotransmitters/neuromodulators are involved in the environmental cueevoked dopamine release associated with drug use and other rewards. In other words,
cannabinoids are involved more in the signaling of reward-relevant stimuli, rather than being a
substrate for reward. Many studies show that cannabinoid antagonism disrupts behavior for drug
rewards including nicotine (Cohen, Perrault, Voltz, Steinberg, & Soubrie, 2002; Le Foll &
Goldberg, 2004), methamphetamine (Vinklerova, Novakova, & Sulcova, 2002), opioids (Caille
& Parsons, 2003), alcohol (Arnone et al., 1997; Economidou et al., 2006), and cocaine (Xi, et al.,
2008). The evidence with cocaine may be the most revealing of cannabinoid effects on
dopamine-evoked events. CB1 receptor blockade interferes with progressive ratio responding to
receive cocaine, and prevents drug-induced and cue-induced reinstatement to drug-seeking
behavior (De Vries et al., 2001; Xi, et al., 2008; Xi et al., 2007). However, CB1 antagonism is
less efficacious in reducing ongoing self-administration (De Vries, et al., 2001; Filip et al., 2006;
Tanda, et al., 2000). This is especially relevant to ICSS, as it directly stimulates the mesolimbic
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system, which is thought to indirectly activate dopaminergic neurons in the VTA projecting to
the NAc. However, there are cues present with ICSS as there are with almost all behaviors, so
cannabinoids could be affecting cues associated with ICSS responding. Though this is not likely
the case, as ICSS is a well-trained behavior with extremely salient reinforcement.
This cue-evoking role of endocannabinoids fits with the data from these studies. If the
role of endocannabinoids is to signal reward-relevant stimuli, then disruption of cannabinoid
signaling through either blockade or over-activation of CB1 receptors could disrupt rewardrelated behavior. This would help explain why both CB1 agonists (Arnold, et al., 2001; Vlachou,
et al., 2005, 2006; Vlachou, et al., 2007) and antagonists (Arnold, et al., 2001; DerocheGamonet, et al., 2001; Trujillo-Pisanty, et al., 2011; Xi, et al., 2008) have been shown to reduce
ICSS behavior. This is particularly interesting given the fact that high doses of CB1 antagonists
are typically required to disrupt ICSS, presumably by disrupting endocannabinoid tone, while
relatively low doses of exogenous agonists typically disrupt ICSS, presumably by disrupting
normal CB1 signaling. Although RIM (10.0 mg/kg) did not attenuate ICSS in the current study,
this may be a species-specific effect in the mouse. Thus, even though endocannabinoid tone may
be necessary for cue-evoked dopamine release that shapes behavior, enhancing endocannabinoid
tone without the ability of metabolic clearance may cause endocannabinoids to affect receptors
similar to exogenous agonists and disrupt reward-motivated behavior rather than facilitate it.
It is important to consider that with ICSS we are assessing drugs by how they affect the
brain during activation of the mesolimbic dopamine system. There is much evidence that this
system is part of a common reward pathway, but of course it is not the only reward-mediating
area of the brain. Cannabinoids may be exerting their rewarding effects in humans through
activation of cannabinoid receptors in other areas of the brain that interact with the mesolimbic
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system, with areas completely independent of that system. For example, cannabinoids have
effects on stress and anxiety (Hill, Hunter, & McEwen, 2009; Hill & McEwen, 2010; Hill et al.,
2009). Marijuana use has been reported to produce anxiolytic and mood-elevating effects that
reduces stress and promotes relaxation, which likely contributes to its recreational use (Green,
Kavanagh, & Young, 2003). The presence of endocannabinoids and cannabinoid receptors in
stress-responsive areas of the brain including the amygdala and hypothalamus, and
responsiveness of the endocannabinoid system to stress manipulations, suggests that they are
involved in altering stress responses. Endocannabinoids have been shown to both activate and
deactivate the hypothalamic-pituitary-adrenal (HPA) axis, which mediates stress responses (Hill
et al., 2010). Stress causes and increase in glutamate release in the HPA axis, and specifically the
basolateral amygdala. Endocannabinoids are located within this region, and can modulate
glutamate release, which provides a mechanism for exogenous cannabinoids to be used for the
management of stress responses.
Clearly, more effort will need to be devoted to understanding the discrepancies
underlying this and other preclinical models of reward (CPP) and reinforcement (selfadministration), as cannabinoid effects in these models may not accurately reflect the abuseliability seen with marijuana in humans. It is also important to note that we are modeling
marijuana use with THC in animals. THC can produce different effects than marijuana in
humans, specifically it has been shown to sometimes produce aversive effects (Calhoun, et al.,
1998) and produces only modes reinforcing effects in experienced marijuana users (Hart, et al.,
2005; Vandrey, et al., 2013). In light of these studies, perhaps we are accurately representing
abuse-liability of THC in humans, as it is not typically used by humans for recreational purposes
(Calhoun, et al., 1998). Thus, the failure of cannabinoids to produce effects in preclinical models
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may be due to the fact that we are assessing THC rather than marijuana. Future studies assessing
inhaled marijuana or synthetic cannabinoids in similar assays would provide an important
contribution to this literature.
In conclusion, THC and endocannabinoid catabolic enzyme inhibitors do not produce
facilitation of ICSS in C57BL/6 mice. In fact, at higher doses, they tend to produce the opposite
effect, attenuation. This reduction of ICSS after cannabinoids is correlated with reduction of
other behaviors including operant responding (nose-poking) for food and spontaneous locomotor
activity. It does appear that ICSS is more sensitive to attenuation produced by cannabinoids than
these other behaviors are. ICSS was consistently shown to be affected by lower doses of THC or
cannabinoid enzyme inhibitors than other behaviors. With the exception of PF-3845, these
effects were found to be mediated through CB1, but not CB2 receptors. Interestingly, PF-3845induced attenuation of ICSS was not reversed by either CB1 or CB2 antagonism. All time-course
evaluations of the drugs tested were in line with previous determinations of their duration of
action. 2-AG was shown to be important for the attenuation of ICSS with endocannabinoid
inhibitors JZL184 and SA-57, as JZL184 produced an attenuation of ICSS, and principally
elevated 2-AG levels. AEA does play a role also, though, as combined FAAH/MAGL inhibition
produces a higher degree of ICSS attenuation than either enzyme inhibitor assessed alone and
more similar to THC or other exogenous agonists. It seems that AEA and 2-AG produce a
cooperative effect when elevated at the same time. Overall, it is unclear how exogenous and
endocannabinoids modulate rewarding effects in the human brain. Based on the results from this
and other studies, endocannabinoid modulation of reward may not result entirely from activity in
the mesolimbic system.

139

List of References

140

List of References

Ahn, K., Johnson, D. S., Fitzgerald, L. R., Liimatta, M., Arendse, A., Stevenson, T., . . . Cravatt,
B. F. (2007). Novel mechanistic class of fatty acid amide hydrolase inhibitors with
remarkable selectivity. [Research Support, N.I.H., Extramural Research Support, NonU.S. Gov't]. Biochemistry, 46(45), 13019-13030. doi: 10.1021/bi701378g
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., . . . Cravatt, B.
F. (2009). Discovery and characterization of a highly selective FAAH inhibitor that
reduces inflammatory pain. [Research Support, N.I.H., Extramural Research Support,
Non-U.S. Gov't]. Chemistry & biology, 16(4), 411-420. doi:
10.1016/j.chembiol.2009.02.013
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008). Enzymatic pathways that regulate
endocannabinoid signaling in the nervous system. [Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't Review]. Chemical reviews, 108(5), 1687-1707. doi:
10.1021/cr0782067
Alhouayek, M., Lambert, D. M., Delzenne, N. M., Cani, P. D., & Muccioli, G. G. (2011).
Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related
systemic inflammation. [Research Support, Non-U.S. Gov't]. FASEB journal : official
publication of the Federation of American Societies for Experimental Biology, 25(8),
2711-2721. doi: 10.1096/fj.10-176602
Aliczki, M., Balogh, Z., Tulogdi, A., & Haller, J. (2012). The temporal dynamics of the effects
of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature.
[Research Support, Non-U.S. Gov't]. Behavioural pharmacology, 23(4), 348-357. doi:
10.1097/FBP.0b013e3283564dfa
Antoniou, K., Galanopoulos, A., Vlachou, S., Kourouli, T., Nahmias, V., Thermos, K., . . .
Spyraki, C. (2005). Behavioral pharmacological properties of a novel cannabinoid 1',1'dithiolane delta8-THC analog, AMG-3. [Comparative Study Research Support, Non-U.S.
Gov't]. Behavioural pharmacology, 16(5-6), 499-510.
Arnold, J. C., Hunt, G. E., & McGregor, I. S. (2001). Effects of the cannabinoid receptor agonist
CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial selfstimulation in Lewis rats. [Research Support, Non-U.S. Gov't]. Life sciences, 70(1), 97108.
Arnone, M., Maruani, J., Chaperon, F., Thiebot, M. H., Poncelet, M., Soubrie, P., & Le Fur, G.
(1997). Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of
central cannabinoid (CB1) receptors. [Comparative Study]. Psychopharmacology,
132(1), 104-106.

141

Ashton, J. C., Friberg, D., Darlington, C. L., & Smith, P. F. (2006). Expression of the
cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study.
Neuroscience letters, 396(2), 113-116. doi: 10.1016/j.neulet.2005.11.038
Baek, J. H., Zheng, Y., Darlington, C. L., & Smith, P. F. (2008). Cannabinoid CB2 receptor
expression in the rat brainstem cochlear and vestibular nuclei. [Research Support, NonU.S. Gov't]. Acta oto-laryngologica, 128(9), 961-967. doi: 10.1080/00016480701796944
Belfrage, P., Jergil, B., Stralfors, P., & Tornqvist, H. (1977). Hormone-sensitive lipase of rat
adipose tissue: identification and some properties of the enzyme protein. FEBS letters,
75(1), 259-264.
Bewernick, B. H., Kayser, S., Sturm, V., & Schlaepfer, T. E. (2012). Long-term effects of
nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for
sustained efficacy. Neuropsychopharmacology : official publication of the American
College of Neuropsychopharmacology, 37(9), 1975-1985. doi: 10.1038/npp.2012.44
Bielajew, C., & Shizgal, P. (1986). Evidence implicating descending fibers in self-stimulation of
the medial forebrain bundle. [Research Support, Non-U.S. Gov't]. The Journal of
neuroscience : the official journal of the Society for Neuroscience, 6(4), 919-929.
Bisogno, T., Melck, D., Bobrov, M., Gretskaya, N. M., Bezuglov, V. V., De Petrocellis, L., & Di
Marzo, V. (2000). N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor
ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro
and in vivo. [Research Support, Non-U.S. Gov't]. The Biochemical journal, 351 Pt 3,
817-824.
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007). A comprehensive profile of brain
enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. [Research Support,
N.I.H., Extramural Research Support, Non-U.S. Gov't]. Chemistry & biology, 14(12),
1347-1356. doi: 10.1016/j.chembiol.2007.11.006
Boger, D. L., Miyauchi, H., Du, W., Hardouin, C., Fecik, R. A., Cheng, H., . . . Cravatt, B. F.
(2005). Discovery of a potent, selective, and efficacious class of reversible alphaketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.
[Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Journal of
medicinal chemistry, 48(6), 1849-1856. doi: 10.1021/jm049614v
Booker, L., Kinsey, S. G., Abdullah, R. A., Blankman, J. L., Long, J. Z., Ezzili, C., . . .
Lichtman, A. H. (2012). The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts
in the nervous system to reverse LPS-induced tactile allodynia in mice. [Research
Support, N.I.H., Extramural]. British journal of pharmacology, 165(8), 2485-2496. doi:
10.1111/j.1476-5381.2011.01445.x
Braida, D., Pozzi, M., Cavallini, R., & Sala, M. (2001). Conditioned place preference induced by
the cannabinoid agonist CP 55,940: interaction with the opioid system. [Research
Support, Non-U.S. Gov't]. Neuroscience, 104(4), 923-926.

142

Brents, L. K., & Prather, P. L. (2013). The K2/Spice Phenomenon: emergence, identification,
legislation and metabolic characterization of synthetic cannabinoids in herbal incense
products. Drug metabolism reviews. doi: 10.3109/03602532.2013.839700
Cadogan, A. K., Alexander, S. P., Boyd, E. A., & Kendall, D. A. (1997). Influence of
cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the
rat striatum. [In Vitro Research Support, Non-U.S. Gov't]. Journal of neurochemistry,
69(3), 1131-1137.
Caille, S., & Parsons, L. H. (2003). SR141716A reduces the reinforcing properties of heroin but
not heroin-induced increases in nucleus accumbens dopamine in rats. [Comparative
Study Research Support, Non-U.S. Gov't]. The European journal of neuroscience,
18(11), 3145-3149.
Calhoun, S. R., Galloway, G. P., & Smith, D. E. (1998). Abuse potential of dronabinol
(Marinol). [Research Support, Non-U.S. Gov't]. Journal of psychoactive drugs, 30(2),
187-196.
Caprioli, A., Coccurello, R., Rapino, C., Di Serio, S., Di Tommaso, M., Vertechy, M., . . .
Borsini, F. (2012). The novel reversible fatty acid amide hydrolase inhibitor ST4070
increases endocannabinoid brain levels and counteracts neuropathic pain in different
animal models. [Research Support, Non-U.S. Gov't]. The Journal of pharmacology and
experimental therapeutics, 342(1), 188-195. doi: 10.1124/jpet.111.191403
Carlezon, W. A., Jr., & Chartoff, E. H. (2007). Intracranial self-stimulation (ICSS) in rodents to
study the neurobiology of motivation. [Research Support, N.I.H., Extramural]. Nature
protocols, 2(11), 2987-2995. doi: 10.1038/nprot.2007.441
Carlson, R. H., & Lydic, R. (1976). The effects of ethanol upon threshold and response rate for
self-stimulation. Psychopharmacology, 50(1), 61-64.
Cazala, P., & Cardo, B. (1972). [Preliminary study on self stimulation in the mouse]. Physiology
& behavior, 9(2), 255-257.
Cheer, J. F., Aragona, B. J., Heien, M. L., Seipel, A. T., Carelli, R. M., & Wightman, R. M.
(2007). Coordinated accumbal dopamine release and neural activity drive goal-directed
behavior. [Research Support, N.I.H., Extramural]. Neuron, 54(2), 237-244. doi:
10.1016/j.neuron.2007.03.021
Cheer, J. F., Kendall, D. A., & Marsden, C. A. (2000). Cannabinoid receptors and reward in the
rat: a conditioned place preference study. Psychopharmacology, 151(1), 25-30.
Cheer, J. F., Wassum, K. M., Heien, M. L., Phillips, P. E., & Wightman, R. M. (2004).
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake
rats. [Research Support, U.S. Gov't, P.H.S.]. The Journal of neuroscience : the official
journal of the Society for Neuroscience, 24(18), 4393-4400. doi:
10.1523/JNEUROSCI.0529-04.2004

143

Cheer, J. F., Wassum, K. M., Sombers, L. A., Heien, M. L., Ariansen, J. L., Aragona, B. J., . . .
Wightman, R. M. (2007). Phasic dopamine release evoked by abused substances requires
cannabinoid receptor activation. [Comparative Study Research Support, N.I.H.,
Extramural]. The Journal of neuroscience : the official journal of the Society for
Neuroscience, 27(4), 791-795. doi: 10.1523/JNEUROSCI.4152-06.2007
Chen, J., Marmur, R., Pulles, A., Paredes, W., & Gardner, E. L. (1993). Ventral tegmental
microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental
somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local
neural action by marijuana's psychoactive ingredient. [Comparative Study Research
Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support,
U.S. Gov't, P.H.S.]. Brain research, 621(1), 65-70.
Chen, J., Paredes, W., Lowinson, J. H., & Gardner, E. L. (1990). Delta 9-tetrahydrocannabinol
enhances presynaptic dopamine efflux in medial prefrontal cortex. [Research Support,
U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. European journal of
pharmacology, 190(1-2), 259-262.
Chen, J. P., Paredes, W., Li, J., Smith, D., Lowinson, J., & Gardner, E. L. (1990). Delta 9tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal
dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by
intracerebral microdialysis. [Research Support, Non-U.S. Gov't Research Support, U.S.
Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Psychopharmacology, 102(2),
156-162.
Chen, J. P., Paredes, W., Lowinson, J. H., & Gardner, E. L. (1991). Strain-specific facilitation of
dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in
vivo microdialysis study. [Research Support, Non-U.S. Gov't Research Support, U.S.
Gov't, P.H.S.]. Neuroscience letters, 129(1), 136-180.
Chen, S. A., O'Dell, L. E., Hoefer, M. E., Greenwell, T. N., Zorrilla, E. P., & Koob, G. F. (2006).
Unlimited access to heroin self-administration: independent motivational markers of
opiate dependence. [Research Support, N.I.H., Extramural Validation Studies].
Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology, 31(12), 2692-2707. doi: 10.1038/sj.npp.1301008
Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrie, P. (2002). SR141716, a central
cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing
effects of nicotine in rats. Behavioural pharmacology, 13(5-6), 451-463.
Compton, D. R., Aceto, M. D., Lowe, J., & Martin, B. R. (1996). In vivo characterization of a
specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9tetrahydrocannabinol-induced responses and apparent agonist activity. [Research
Support, U.S. Gov't, P.H.S.]. The Journal of pharmacology and experimental
therapeutics, 277(2), 586-594.
Corbett, D. (1991). Cocaine enhances the reward value of medial prefrontal cortex selfstimulation. [Research Support, Non-U.S. Gov't]. Neuroreport, 2(12), 805-808.
144

Cravatt, B. F., Prospero-Garcia, O., Siuzdak, G., Gilula, N. B., Henriksen, S. J., Boger, D. L., &
Lerner, R. A. (1995). Chemical characterization of a family of brain lipids that induce
sleep. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.]. Science, 268(5216), 1506-1509.
Cryan, J. F., Hoyer, D., & Markou, A. (2003). Withdrawal from chronic amphetamine induces
depressive-like behavioral effects in rodents. [Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.]. Biological psychiatry, 54(1), 49-58.
D'Angio, M., Serrano, A., Rivy, J. P., & Scatton, B. (1987). Tail-pinch stress increases
extracellular DOPAC levels (as measured by in vivo voltammetry) in the rat nucleus
accumbens but not frontal cortex: antagonism by diazepam and zolpidem. [Comparative
Study]. Brain research, 409(1), 169-174.
D'Cunha, T. M., Sedki, F., Macri, J., Casola, C., & Shalev, U. (2013). The effects of chronic
food restriction on cue-induced heroin seeking in abstinent male rats. [Research Support,
Non-U.S. Gov't]. Psychopharmacology, 225(1), 241-250. doi: 10.1007/s00213-012-28101
De Vries, T. J., Shaham, Y., Homberg, J. R., Crombag, H., Schuurman, K., Dieben, J., . . .
Schoffelmeer, A. N. (2001). A cannabinoid mechanism in relapse to cocaine seeking.
[Research Support, U.S. Gov't, P.H.S.]. Nature medicine, 7(10), 1151-1154. doi:
10.1038/nm1001-1151
De Vry, J., Schreiber, R., Eckel, G., & Jentzsch, K. R. (2004). Behavioral mechanisms
underlying inhibition of food-maintained responding by the cannabinoid receptor
antagonist/inverse agonist SR141716A. European journal of pharmacology, 483(1), 5563.
Deroche-Gamonet, V., Le Moal, M., Piazza, P. V., & Soubrie, P. (2001). SR141716, a CB1
receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain
stimulation in rats. Psychopharmacology, 157(3), 254-259. doi: 10.1007/s002130100804
Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., . . .
Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the
cannabinoid receptor. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't,
P.H.S.]. Science, 258(5090), 1946-1949.
Dinh, T. P., Freund, T. F., & Piomelli, D. (2002). A role for monoglyceride lipase in 2arachidonoylglycerol inactivation. [Research Support, Non-U.S. Gov't Research Support,
U.S. Gov't, P.H.S. Review]. Chemistry and physics of lipids, 121(1-2), 149-158.
Economidou, D., Mattioli, L., Cifani, C., Perfumi, M., Massi, M., Cuomo, V., . . . Ciccocioppo,
R. (2006). Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol
self-administration and ethanol-seeking behaviour in rats. [Research Support, Non-U.S.
Gov't]. Psychopharmacology, 183(4), 394-403. doi: 10.1007/s00213-005-0199-9

145

Elmer, G. I., Meisch, R. A., & George, F. R. (1987). Mouse strain differences in operant selfadministration of ethanol. [Comparative Study Research Support, U.S. Gov't, P.H.S.].
Behavior genetics, 17(5), 439-451.
Falenski, K. W., Thorpe, A. J., Schlosburg, J. E., Cravatt, B. F., Abdullah, R. A., Smith, T. H., . .
. Sim-Selley, L. J. (2010). FAAH-/- mice display differential tolerance, dependence, and
cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide
administration. [Research Support, N.I.H., Extramural Research Support, Non-U.S.
Gov't]. Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology, 35(8), 1775-1787. doi: 10.1038/npp.2010.44
Fattore, L., Cossu, G., Martellotta, C. M., & Fratta, W. (2001). Intravenous self-administration of
the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology,
156(4), 410-416.
Fernandez-Ruiz, J., Hernandez, M., & Ramos, J. A. (2010). Cannabinoid-dopamine interaction
in the pathophysiology and treatment of CNS disorders. [Research Support, Non-U.S.
Gov't Review]. CNS neuroscience & therapeutics, 16(3), e72-91. doi: 10.1111/j.17555949.2010.00144.x
Filip, M., Golda, A., Zaniewska, M., McCreary, A. C., Nowak, E., Kolasiewicz, W., &
Przegalinski, E. (2006). Involvement of cannabinoid CB1 receptors in drug addiction:
effects of rimonabant on behavioral responses induced by cocaine. [Research Support,
Non-U.S. Gov't]. Pharmacological reports : PR, 58(6), 806-819.
Fish, E. W., Riday, T. T., McGuigan, M. M., Faccidomo, S., Hodge, C. W., & Malanga, C. J.
(2010). Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice.
[Comparative Study Research Support, N.I.H., Extramural]. Alcoholism, clinical and
experimental research, 34(1), 81-89. doi: 10.1111/j.1530-0277.2009.01069.x
Fish, E. W., Robinson, J. E., Krouse, M. C., Hodge, C. W., Reed, C., Phillips, T. J., & Malanga,
C. J. (2012). Intracranial self-stimulation in FAST and SLOW mice: effects of alcohol
and cocaine. [Comparative Study, Research Support, N.I.H., Extramural, Research
Support, U.S. Gov't, Non-P.H.S.]. Psychopharmacology, 220(4), 719-730. doi:
10.1007/s00213-011-2523-x
Flores, A., Maldonado, R., & Berrendero, F. (2013). The Hypocretin/Orexin Receptor-1 as a
Novel Target to Modulate Cannabinoid Reward. Biological psychiatry. doi:
10.1016/j.biopsych.2013.06.012
Fokos, S., & Panagis, G. (2010). Effects of delta9-tetrahydrocannabinol on reward and anxiety in
rats exposed to chronic unpredictable stress. [Research Support, Non-U.S. Gov't].
Journal of psychopharmacology, 24(5), 767-777. doi: 10.1177/0269881109104904
French, E. D. (1997). delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through
activation of cannabinoid CB1 but not opioid receptors. [Comparative Study Research
Support, U.S. Gov't, P.H.S.]. Neuroscience letters, 226(3), 159-162.

146

French, E. D., Dillon, K., & Wu, X. (1997). Cannabinoids excite dopamine neurons in the
ventral tegmentum and substantia nigra. [Research Support, U.S. Gov't, P.H.S.].
Neuroreport, 8(3), 649-652.
Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., . . .
Doherty, P. (2010). Loss of retrograde endocannabinoid signaling and reduced adult
neurogenesis in diacylglycerol lipase knock-out mice. [Research Support, Non-U.S.
Gov't]. The Journal of neuroscience : the official journal of the Society for Neuroscience,
30(6), 2017-2024. doi: 10.1523/JNEUROSCI.5693-09.2010
Gardner, E. L., Paredes, W., Smith, D., Donner, A., Milling, C., Cohen, D., & Morrison, D.
(1988). Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol.
[Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
Psychopharmacology, 96(1), 142-144.
Gerard, C. M., Mollereau, C., Vassart, G., & Parmentier, M. (1991). Molecular cloning of a
human cannabinoid receptor which is also expressed in testis. [Research Support, NonU.S. Gov't]. The Biochemical journal, 279 ( Pt 1), 129-134.
Gerhardt, S., & Liebman, J. M. (1981). Differential effects of drug treatments on nose-poke and
bar-press self-stimulation. Pharmacology, biochemistry, and behavior, 15(5), 767-771.
Gessa, G. L., Melis, M., Muntoni, A. L., & Diana, M. (1998). Cannabinoids activate mesolimbic
dopamine neurons by an action on cannabinoid CB1 receptors. [Comparative Study].
European journal of pharmacology, 341(1), 39-44.
Ghosh, S., Wise, L. E., Chen, Y., Gujjar, R., Mahadevan, A., Cravatt, B. F., & Lichtman, A. H.
(2012). The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in
the mouse carrageenan model. Life sciences. doi: 10.1016/j.lfs.2012.06.020
Ghozland, S., Matthes, H. W., Simonin, F., Filliol, D., Kieffer, B. L., & Maldonado, R. (2002).
Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid
receptors. [Research Support, Non-U.S. Gov't]. The Journal of neuroscience : the official
journal of the Society for Neuroscience, 22(3), 1146-1154.
Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., . . .
Piomelli, D. (2005). Antidepressant-like activity and modulation of brain monoaminergic
transmission by blockade of anandamide hydrolysis. [Research Support, N.I.H.,
Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't].
Proceedings of the National Academy of Sciences of the United States of America,
102(51), 18620-18625. doi: 10.1073/pnas.0509591102
Goldman, M., Szucs-Reed, R. P., Jagannathan, K., Ehrman, R. N., Wang, Z., Li, Y., . . .
Franklin, T. R. (2013). Reward-related brain response and craving correlates of marijuana
cue exposure: a preliminary study in treatment-seeking marijuana-dependent subjects.
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research
Support, U.S. Gov't, Non-P.H.S.]. Journal of addiction medicine, 7(1), 8-16. doi:
10.1097/ADM.0b013e318273863a

147

Gong, J. P., Onaivi, E. S., Ishiguro, H., Liu, Q. R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R.
(2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain.
[Comparative Study In Vitro Research Support, N.I.H., Extramural Research Support,
Non-U.S. Gov't]. Brain research, 1071(1), 10-23. doi: 10.1016/j.brainres.2005.11.035
Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D., & Hipkin, R. W. (2000).
Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2
cannabinoid receptor: antagonism by anandamide. Molecular pharmacology, 57(5),
1045-1050.
Goparaju, S. K., Ueda, N., Yamaguchi, H., & Yamamoto, S. (1998). Anandamide
amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor
ligand. [Research Support, Non-U.S. Gov't]. FEBS letters, 422(1), 69-73.
Green, B., Kavanagh, D., & Young, R. (2003). Being stoned: a review of self-reported cannabis
effects. [Review]. Drug and alcohol review, 22(4), 453-460. doi:
10.1080/09595230310001613976
Guindon, J., Guijarro, A., Piomelli, D., & Hohmann, A. G. (2011). Peripheral antinociceptive
effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain.
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. British
journal of pharmacology, 163(7), 1464-1478. doi: 10.1111/j.1476-5381.2010.01192.x
Hajos, N., & Freund, T. F. (2002a). Distinct cannabinoid sensitive receptors regulate
hippocampal excitation and inhibition. [Research Support, Non-U.S. Gov't Research
Support, U.S. Gov't, P.H.S. Review]. Chemistry and physics of lipids, 121(1-2), 73-82.
Hajos, N., & Freund, T. F. (2002b). Pharmacological separation of cannabinoid sensitive
receptors on hippocampal excitatory and inhibitory fibers. [Research Support, Non-U.S.
Gov't Research Support, U.S. Gov't, P.H.S.]. Neuropharmacology, 43(4), 503-510.
Haller, J., Goldberg, S. R., Pelczer, K. G., Aliczki, M., & Panlilio, L. V. (2013). The effects of
anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats.
Psychopharmacology. doi: 10.1007/s00213-013-3161-2
Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., . . . Mechoulam, R.
(2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1
receptor. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
Proceedings of the National Academy of Sciences of the United States of America, 98(7),
3662-3665. doi: 10.1073/pnas.061029898
Hart, C. L., Haney, M., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2005). Reinforcing
effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.
[Controlled Clinical Trial Research Support, N.I.H., Extramural Research Support, U.S.
Gov't, P.H.S.]. Psychopharmacology, 181(2), 237-243. doi: 10.1007/s00213-005-2234-2
Hart, C. L., Ilan, A. B., Gevins, A., Gunderson, E. W., Role, K., Colley, J., & Foltin, R. W.
(2010). Neurophysiological and cognitive effects of smoked marijuana in frequent users.

148

[Research Support, N.I.H., Extramural]. Pharmacology, biochemistry, and behavior,
96(3), 333-341. doi: 10.1016/j.pbb.2010.06.003
Hart, C. L., van Gorp, W., Haney, M., Foltin, R. W., & Fischman, M. W. (2001). Effects of acute
smoked marijuana on complex cognitive performance. [Clinical Trial Research Support,
U.S. Gov't, P.H.S.]. Neuropsychopharmacology : official publication of the American
College of Neuropsychopharmacology, 25(5), 757-765. doi: 10.1016/S0893133X(01)00273-1
Hill, M. N., Hunter, R. G., & McEwen, B. S. (2009). Chronic stress differentially regulates
cannabinoid CB1 receptor binding in distinct hippocampal subfields. [Research Support,
N.I.H., Extramural Research Support, Non-U.S. Gov't]. European journal of
pharmacology, 614(1-3), 66-69. doi: 10.1016/j.ejphar.2009.04.048
Hill, M. N., Kumar, S. A., Filipski, S. B., Iverson, M., Stuhr, K. L., Keith, J. M., . . . McEwen, B.
S. (2012). Disruption of fatty acid amide hydrolase activity prevents the effects of
chronic stress on anxiety and amygdalar microstructure. Molecular psychiatry. doi:
10.1038/mp.2012.90
Hill, M. N., & McEwen, B. S. (2010). Involvement of the endocannabinoid system in the
neurobehavioural effects of stress and glucocorticoids. [Review]. Progress in neuropsychopharmacology & biological psychiatry, 34(5), 791-797. doi:
10.1016/j.pnpbp.2009.11.001
Hill, M. N., McLaughlin, R. J., Morrish, A. C., Viau, V., Floresco, S. B., Hillard, C. J., &
Gorzalka, B. B. (2009). Suppression of amygdalar endocannabinoid signaling by stress
contributes to activation of the hypothalamic-pituitary-adrenal axis. [Research Support,
N.I.H., Extramural Research Support, Non-U.S. Gov't]. Neuropsychopharmacology :
official publication of the American College of Neuropsychopharmacology, 34(13), 27332745. doi: 10.1038/npp.2009.114
Hill, M. N., Patel, S., Campolongo, P., Tasker, J. G., Wotjak, C. T., & Bains, J. S. (2010).
Functional interactions between stress and the endocannabinoid system: from synaptic
signaling to behavioral output. [Research Support, N.I.H., Extramural Research Support,
Non-U.S. Gov't Review]. The Journal of neuroscience : the official journal of the Society
for Neuroscience, 30(45), 14980-14986. doi: 10.1523/JNEUROSCI.4283-10.2010
Howlett, A. C., Bidaut-Russell, M., Devane, W. A., Melvin, L. S., Johnson, M. R., &
Herkenham, M. (1990). The cannabinoid receptor: biochemical, anatomical and
behavioral characterization. [Review]. Trends in neurosciences, 13(10), 420-423.
Hrabovszky, E., Wittmann, G., Kallo, I., Fuzesi, T., Fekete, C., & Liposits, Z. (2012).
Distribution of type 1 cannabinoid receptor-expressing neurons in the septalhypothalamic region of the mouse: colocalization with GABAergic and glutamatergic
markers. [Comparative Study Research Support, Non-U.S. Gov't]. The Journal of
comparative neurology, 520(5), 1005-1020. doi: 10.1002/cne.22766
Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., & Young, T. (2012). An efficient
randomised, placebo-controlled clinical trial with the irreversible fatty acid amide
149

hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to
induce effective analgesia in patients with pain due to osteoarthritis of the knee.
[Randomized Controlled Trial Research Support, Non-U.S. Gov't]. Pain, 153(9), 18371846. doi: 10.1016/j.pain.2012.04.020
Ignatowska-Jankowska, B. M., Ghosh, S., Crowe, M. S., Kinsey, S. G., Niphakis, M. J.,
Abdullah, R. A., . . . Lichtman, A. H. (2013). In vivo characterization of the highly
selective monoacylglycerol lipase inhibitor KML29: Antinociceptive activity without
cannabimimetic side effects. British journal of pharmacology. doi: 10.1111/bph.12298
Ignatowska-Jankowska, B. M., Muldoon, P. P., Lichtman, A. H., & Damaj, M. I. (2013). The
cannabinoid CB receptor is necessary for nicotine-conditioned place preference, but not
other behavioral effects of nicotine in mice. Psychopharmacology. doi: 10.1007/s00213013-3117-6
Jhaveri, M. D., Richardson, D., Robinson, I., Garle, M. J., Patel, A., Sun, Y., . . . Chapman, V.
(2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of
endocannabinoid related molecules and produces analgesia via peroxisome proliferatoractivated receptor-alpha in a model of inflammatory pain. [Research Support, Non-U.S.
Gov't]. Neuropharmacology, 55(1), 85-93. doi: 10.1016/j.neuropharm.2008.04.018
Justinova, Z., Solinas, M., Tanda, G., Redhi, G. H., & Goldberg, S. R. (2005). The endogenous
cannabinoid anandamide and its synthetic analog R(+)-methanandamide are
intravenously self-administered by squirrel monkeys. [Research Support, N.I.H.,
Intramural Research Support, U.S. Gov't, P.H.S.]. The Journal of neuroscience : the
official journal of the Society for Neuroscience, 25(23), 5645-5650. doi:
10.1523/JNEUROSCI.0951-05.2005
Justinova, Z., Tanda, G., Redhi, G. H., & Goldberg, S. R. (2003). Self-administration of delta9tetrahydrocannabinol (THC) by drug naive squirrel monkeys. [Research Support, U.S.
Gov't, P.H.S.]. Psychopharmacology, 169(2), 135-140. doi: 10.1007/s00213-003-1484-0
Justinova, Z., Yasar, S., Redhi, G. H., & Goldberg, S. R. (2011). The endogenous cannabinoid 2arachidonoylglycerol is intravenously self-administered by squirrel monkeys. [Research
Support, N.I.H., Intramural]. The Journal of neuroscience : the official journal of the
Society for Neuroscience, 31(19), 7043-7048. doi: 10.1523/JNEUROSCI.6058-10.2011
Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A., Tontini, A., . . . Piomelli, D. (2003).
Modulation of anxiety through blockade of anandamide hydrolysis. [Research Support,
Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Nature medicine, 9(1), 76-81. doi:
10.1038/nm803
Katona, I., Sperlagh, B., Magloczky, Z., Santha, E., Kofalvi, A., Czirjak, S., . . . Freund, T. F.
(2000). GABAergic interneurons are the targets of cannabinoid actions in the human
hippocampus. [In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't,
P.H.S.]. Neuroscience, 100(4), 797-804.
Katsidoni, V., Kastellakis, A., & Panagis, G. (2013). Biphasic effects of Delta9tetrahydrocannabinol on brain stimulation reward and motor activity. The international
150

journal of neuropsychopharmacology / official scientific journal of the Collegium
Internationale Neuropsychopharmacologicum, 1-12. doi: 10.1017/S1461145713000709
Kim, J., & Alger, B. E. (2004). Inhibition of cyclooxygenase-2 potentiates retrograde
endocannabinoid effects in hippocampus. [Comparative Study In Vitro Research Support,
U.S. Gov't, P.H.S.]. Nature neuroscience, 7(7), 697-698. doi: 10.1038/nn1262
Kinsey, S. G., Long, J. Z., O'Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., . . .
Lichtman, A. H. (2009). Blockade of endocannabinoid-degrading enzymes attenuates
neuropathic pain. [Research Support, N.I.H., Extramural Research Support, Non-U.S.
Gov't]. The Journal of pharmacology and experimental therapeutics, 330(3), 902-910.
doi: 10.1124/jpet.109.155465
Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T., & Lichtman, A. H. (2011). Fatty acid
amide hydrolase blockade attenuates the development of collagen-induced arthritis and
related thermal hyperalgesia in mice. [Research Support, N.I.H., Extramural].
Pharmacology, biochemistry, and behavior, 99(4), 718-725. doi:
10.1016/j.pbb.2011.06.022
Kinsey, S. G., Nomura, D. K., O'Neal, S. T., Long, J. Z., Mahadevan, A., Cravatt, B. F., . . .
Lichtman, A. H. (2011). Inhibition of monoacylglycerol lipase attenuates nonsteroidal
anti-inflammatory drug-induced gastric hemorrhages in mice. [Research Support, N.I.H.,
Extramural]. The Journal of pharmacology and experimental therapeutics, 338(3), 795802. doi: 10.1124/jpet.110.175778
Kinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011). Inhibition of
endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying
assay. [Research Support, N.I.H., Extramural]. Pharmacology, biochemistry, and
behavior, 98(1), 21-27. doi: 10.1016/j.pbb.2010.12.002
Kinsey, S. G., Wise, L. E., Ramesh, D., Abdullah, R., Selley, D. E., Cravatt, B. F., & Lichtman,
A. H. (2013). Repeated low-dose administration of the monoacylglycerol lipase inhibitor
JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and
gastroprotective effects. [Research Support, N.I.H., Extramural Research Support, NonU.S. Gov't]. The Journal of pharmacology and experimental therapeutics, 345(3), 492501. doi: 10.1124/jpet.112.201426
Kornetsky, C. (2004). Brain-stimulation reward, morphine-induced oral stereotypy, and
sensitization: implications for abuse. [Review]. Neuroscience and biobehavioral reviews,
27(8), 777-786. doi: 10.1016/j.neubiorev.2003.11.014
Kortleven, C., Fasano, C., Thibault, D., Lacaille, J. C., & Trudeau, L. E. (2011). The
endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic
synapses onto ventral tegmental area dopamine neurons in mice. [Research Support,
Non-U.S. Gov't]. The European journal of neuroscience, 33(10), 1751-1760. doi:
10.1111/j.1460-9568.2011.07648.x

151

Kucharski, L. T., Williams, J. E., & Kornetsky, C. (1983). The effects of levonantradol on
rewarding brain stimulation thresholds in the rat. [Research Support, U.S. Gov't, P.H.S.].
Pharmacology, biochemistry, and behavior, 19(1), 149-151.
Kwilasz, A. J., & Negus, S. S. (2012). Dissociable effects of the cannabinoid receptor agonists
Delta9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed
behavior in rats. [Research Support, N.I.H., Extramural]. The Journal of pharmacology
and experimental therapeutics, 343(2), 389-400. doi: 10.1124/jpet.112.197780
Lafourcade, M., Elezgarai, I., Mato, S., Bakiri, Y., Grandes, P., & Manzoni, O. J. (2007).
Molecular components and functions of the endocannabinoid system in mouse prefrontal
cortex. [Research Support, Non-U.S. Gov't]. PloS one, 2(8), e709. doi:
10.1371/journal.pone.0000709
Le Foll, B., & Goldberg, S. R. (2004). Rimonabant, a CB1 antagonist, blocks nicotineconditioned place preferences. [Comparative Study Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.]. Neuroreport, 15(13), 2139-2143.
Lepore, M., Liu, X., Savage, V., Matalon, D., & Gardner, E. L. (1996). Genetic differences in
delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured
by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat
strains. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Life
sciences, 58(25), PL365-372.
Lepore, M., Vorel, S. R., Lowinson, J., & Gardner, E. L. (1995). Conditioned place preference
induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food
reward. [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S.
Gov't, P.H.S.]. Life sciences, 56(23-24), 2073-2080.
Leung, D., Saghatelian, A., Simon, G. M., & Cravatt, B. F. (2006). Inactivation of N-acyl
phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the
biosynthesis of endocannabinoids. [Research Support, N.I.H., Extramural Research
Support, Non-U.S. Gov't]. Biochemistry, 45(15), 4720-4726. doi: 10.1021/bi060163l
Li, G. L., Winter, H., Arends, R., Jay, G. W., Le, V., Young, T., & Huggins, J. P. (2012).
Assessment of the pharmacology and tolerability of PF-04457845, an irreversible
inhibitor of fatty acid amide hydrolase-1, in healthy subjects. [Randomized Controlled
Trial Research Support, Non-U.S. Gov't]. British journal of clinical pharmacology,
73(5), 706-716. doi: 10.1111/j.1365-2125.2011.04137.x
Liu, J., Wang, L., Harvey-White, J., Osei-Hyiaman, D., Razdan, R., Gong, Q., . . . Kunos, G.
(2006). A biosynthetic pathway for anandamide. [In Vitro Research Support, N.I.H.,
Intramural]. Proceedings of the National Academy of Sciences of the United States of
America, 103(36), 13345-13350. doi: 10.1073/pnas.0601832103
Long, J. Z., Li, W., Booker, L., Burston, J. J., Kinsey, S. G., Schlosburg, J. E., . . . Cravatt, B. F.
(2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid
behavioral effects. [Research Support, N.I.H., Extramural Research Support, Non-U.S.
Gov't]. Nature chemical biology, 5(1), 37-44. doi: 10.1038/nchembio.129
152

Long, J. Z., Nomura, D. K., Vann, R. E., Walentiny, D. M., Booker, L., Jin, X., . . . Cravatt, B. F.
(2009). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by
endocannabinoid crosstalk in vivo. [Research Support, N.I.H., Extramural Research
Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the
United States of America, 106(48), 20270-20275. doi: 10.1073/pnas.0909411106
Long, L. E., Chesworth, R., Huang, X. F., McGregor, I. S., Arnold, J. C., & Karl, T. (2010). A
behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and
cannabidiol in C57BL/6JArc mice. [Comparative Study Research Support, Non-U.S.
Gov't]. The international journal of neuropsychopharmacology / official scientific
journal of the Collegium Internationale Neuropsychopharmacologicum, 13(7), 861-876.
doi: 10.1017/S1461145709990605
Lu, X. R., Ong, W. Y., & Mackie, K. (1999). A light and electron microscopic study of the CB1
cannabinoid receptor in monkey basal forebrain. [Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.]. Journal of neurocytology, 28(12), 1045-1051.
Luchicchi, A., Lecca, S., Carta, S., Pillolla, G., Muntoni, A. L., Yasar, S., . . . Pistis, M. (2010).
Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine,
cocaine and morphine in the nucleus accumbens shell and ventral tegmental area:
involvement of PPAR-alpha nuclear receptors. [Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't]. Addiction biology, 15(3), 277-288. doi:
10.1111/j.1369-1600.2010.00222.x
Lupica, C. R., & Riegel, A. C. (2005). Endocannabinoid release from midbrain dopamine
neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
[Review]. Neuropharmacology, 48(8), 1105-1116. doi:
10.1016/j.neuropharm.2005.03.016
Malone, D. T., & Taylor, D. A. (1999). Modulation by fluoxetine of striatal dopamine release
following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. British
journal of pharmacology, 128(1), 21-26. doi: 10.1038/sj.bjp.0702753
Markou, A., & Koob, G. F. (1991). Postcocaine anhedonia. An animal model of cocaine
withdrawal. [Research Support, U.S. Gov't, P.H.S.]. Neuropsychopharmacology : official
publication of the American College of Neuropsychopharmacology, 4(1), 17-26.
Marsicano, G., & Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct
neuronal subpopulations in the adult mouse forebrain. The European journal of
neuroscience, 11(12), 4213-4225.
Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., & Fratta, W. (1998). Self-administration
of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. [Research
Support, Non-U.S. Gov't]. Neuroscience, 85(2), 327-330.
Marusich, J. A., & Wiley, J. L. (2012). Rimonabant abolishes sensitivity to workload changes in
a progressive ratio procedure. [Research Support, N.I.H., Extramural]. Pharmacology,
biochemistry, and behavior, 101(4), 575-580. doi: 10.1016/j.pbb.2012.03.004

153

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure
of a cannabinoid receptor and functional expression of the cloned cDNA. [Research
Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Nature, 346(6284), 561564. doi: 10.1038/346561a0
Matyas, F., Urban, G. M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T. F., & Katona, I.
(2008). Identification of the sites of 2-arachidonoylglycerol synthesis and action imply
retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in
the ventral tegmental area. [In Vitro Research Support, N.I.H., Extramural Research
Support, Non-U.S. Gov't]. Neuropharmacology, 54(1), 95-107. doi:
10.1016/j.neuropharm.2007.05.028
Mavrikaki, M., Markaki, E., Nomikos, G. G., & Panagis, G. (2010). Chronic WIN55,212-2
elicits sustained and conditioned increases in intracranial self-stimulation thresholds in
the rat. [Research Support, Non-U.S. Gov't]. Behavioural Brain Research, 209(1), 114118. doi: 10.1016/j.bbr.2010.01.024
McGregor, I. S., Issakidis, C. N., & Prior, G. (1996). Aversive effects of the synthetic
cannabinoid CP 55,940 in rats. [Research Support, Non-U.S. Gov't]. Pharmacology,
biochemistry, and behavior, 53(3), 657-664.
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., . . . et
al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that
binds to cannabinoid receptors. [Research Support, Non-U.S. Gov't Research Support,
U.S. Gov't, P.H.S.]. Biochemical pharmacology, 50(1), 83-90.
Melis, M., Carta, S., Fattore, L., Tolu, S., Yasar, S., Goldberg, S. R., . . . Pistis, M. (2010).
Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity
through nicotinic receptors. [Research Support, N.I.H., Intramural Research Support,
Non-U.S. Gov't]. Biological psychiatry, 68(3), 256-264. doi:
10.1016/j.biopsych.2010.04.016
Melis, M., Pillolla, G., Bisogno, T., Minassi, A., Petrosino, S., Perra, S., . . . Pistis, M. (2006).
Protective activation of the endocannabinoid system during ischemia in dopamine
neurons. [In Vitro Research Support, Non-U.S. Gov't]. Neurobiology of disease, 24(1),
15-27. doi: 10.1016/j.nbd.2006.04.010
Mendizabal, V., Zimmer, A., & Maldonado, R. (2006). Involvement of kappa/dynorphin system
in WIN 55,212-2 self-administration in mice. [Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't]. Neuropsychopharmacology : official publication of
the American College of Neuropsychopharmacology, 31(9), 1957-1966. doi:
10.1038/sj.npp.1300957
Milner, P. M. (1989). The discovery of self-stimulation and other stories. [Historical Article].
Neuroscience and biobehavioral reviews, 13(2-3), 61-67.
Mittleman, G., Van Brunt, C. L., & Matthews, D. B. (2003). Schedule-induced ethanol selfadministration in DBA/2J and C57BL/6J mice. [Comparative Study Research Support,

154

U.S. Gov't, P.H.S.]. Alcoholism, clinical and experimental research, 27(6), 918-925. doi:
10.1097/01.ALC.0000071930.48632.AE
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007).
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality.
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
Psychopharmacology, 192(1), 61-70. doi: 10.1007/s00213-006-0689-4
Negus, S. S., Morrissey, E. M., Rosenberg, M., Cheng, K., & Rice, K. C. (2010). Effects of
kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.
[Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural].
Psychopharmacology, 210(2), 149-159. doi: 10.1007/s00213-009-1770-6
Neill, D. B., Fenton, H., & Justice, J. B., Jr. (2002). Increase in accumbal dopaminergic
transmission correlates with response cost not reward of hypothalamic stimulation.
[Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
Behavioural Brain Research, 137(1-2), 129-138.
Ng Cheong Ton, J. M., Gerhardt, G. A., Friedemann, M., Etgen, A. M., Rose, G. M., Sharpless,
N. S., & Gardner, E. L. (1988). The effects of delta 9-tetrahydrocannabinol on potassiumevoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in
vivo microdialysis study. [Research Support, Non-U.S. Gov't Research Support, U.S.
Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Brain research, 451(1-2), 5968.
Niphakis, M. J., Cognetta, A. B., 3rd, Chang, J. W., Buczynski, M. W., Parsons, L. H., Byrne, F.,
. . . Cravatt, B. F. (2013). Evaluation of NHS Carbamates as a Potent and Selective Class
of Endocannabinoid Hydrolase Inhibitors. ACS chemical neuroscience. doi:
10.1021/cn400116z
Niphakis, M. J., Johnson, D. S., Ballard, T. E., Stiff, C., & Cravatt, B. F. (2012). Ohydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid
hydrolase inhibitors. ACS chemical neuroscience, 3(5), 418-426. doi: 10.1021/cn200089j
Niyuhire, F., Varvel, S. A., Martin, B. R., & Lichtman, A. H. (2007). Exposure to marijuana
smoke impairs memory retrieval in mice. [Research Support, N.I.H., Extramural]. The
Journal of pharmacology and experimental therapeutics, 322(3), 1067-1075. doi:
10.1124/jpet.107.119594
Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C., .
. . Cravatt, B. F. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that
promote neuroinflammation. [Research Support, N.I.H., Extramural Research Support,
Non-U.S. Gov't]. Science, 334(6057), 809-813. doi: 10.1126/science.1209200
Ohno-Shosaku, T., Tsubokawa, H., Mizushima, I., Yoneda, N., Zimmer, A., & Kano, M. (2002).
Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced
retrograde suppression at hippocampal synapses. [In Vitro Research Support, Non-U.S.
Gov't]. The Journal of neuroscience : the official journal of the Society for Neuroscience,
22(10), 3864-3872. doi: 20026387
155

Olds, J., & Milner, P. (1954). Positive reinforcement produced by electrical stimulation of septal
area and other regions of rat brain. Journal of comparative and physiological psychology,
47(6), 419-427.
Onaivi, E. S. (2006). Neuropsychobiological evidence for the functional presence and expression
of cannabinoid CB2 receptors in the brain. Neuropsychobiology, 54(4), 231-246. doi:
10.1159/000100778
Onaivi, E. S., Ishiguro, H., Gong, J. P., Patel, S., Perchuk, A., Meozzi, P. A., . . . Uhl, G. R.
(2006). Discovery of the presence and functional expression of cannabinoid CB2
receptors in brain. [Research Support, N.I.H., Extramural Research Support, Non-U.S.
Gov't Review]. Annals of the New York Academy of Sciences, 1074, 514-536. doi:
10.1196/annals.1369.052
Ong, W. Y., & Mackie, K. (1999). A light and electron microscopic study of the CB1
cannabinoid receptor in primate brain. [Research Support, Non-U.S. Gov't Research
Support, U.S. Gov't, P.H.S.]. Neuroscience, 92(4), 1177-1191.
Pan, B., Wang, W., Long, J. Z., Sun, D., Hillard, C. J., Cravatt, B. F., & Liu, Q. S. (2009).
Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase
inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. [Research
Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. The Journal of
pharmacology and experimental therapeutics, 331(2), 591-597. doi:
10.1124/jpet.109.158162
Panagis, G., Vlachou, S., & Nomikos, G. G. (2008). Behavioral pharmacology of cannabinoids
with a focus on preclinical models for studying reinforcing and dependence-producing
properties. [Research Support, Non-U.S. Gov't Review]. Current drug abuse reviews,
1(3), 350-374.
Panlilio, L. V., & Goldberg, S. R. (2007). Self-administration of drugs in animals and humans as
a model and an investigative tool. [Research Support, N.I.H., Intramural Review].
Addiction, 102(12), 1863-1870. doi: 10.1111/j.1360-0443.2007.02011.x
Panos, J. J., & Baker, L. E. (2010). An in vivo microdialysis assessment of concurrent MDMA
and cocaine administration in Sprague-Dawley rats. [Research Support, N.I.H.,
Extramural]. Psychopharmacology, 209(1), 95-102. doi: 10.1007/s00213-009-1774-2
Patel, S., & Hillard, C. J. (2006). Pharmacological evaluation of cannabinoid receptor ligands in
a mouse model of anxiety: further evidence for an anxiolytic role for endogenous
cannabinoid signaling. [Comparative Study Research Support, N.I.H., Extramural]. The
Journal of pharmacology and experimental therapeutics, 318(1), 304-311. doi:
10.1124/jpet.106.101287
Pertwee, R. G. (2012). Targeting the endocannabinoid system with cannabinoid receptor
agonists: pharmacological strategies and therapeutic possibilities. [Review].
Philosophical transactions of the Royal Society of London. Series B, Biological sciences,
367(1607), 3353-3363. doi: 10.1098/rstb.2011.0381
156

Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., . .
. Ross, R. A. (2010). International Union of Basic and Clinical Pharmacology. LXXIX.
Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). [Research Support,
N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S.
Gov't Review]. Pharmacological reviews, 62(4), 588-631. doi: 10.1124/pr.110.003004
Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., . . . Putman, D.
(2006). Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. CNS
drug reviews, 12(1), 21-38. doi: 10.1111/j.1527-3458.2006.00021.x
Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., . . . Felder, C.
C. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist
activity at the CB1 receptor. [Research Support, U.S. Gov't, P.H.S.]. The Journal of
pharmacology and experimental therapeutics, 301(3), 1020-1024.
Pryce, G., Cabranes, A., Fernandez-Ruiz, J., Bisogno, T., Di Marzo, V., Long, J., . . . Baker, D.
(2013). Control of experimental spasticity by targeting the degradation of
endocannabinoids using selective fatty acid amide hydrolase inhibitors. Multiple
sclerosis. doi: 10.1177/1352458513485982
Ramesh, D., Gamage, T. F., Vanuytsel, T., Owens, R. A., Abdullah, R. A., Niphakis, M. J., . . .
Lichtman, A. H. (2013). Dual Inhibition of Endocannabinoid Catabolic Enzymes
Produces Enhanced Antiwithdrawal Effects in Morphine-Dependent Mice.
Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology. doi: 10.1038/npp.2012.269
Ramesh, D., Ross, G. R., Schlosburg, J. E., Owens, R. A., Abdullah, R. A., Kinsey, S. G., . . .
Lichtman, A. H. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates
precipitated opioid withdrawal symptoms in mice. [Research Support, N.I.H.,
Extramural]. The Journal of pharmacology and experimental therapeutics, 339(1), 173185. doi: 10.1124/jpet.111.181370
Randt, C. T., & Quartermain, D. (1972). Motivation for electrical stimulation of the brain and for
natural reinforcement in mice. Experimental neurology, 35(2), 366-377.
Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., . . . et al.
(1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.
[In Vitro]. FEBS letters, 350(2-3), 240-244.
Robbe, D., Alonso, G., Duchamp, F., Bockaert, J., & Manzoni, O. J. (2001). Localization and
mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the
mouse nucleus accumbens. [In Vitro Research Support, Non-U.S. Gov't]. The Journal of
neuroscience : the official journal of the Society for Neuroscience, 21(1), 109-116.
Robinson, J. E., Agoglia, A. E., Fish, E. W., Krouse, M. C., & Malanga, C. J. (2012).
Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J
mice: comparison to cocaine. [Comparative Study Research Support, N.I.H., Extramural].
Behavioural Brain Research, 234(1), 76-81. doi: 10.1016/j.bbr.2012.06.012
157

Robledo, P., Trigo, J. M., Panayi, F., de la Torre, R., & Maldonado, R. (2007). Behavioural and
neurochemical effects of combined MDMA and THC administration in mice. [Research
Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Psychopharmacology,
195(2), 255-264. doi: 10.1007/s00213-007-0879-8
Rolls, E. T., Burton, M. J., & Mora, F. (1980). Neurophysiological analysis of brain-stimulation
reward in the monkey. Brain research, 194(2), 339-357. doi:
http://dx.doi.org/10.1016/0006-8993(80)91216-0
Ross, R. A. (2003). Anandamide and vanilloid TRPV1 receptors. [Review]. British journal of
pharmacology, 140(5), 790-801. doi: 10.1038/sj.bjp.0705467
Sagar, D. R., Staniaszek, L. E., Okine, B. N., Woodhams, S., Norris, L. M., Pearson, R. G., . . .
Chapman, V. (2010). Tonic modulation of spinal hyperexcitability by the
endocannabinoid receptor system in a rat model of osteoarthritis pain. [Research Support,
Non-U.S. Gov't]. Arthritis and rheumatism, 62(12), 3666-3676. doi: 10.1002/art.27698
Sanudo-Pena, M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., & Walker, J. M. (1997).
Endogenous cannabinoids as an aversive or counter-rewarding system in the rat.
[Research Support, U.S. Gov't, P.H.S.]. Neuroscience letters, 223(2), 125-128.
Schaefer, G. J., & Michael, R. P. (1992). Interactions between alcohol and nicotine on
intracranial self-stimulation and locomotor activity in rats. [Research Support, Non-U.S.
Gov't]. Drug and alcohol dependence, 30(1), 37-47.
Schaefer, G. J., Richardson, W. R., Bonsall, R. W., & Michael, R. P. (1988). Brain selfstimulation, locomotor activity and tissue concentrations of ethanol in male rats.
[Research Support, Non-U.S. Gov't]. Drug and alcohol dependence, 21(1), 67-75.
Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., . . .
Cravatt, B. F. (2010). Chronic monoacylglycerol lipase blockade causes functional
antagonism of the endocannabinoid system. [Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't]. Nature neuroscience, 13(9), 1113-1119. doi:
10.1038/nn.2616
Schulteis, G., Markou, A., Cole, M., & Koob, G. F. (1995). Decreased brain reward produced by
ethanol withdrawal. [Comparative Study Research Support, U.S. Gov't, P.H.S.].
Proceedings of the National Academy of Sciences of the United States of America,
92(13), 5880-5884.
Sciolino, N. R., Zhou, W., & Hohmann, A. G. (2011). Enhancement of endocannabinoid
signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme
monoacylglycerol lipase, produces anxiolytic effects under conditions of high
environmental aversiveness in rats. [Research Support, N.I.H., Extramural].
Pharmacological research : the official journal of the Italian Pharmacological Society,
64(3), 226-234. doi: 10.1016/j.phrs.2011.04.010

158

Shalev, U. (2012). Chronic food restriction augments the reinstatement of extinguished heroinseeking behavior in rats. [Research Support, Non-U.S. Gov't]. Addiction biology, 17(4),
691-693. doi: 10.1111/j.1369-1600.2010.00303.x
Shizgal, P., Schindler, D., & Rompre, P. P. (1989). Forebrain neurons driven by rewarding
stimulation of the medial forebrain bundle in the rat: comparison of psychophysical and
electrophysiological estimates of refractory periods. [Research Support, Non-U.S. Gov't].
Brain research, 499(2), 234-248.
Stark, P., & Dews, P. B. (1980). Cannabinoids. I. Behavioral effects. The Journal of
pharmacology and experimental therapeutics, 214(1), 124-130.
Stella, N. (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and
astrocytomas. [Research Support, N.I.H., Extramural Review]. Glia, 58(9), 1017-1030.
doi: 10.1002/glia.20983
Straub, C. J., Carlezon, W. A., Jr., & Rudolph, U. (2010). Diazepam and cocaine potentiate brain
stimulation reward in C57BL/6J mice. [Research Support, Non-U.S. Gov't]. Behavioural
Brain Research, 206(1), 17-20. doi: 10.1016/j.bbr.2009.08.025
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., . . . Waku, K. (1995). 2Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.
Biochemical and biophysical research communications, 215(1), 89-97.
Takahashi, R. N., & Singer, G. (1979). Self-administration of delta 9-tetrahydrocannabinol by
rats. [Research Support, U.S. Gov't, P.H.S.]. Pharmacology, biochemistry, and behavior,
11(6), 737-740.
Takahashi, R. N., & Singer, G. (1980). Effects of body weight levels on cannabis self-injection.
[Research Support, Non-U.S. Gov't]. Pharmacology, biochemistry, and behavior, 13(6),
877-881.
Tanda, G., & Goldberg, S. R. (2003). Cannabinoids: reward, dependence, and underlying
neurochemical mechanisms--a review of recent preclinical data. [Research Support, U.S.
Gov't, P.H.S. Review]. Psychopharmacology, 169(2), 115-134. doi: 10.1007/s00213-0031485-z
Tanda, G., Munzar, P., & Goldberg, S. R. (2000). Self-administration behavior is maintained by
the psychoactive ingredient of marijuana in squirrel monkeys. Nature neuroscience,
3(11), 1073-1074. doi: 10.1038/80577
Tanda, G., Pontieri, F. E., & Di Chiara, G. (1997). Cannabinoid and heroin activation of
mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
[Comparative Study Research Support, Non-U.S. Gov't]. Science, 276(5321), 2048-2050.
Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., . . .
Kano, M. (2010). The endocannabinoid 2-arachidonoylglycerol produced by
diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. [In

159

Vitro Research Support, Non-U.S. Gov't]. Neuron, 65(3), 320-327. doi:
10.1016/j.neuron.2010.01.021
Trujillo-Pisanty, I., Hernandez, G., Moreau-Debord, I., Cossette, M. P., Conover, K., Cheer, J.
F., & Shizgal, P. (2011). Cannabinoid receptor blockade reduces the opportunity cost at
which rats maintain operant performance for rewarding brain stimulation. [Research
Support, Non-U.S. Gov't]. The Journal of neuroscience : the official journal of the
Society for Neuroscience, 31(14), 5426-5435. doi: 10.1523/JNEUROSCI.0079-11.2011
Tsuboi, K., Sun, Y. X., Okamoto, Y., Araki, N., Tonai, T., & Ueda, N. (2005). Molecular
characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the
choloylglycine hydrolase family with structural and functional similarity to acid
ceramidase. [Research Support, Non-U.S. Gov't]. The Journal of biological chemistry,
280(12), 11082-11092. doi: 10.1074/jbc.M413473200
Ueda, N., Yamanaka, K., & Yamamoto, S. (2001). Purification and characterization of an acid
amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory
substance. [Research Support, Non-U.S. Gov't]. The Journal of biological chemistry,
276(38), 35552-35557. doi: 10.1074/jbc.M106261200
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., . . .
Sharkey, K. A. (2005). Identification and functional characterization of brainstem
cannabinoid CB2 receptors. [Research Support, N.I.H., Extramural Research Support,
Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Science, 310(5746), 329-332. doi:
10.1126/science.1115740
van Tienhoven, M., Atkins, J., Li, Y., & Glynn, P. (2002). Human neuropathy target esterase
catalyzes hydrolysis of membrane lipids. [Research Support, Non-U.S. Gov't]. The
Journal of biological chemistry, 277(23), 20942-20948. doi: 10.1074/jbc.M200330200
Vandrey, R., Stitzer, M. L., Mintzer, M. Z., Huestis, M. A., Murray, J. A., & Lee, D. (2013). The
dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.
[Clinical Trial Research Support, N.I.H., Extramural]. Drug and alcohol dependence,
128(1-2), 64-70. doi: 10.1016/j.drugalcdep.2012.08.001
Varvel, S. A., Wiley, J. L., Yang, R., Bridgen, D. T., Long, K., Lichtman, A. H., & Martin, B. R.
(2006). Interactions between THC and cannabidiol in mouse models of cannabinoid
activity. [Research Support, N.I.H., Extramural]. Psychopharmacology, 186(2), 226-234.
doi: 10.1007/s00213-006-0356-9
Varvel, S. A., Wise, L. E., Niyuhire, F., Cravatt, B. F., & Lichtman, A. H. (2007). Inhibition of
fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial
memory task. [Research Support, N.I.H., Extramural]. Neuropsychopharmacology :
official publication of the American College of Neuropsychopharmacology, 32(5), 10321041. doi: 10.1038/sj.npp.1301224
Vinklerova, J., Novakova, J., & Sulcova, A. (2002). Inhibition of methamphetamine selfadministration in rats by cannabinoid receptor antagonist AM 251. [Research Support,
Non-U.S. Gov't]. Journal of psychopharmacology, 16(2), 139-143.
160

Vlachou, S., Nomikos, G. G., & Panagis, G. (2003). WIN 55,212-2 decreases the reinforcing
actions of cocaine through CB1 cannabinoid receptor stimulation. Behavioural Brain
Research, 141(2), 215-222. doi: 10.1016/s0166-4328(02)00370-4
Vlachou, S., Nomikos, G. G., & Panagis, G. (2005). CB1 cannabinoid receptor agonists increase
intracranial self-stimulation thresholds in the rat. [Research Support, Non-U.S. Gov't].
Psychopharmacology, 179(2), 498-508. doi: 10.1007/s00213-004-2050-0
Vlachou, S., Nomikos, G. G., & Panagis, G. (2006). Effects of endocannabinoid
neurotransmission modulators on brain stimulation reward. [Research Support, Non-U.S.
Gov't]. Psychopharmacology, 188(3), 293-305. doi: 10.1007/s00213-006-0506-0
Vlachou, S., Nomikos, G. G., Stephens, D. N., & Panagis, G. (2007). Lack of evidence for
appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and
conditioned place preference procedures in rodents. [Research Support, Non-U.S. Gov't].
Behavioural pharmacology, 18(4), 311-319. doi: 10.1097/FBP.0b013e3282186cf2
Vlachou, S., Stamatopoulou, F., Nomikos, G. G., & Panagis, G. (2008). Enhancement of
endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the
reinforcing and psychostimulant effects of cocaine. [Research Support, Non-U.S. Gov't].
The international journal of neuropsychopharmacology / official scientific journal of the
Collegium Internationale Neuropsychopharmacologicum, 11(7), 905-923. doi:
10.1017/S1461145708008717
Wei, B. Q., Mikkelsen, T. S., McKinney, M. K., Lander, E. S., & Cravatt, B. F. (2006). A second
fatty acid amide hydrolase with variable distribution among placental mammals.
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. The Journal
of biological chemistry, 281(48), 36569-36578. doi: 10.1074/jbc.M606646200
Wiebelhaus, J. M., Poklis, J. L., Poklis, A., Vann, R. E., Lichtman, A. H., & Wise, L. E. (2012).
Inhalation exposure to smoke from synthetic "marijuana" produces potent
cannabimimetic effects in mice. [Research Support, N.I.H., Extramural]. Drug and
alcohol dependence, 126(3), 316-323. doi: 10.1016/j.drugalcdep.2012.05.034
Wiley, J. L., Burston, J. J., Leggett, D. C., Alekseeva, O. O., Razdan, R. K., Mahadevan, A., &
Martin, B. R. (2005). CB1 cannabinoid receptor-mediated modulation of food intake in
mice. [Comparative Study Research Support, N.I.H., Extramural Research Support, U.S.
Gov't, P.H.S.]. British journal of pharmacology, 145(3), 293-300. doi:
10.1038/sj.bjp.0706157
Wiley, J. L., Lowe, J. A., Balster, R. L., & Martin, B. R. (1995). Antagonism of the
discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus
monkeys. [Research Support, U.S. Gov't, P.H.S.]. The Journal of pharmacology and
experimental therapeutics, 275(1), 1-6.
Wiley, J. L., Marusich, J. A., Lefever, T. W., Grabenauer, M., Moore, K. N., & Thomas, B. F.
(2013). Cannabinoids in disguise: Delta-Tetrahydrocannabinol-like effects of
tetramethylcyclopropyl ketone indoles. Neuropharmacology, 75C, 145-154. doi:
10.1016/j.neuropharm.2013.07.022
161

Wise, L. E., Harloe, J. P., & Lichtman, A. H. (2009). Fatty acid amide hydrolase (FAAH)
knockout mice exhibit enhanced acquisition of an aversive, but not of an appetitive,
Barnes maze task. [Comparative Study Research Support, N.I.H., Extramural].
Neurobiology of learning and memory, 92(4), 597-601. doi: 10.1016/j.nlm.2009.06.001
Wise, L. E., Long, K. A., Abdullah, R. A., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2012).
Dual Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Blockade Produces
THC-Like Morris Water Maze Deficits in Mice. ACS chemical neuroscience, 3(5), 369378. doi: 10.1021/cn200130s
Wise, R. A. (2002). Brain Reward Circuitry: Insights from Unsensed Incentives. Neuron, 36(2),
229-240. doi: http://dx.doi.org/10.1016/S0896-6273(02)00965-0
Wise, R. A. (2005). Forebrain substrates of reward and motivation. [Review]. The Journal of
comparative neurology, 493(1), 115-121. doi: 10.1002/cne.20689
Wiskerke, J., Irimia, C., Cravatt, B. F., De Vries, T. J., Schoffelmeer, A. N., Pattij, T., &
Parsons, L. H. (2012). Characterization of the effects of reuptake and hydrolysis
inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis
study. ACS chemical neuroscience, 3(5), 407-417. doi: 10.1021/cn300036b
Xi, Z. X., Peng, X. Q., Li, X., Song, R., Zhang, H. Y., Liu, Q. R., . . . Gardner, E. L. (2011).
Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice. [Research
Support, N.I.H., Intramural]. Nature neuroscience, 14(9), 1160-1166. doi:
10.1038/nn.2874
Xi, Z. X., Spiller, K., Pak, A. C., Gilbert, J., Dillon, C., Li, X., . . . Gardner, E. L. (2008).
Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments
with self-administration and brain-stimulation reward in rats. [Research Support, N.I.H.,
Intramural]. Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology, 33(7), 1735-1745. doi: 10.1038/sj.npp.1301552
Xi, Z. X., Yang, Z., Li, S. J., Li, X., Dillon, C., Peng, X. Q., . . . Gardner, E. L. (2007). Levotetrahydropalmatine inhibits cocaine's rewarding effects: experiments with selfadministration and brain-stimulation reward in rats. [Research Support, N.I.H.,
Intramural Research Support, Non-U.S. Gov't]. Neuropharmacology, 53(6), 771-782. doi:
10.1016/j.neuropharm.2007.08.004
Yoshida, T., Fukaya, M., Uchigashima, M., Miura, E., Kamiya, H., Kano, M., & Watanabe, M.
(2006). Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests
close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol,
and presynaptic cannabinoid CB1 receptor. [Comparative Study Research Support, NonU.S. Gov't]. The Journal of neuroscience : the official journal of the Society for
Neuroscience, 26(18), 4740-4751. doi: 10.1523/JNEUROSCI.0054-06.2006
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., . . .
Hogestatt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator
action of anandamide. [In Vitro Research Support, Non-U.S. Gov't Research Support,
U.S. Gov't, P.H.S.]. Nature, 400(6743), 452-457. doi: 10.1038/22761
162

Vita

Jason Michael Wiebelhaus was born September 8, 1982 in Whittier, CA. He grew up in
Austin, MN. He received his Bachelor of Science degree in psychology from the University of
WI-Eau Claire in 2006. Jason entered the department of psychology (biopsychology) at Virginia
Commonwealth University as a graduate student in 2007, where he earned his Master of Science
degree while working under Dr. Joseph H. Porter studying the discriminative stimulus properties
of antipsychotic drugs in 2009.

163

